



AUSTRALIAN NSP SURVEY

NATIONAL DATA REPORT 2007 - 2011

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

Never Stand Still

Medicine

The Kirby Institute

Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Drutt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston. Biala Community Alcohol and Drug Services, Townsville ATODS. QUIHN Brisbane, Gold Coast, Sunshine Coast. West Moreton Sexual Health Service, Ipswich. Cairns B Hospital, Kobi House, Toowoomba. SAVIVE, Norwood, Parks, Port Adelaide, Northern Metropolitan, Shopfront. Hindmarsh Centre. Nunkuwarrin Yunti Community Health Centre, Noarlunga Community Health Centre. Clarence Community Health Centre, Anglicare Hobart, Glenorchy. Salvation Army Launceston. Barwon Health Drug and Alcohol Services. Bendigo NSP. InnerSpace, Collingwood. Health Works, Footscray. North Richmond NSP Services. Health Information Exchange, St Kilda. Western Australia Substance Users Association (WASUA), Northbridge, South West Coast. WA AIDS Council Mobile NSP. Directions ACT, Canberra. Albury Community Health Centre. Wagga Wagga Community Health Centre. Harm Reduction Services Ballina/Byron, Nimbin/Lismore, Murwillumbah/Tweed Coffs Harbour/Grafton. HIV/Hepatitis C Prevention Services, Blacktown, Parramatta, Mt Drutt. South Court Primary Care NSP, Nepean. Resource and Education Program for IDUs (REPIDU), Redfern. Gosford Needle and Syringe Program. Long Jetty Needle and Syringe Program. Health ConneXions, Liverpool. Kirketon Road Centre, K2, Kings Cross. St George NSP, Hunter Harm Reduction Services, ACON Hunter. First Step Program Illawarra, Nowra. NSW Users and AIDS Association (NUAA). Northern Territory AIDS Council, Alice Springs, Darwin, Palmerston.



Kirby Institute

©The Kirby Institute
for infection and immunity in society

ISSN 1448-5915

This publication is available at: <http://www.kirby.unsw.edu.au>

The Kirby Institute
for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

Telephone: **02 9385 0900**
International prefix: **612**

Facsimile: **02 9385 0920**
Email: recept@kirby.unsw.edu.au

Suggested citation: Iversen, J. and Maher, L. Australian Needle and Syringe Program National Data Report 2007-2011. The Kirby Institute, University of New South Wales, 2012. ISBN: 1448-5915.

AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and
sexual behaviour among NSP attendees

NATIONAL DATA REPORT

2007 - 2011

Report prepared by Jenny Iversen and Lisa Maher

The Kirby Institute

for infection and immunity in society
University of New South Wales
Sydney NSW 2052
Australia

July 2012

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales.

ACKNOWLEDGEMENTS

We would like to acknowledge the many people who assist in the development and conduct of the Australian NSP Survey, and particularly the NSP clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project, and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

Special thanks also go to laboratory staff at St Vincent's Centre for Applied Medical Research (AMR) and the NSW State Reference Laboratory for HIV at St Vincent's Hospital, especially Philip Cunningham and Beth Catlett. Thanks are also due to Rachel McCleave from the Kirby Institute and to Greg Smith from Educational Assessment Australia for scanning and validating completed surveys.

The project currently receives support and input from the following members of the Australian NSP Survey National Advisory Group: Ms Tammy Waters (ACT); Ms Rose Mason (NSW); Mr Shayne Kilford (NT); Mr Robert Kemp/Mr Gregory Perry (QLD); Mr Stephen Lymb/Mr Michael Oster (SA); Ms Francine Smith (TAS); Mr Roland Jauernig (VIC); Ms Jude Bevan (WA); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX); and Professor Lisa Maher, Dr Libby Topp, Professor John Kaldor, Associate Professor Tony Butler and Ms Jenny Iversen (Kirby Institute). We are particularly grateful to Dr. Alex Wodak (Drug & Alcohol Services, St Vincent's Hospital) who resigned from the advisory group in 2011 having served as chair since the Advisory Group's inception.

Ethical approvals were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, The University of New South Wales.

TABLE OF CONTENTS

Summary

Key Points	i
Introduction	1
Injecting behaviour.....	2
Sexual behaviour	4
BBV testing, drug treatment and prison history	5
HIV antibody prevalence	5
HCV antibody prevalence	7
Alcohol consumption	9

Tables

1. National	11
2. Australian Capital Territory	29
3. New South Wales	40
4. Northern Territory.....	58
5. Queensland	69
6. South Australia	87
7. Tasmania	101
8. Victoria	112
9. Western Australia	123

Appendix

Participating NSP services	134
Methodological notes	136
List of tables	137

SUMMARY: KEY POINTS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and associated risk behaviour among people who inject drugs.
- In 2011, 53 NSP services participated in the ANSPS and 2,395 NSP attendees completed the survey.

Demographic characteristics:

- The median age of survey respondents increased from 35 years to 37 years over the period 2007 to 2011 with a concurrent decrease in the proportion of young people (aged less than 25 years) from 10% in 2007 to 8% in 2011.
- The median time since first injection increased from 15 years to 17 years over the period 2007 to 2011, however the proportion of new initiates (first injection less than three years previously) increased from 5% to 7% over the same period.
- Median age at first injection remained stable at 18 years between 2007 and 2011.
- Among males who were new initiates to injecting in 2011, more than half (53%) reported last injecting performance and image-enhancing drugs (PIEDs).

HIV and HCV antibody prevalence:

- Between 2007 and 2011, HIV antibody prevalence remained low at 1.5% or less nationally and at 2.5% or less in all state and territories.
- HIV antibody prevalence was highest among male participants reporting homosexual identity, where prevalence ranged from 23.5% to 37.5% over the period 2007 to 2011.
- HCV antibody prevalence declined significantly over the period, from 62% in 2007 to 53% in 2011, with the decline evident among both men (61% to 54%) and women (64% to 52%).
- HCV antibody prevalence was highest among participants aged 35 years and over and among those who first initiated injecting drugs more than ten years prior to survey participation in all years 2007 to 2011.

Injecting behaviour:


- Over the period 2007 to 2011, the proportion of respondents reporting daily or more frequent injection in the month prior to the survey remained stable at between 47% and 50%.
- Heroin and methamphetamine were the two most commonly reported drugs last injected in all of the past five years, and accounted for around two thirds of respondents.
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2007 to 2011, with prevalence stable at between 14% and 16%.
- While relatively small proportions of survey respondents reported last injecting PIEDs, prevalence increased from 1% in 2007 to 5% in 2011.
- Re-use of needles and syringes declined from 26% in 2007 to 21% in 2011. Receptive sharing of needles and syringes was stable, ranging from 12% to 17% over the period 2007 to 2011.
- Around a third of ANSPS respondents reported receptive sharing of ancillary equipment in all years 2007 to 2011, with spoons and water the most common receptively shared items.

Introduction

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibodies and sexual and injecting behavioural indices of risk among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating NSP services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing. See methodological notes (page 136) for further details on the ANSPS design and implementation. This report presents national and state/territory data for the period 2007 to 2011.

In 2011, 2,395 NSP attendees participated in the ANSPS (range 1,912 in 2007 to 2,697 in 2009) with representation from states and territories relatively proportional to population sizes (Figure 1). Fifty three NSP sites participated in the ANSPS in 2011, all of whom had participated previously, and the vast majority of 2011 respondents (91%) were recruited from survey sites that had participated in each of the last five years. Annual response rates varied from 39% to 45% over the period 2007-2011 (Table 1.1.1).

Figure 1. Number of survey respondents and population size in 2011, by jurisdiction



Demographic Characteristics

Around two thirds of survey respondents were male in all years 2007 to 2011, with one third female, and less than one percent identifying as transgender. The majority of respondents identified as heterosexual, with 9% identifying as bisexual and 4% as homosexual in 2011. Females comprised a greater proportion of bisexual respondents (70%), while males comprised a greater proportion of respondents identifying as homosexual (56%).


The proportion of respondents from an Indigenous Australian background was stable at 11% to 12% over the period 2007 to 2011. The majority of respondents were born in Australia (84% to 87%), with the United Kingdom and Ireland (5%) and New Zealand (3%) the predominant countries of birth outside Australia in 2011. Most respondents also reported their parents spoke English at home (range 93% to 95% over the period 2007-2011).

The median age at survey completion increased from 35 years in 2007 to 37 years in 2010 and 2011 and there was concurrent decrease in the proportion of young injectors (aged <25 years) from 7% to 5% over the period 2007 to 2011 (χ^2 trend $p=0.022$). The median time since first injection increased from 15 years in 2007 to 17 years in 2011, although the proportion of new injectors (injecting for less than 3 years) increased from 5% in 2007 to 7% in 2011 (χ^2 trend $p=0.018$). The median age at first drug injection remained stable at 18 years for all years between 2007 and 2011 (Table 1.1.1).

Injecting behaviour

Heroin was the most commonly reported drug last injected nationally in all years 2007 to 2011. Reports of heroin injection were stable (χ^2 trend $p=0.416$) over the past five years, with around one third of respondents reporting having last injected this drug (Figure 2). In 2011, heroin was the most commonly injected drug in the Australian Capital Territory (44%), New South Wales (30%), South Australia (36%) and Victoria (61%). Methamphetamine was the second most commonly reported drug last injected nationally, and prevalence was also stable with around one quarter of respondents last injecting this drug between 2007 and 2011 (χ^2 trend $p=0.062$). In 2011, methamphetamine was the most commonly reported drug last injected in Queensland (30%) and Western Australia (33%) and the second most prevalent drug last injected in all other states except Tasmania.

Figure 2. Proportion of respondents (%) reporting last injecting heroin, methamphetamine and other drugs, 2007–2011




The third most commonly reported drug last injected nationally was pharmaceutical opioids (including morphine and oxycodone). The significant increase in the prevalence of pharmaceutical opioid injection which commenced in 2001 appears to have stabilised with no significant increase in the proportion of survey respondents reporting last injecting this drug over the period 2007 to 2011 (χ^2 trend $p=0.413$, Figure 3). In 2011, pharmaceutical opioids were the drug most commonly injected in the Northern Territory (63%) and Tasmania (34%), and the second most commonly injected drug in Queensland (23%).

Methadone was reported as the last drug injected by ten percent or less of the ANSPS sample in all years 2007 to 2011, with a decline in prevalence observed over the period 2007 to 2011 (χ^2 trend $p=0.003$). Methadone was the second most commonly reported drug last injected in Tasmania (31%) in 2011. Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents and reports over the period 2007 to 2011 were stable at between 4% and 5% and 1% and 2% respectively.

A minority of survey respondents (1% to 2%) reported cocaine as the last drug injected, with the majority of reports occurring in New South Wales in all survey years (Table 3.1.2). While relatively small proportions of respondents reported last injecting PIEDs, a significant increase in prevalence occurred over the period 2007 to 2011 (χ^2 trend $p<0.001$, Figure 3). Among males who were new initiates to injecting (less than 3 years since first injection), more than half (53%) reported last injecting PIEDs. Reports of PIEDs injection were most common in New South Wales and Queensland where they comprised 9% and 7% of the sample respectively (Table 3.1.2 and 5.1.2).


Figure 3. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone and performance and image enhancing drugs, 2007–2011



Around half of ANSPS respondents reported daily or more frequent injecting in all of the past five years (Table 1.1.1). In 2011, daily injecting was significantly more common among respondents that reported last injecting an opioid compared to those last injecting a stimulant (62% vs. 38%, $p < 0.001$). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion declined from 46% in 2007 to 42% in 2011 (χ^2 trend $p < 0.043$).

The proportion of respondents reporting reuse of needles and syringes (including one's own) in the month preceding the survey declined from 26% in 2007 to 21% in 2011 (χ^2 trend $p < 0.001$, Figure 4). Over the same period, prevalence of receptive sharing of needles and syringes ranged from 12% to 17% and receptive sharing of ancillary equipment ranged from 25% to 33%. Prevalence of both of these receptive sharing behaviours was higher in 2011 than in 2010, with spoons and water the most commonly identified receptively shared ancillary items in all of the past five years (Table 1.1.2).

Figure 4. Proportion of respondents (%) reporting reuse and receptive sharing of a needle and syringe and receptive sharing of ancillary equipment in the month prior to the survey, 2007–2011



Sexual behaviour

In each of the past five years, around half of respondents reported sex with a regular sex partner in the month prior to survey completion (range 47% to 54%). Of these, a majority (69% to 74%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (14% to 15%) reported sex with other sex partners in the month preceding survey participation, although condom use was higher among this group, with a quarter to a third reporting that they did not use condoms. The proportion of respondents reporting commercial sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years, while use of condoms at last commercial sex was high at between 78% and 87% in all years between 2007 and 2011 (Table 1.1.6).

BBV testing, drug treatment and prison history

ANSPS respondents reported relatively high rates of both HIV and HCV testing in all of the last five years, although testing rates for both HIV and HCV in the 12 months prior to survey participation declined between 2007 and 2011 ($p=0.008$ and $p=0.028$ respectively). In 2011, 49% of respondents reported having a HIV test in the past twelve months, and a slightly greater proportion (54%) reported having a HCV test during that time. In addition, around a third of respondents reported having a HIV or HCV test more than twelve months ago, with relatively few (12% or less) reporting having never been tested for either HIV or HCV (Table 1.1.7).

Respondents also reported high rates of engagement with drug treatment services, with 77% of 2011 respondents reporting current or previous drug treatment. The proportion of respondents reporting methadone maintenance treatment at the time of survey participation remained stable at between 29% and 32% over the last five years, while current buprenorphine treatment was reported by 10% of survey respondents and current buprenorphine-naloxone treatment was reported by 8% of survey respondents in 2011 (Table 1.1.3). Of those not currently engaged in opioid substitution therapy (OST), 11% had tried to access OST in the previous 12 months but reported they were unsuccessful because the program was full (Table 1.1.4).


While the proportion of respondents reporting a lifetime history of imprisonment was stable at 48% to 49% over the period 2007 to 2011, the proportion reporting incarceration in the last 12 months declined from 13% in 2007 to 10% in 2011 (χ^2 trend $p<0.001$). Among those reporting recent incarceration, approximately one in three reported injecting in prison (range 31% to 37%, Table 1.1.1).

HIV antibody prevalence

HIV antibody prevalence remained low at 1.5% or less nationally and less than 2.5% in all states and territories over the past five years (Figure 5). There was a significant decline in the proportion of males testing HIV antibody positive over the period 2007 to 2011 (2.1% in 2007 to 1.4% in 2011, χ^2 trend $p<0.039$). There was also a significant decline in the overall proportion of HIV antibody positive respondents in New South Wales (from 2.2% in 2007 to 1.0% in 2011, χ^2 trend $p<0.027$) and an increase in the proportion of females testing HIV antibody positive in South Australia (from 0% in 2007 to 4.0% in 2011, χ^2 trend $p<0.017$).


In previous years (2007-2010), the majority (74%-90%) of HIV antibody positive respondents resided in New South Wales or Queensland, however in 2011, almost half (48%) resided elsewhere ($n=5$ in South Australia, $n=4$ in Victoria and Western Australia and $n=1$ in Northern Territory). No respondents in Tasmania or the Australian Capital Territory tested positive to HIV antibodies in any of the past five years.

Figure 5. HIV antibody prevalence (%) national and state/territory, 2007–2011



HIV prevalence was consistently higher among homosexual male participants than among bisexual or heterosexual male participants or female participants in all survey years (Figure 6). Methamphetamine was the most commonly reported drug last injected among HIV antibody positive respondents in all survey years 2007 to 2011. In 2011, the median age of HIV antibody positive respondents was 43 years (range 21-58 years) and respondents first injected a median of 19 years prior to survey participation (range 1-38 years).

Figure 6. HIV antibody prevalence (%) by gender and sexual identity, 2007–2011



HCV antibody prevalence

HCV antibody prevalence nationally declined significantly from 62% in 2007 to 53% in 2011 (χ^2 trend $p < 0.001$). Significant declines in HCV prevalence were also observed over the period 2007 to 2011 in New South Wales (69% to 52%, χ^2 trend $p < 0.001$), Queensland (60% to 43%, χ^2 trend $p < 0.001$) and Tasmania (61% to 46%, χ^2 trend $p = 0.007$). An increase in HCV antibody prevalence was observed in South Australia (from 39% in 2007 to 48% in 2011, χ^2 trend $p < 0.001$). Prevalence was stable over the period 2007 to 2011 in all other jurisdictions.

HCV antibody prevalence was consistently higher among participants with longer injection histories and among older participants (Tables 1.3.3 and 1.3.4). Figure 8 illustrates the correlation between HCV antibody prevalence and time since first injection.

Figure 7. HCV antibody prevalence (%) national and state/territory, 2007–2011





Figure 8. HCV antibody prevalence (%) by time since first injection, 2011



In all years between 2007 and 2011, and among both males and females, HCV antibody prevalence was higher among participants reporting heroin or pharmaceutical opioids as the last drug injected than among those reporting methamphetamine (Figure 9). HCV antibody prevalence was also consistently higher among survey participants reporting imprisonment in the year prior to survey completion than among those not reporting recent imprisonment in all of the past five years (Figure 10).

Figure 9. HCV antibody prevalence (%) by drug last injected and gender, 2007–2011





Figure 10. HCV antibody prevalence (%) by imprisonment in the previous 12 months and gender, 2007–2011




Alcohol consumption

The Alcohol Use Disorders Identification Test (AUDIT) was developed by the World Health Organisation to assist in identifying hazardous and harmful alcohol consumption and dependence symptoms. The AUDIT-C is a modified version of the 10 question AUDIT, which asks the first three questions of the AUDIT-10, and is used to assess hazardous alcohol use. The AUDIT-C is scored on a scale of 0-12, with a score of ≥ 4 considered positive among males and a score of ≥ 3 considered positive among women (Bush et al, 1998). The AUDIT-C was included in the 2011 ANSPS questionnaire.

Of the 2395 respondents surveyed in 2011, just over a third (34%) reported they did not drink alcohol, and a further quarter (24%) reported drinking alcohol infrequently (monthly or less). Females were more likely to report abstinence from alcohol than males ($p=0.016$). Respondent who self reported a previous HCV diagnosis were more likely to abstain from drinking alcohol than those who self reported a negative HCV status (40% versus 28%, $p<0.001$). Among respondents who reported alcohol use ($n=1510$), just over two thirds (68%) reported hazardous alcohol use as defined by the AUDIT-C score, with hazardous use equally likely to occur among men and women.

Figure 11 Hazardous and non hazardous alcohol consumption (as defined by the AUDIT-C score) by gender, 2011



Reference:

Bush K, Kivlahan DR, McDonnell MB, Fihn SD, Bradley, KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789-95.

National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	52	53	51	53	53
N° surveyed	N=1912	N=2270	N=2697	N=2396	N=2395
Response (%)	39%	39%	45%	39%	41%
Gender (%)					
Male	1241 (65)	1456 (64)	1756 (65)	1611 (67)	1602 (67)
Female	660 (35)	803 (35)	924 (34)	771 (32)	780 (33)
Transgender	9 (<1)	6 (<1)	9 (<1)	8 (<1)	10 (<1)
Not reported	2 (<1)	5 (<1)	8 (<1)	6 (<1)	3 (<1)
Sexual identity (%)					
Heterosexual	1570 (82)	1843 (81)	2236 (83)	1987 (83)	1982 (83)
Bisexual	177 (9)	219 (10)	236 (9)	195 (8)	208 (9)
Homosexual	116 (6)	115 (5)	89 (3)	88 (4)	96 (4)
Not reported	49 (3)	93 (4)	136 (5)	126 (5)	109 (5)
Age and duration of injection (years)					
<i>Median age</i>	35	36	36	37	37
<i>Age range</i>	14-69	16-70	15-66	15-73	16-65
<i>Age group (%)</i>					
<25 years	183 (10)	208 (9)	285 (11)	203 (8)	182 (8)
25+ years	1726 (90)	2056 (91)	2411 (89)	2191 (91)	2205 (92)
Not reported	3 (<1)	6 (<1)	1 (<1)	2 (<1)	1 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	10-56	10-60	10-58	10-63	10-56
<i>N° not reported</i>	51	46	67	51	62
<i>Median years IDU</i>	15	15	15	16	17
<i>Range</i>	<1-49	<1-48	<1-46	<1-60	<1-41
<i>Duration of drug injection (%)</i>					
<3 years	102 (5)	113 (5)	162 (6)	131 (5)	168 (7)
3+ years	1759 (92)	2110 (93)	2468 (92)	2213 (92)	2162 (90)
Not reported	51 (3)	47 (2)	67 (2)	52 (2)	65 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	1663 (87)	1934 (85)	2296 (85)	2071 (86)	2065 (86)
Yes	203 (11)	250 (11)	323 (12)	275 (11)	276 (12)
Not reported	46 (2)	86 (4)	78 (3)	50 (2)	54 (2)
Region/Country of birth					
Australia	1649 (86)	1918 (84)	2333 (87)	2088 (87)	2046 (85)
Other Oceania	46 (2)	83 (4)	85 (3)	76 (3)	80 (3)
Asia	22 (1)	32 (1)	25 (1)	29 (1)	31 (1)
UK & Ireland	85 (4)	125 (6)	120 (4)	94 (4)	111 (5)
Other	72 (4)	68 (3)	89 (3)	69 (3)	101 (4)
Not reported	38 (2)	44 (2)	45 (2)	40 (2)	26 (1)
Main language spoke at home by parents					
English speaking	1778 (93)	2128 (94)	2548 (94)	2275 (95)	2237 (93)
Non-English speaking	102 (5)	109 (5)	113 (4)	90 (4)	134 (6)
Not reported	32 (2)	33 (1)	36 (1)	31 (1)	24 (1)
Imprisonment last year (%)					
No	1569 (82)	1812 (80)	2238 (83)	1762 (74)	2049 (86)
Yes	254 (13)	287 (13)	339 (13)	226 (9)	238 (10)
Not reported	89 (5)	171 (8)	120 (4)	408 (17)	108 (5)
Injected in prison last year (%)	N=254	N=287	N=339	N=226	N=238
Yes	95 (37)	96 (33)	113 (33)	69 (31)	75 (32)
Frequency of injection last month (%)					
Not last month	155 (8)	230 (10)	270 (10)	259 (11)	250 (10)
Less than weekly	337 (18)	343 (15)	418 (15)	423 (18)	387 (16)
Weekly not daily	484 (25)	576 (25)	618 (23)	563 (24)	563 (24)
Daily or more	900 (47)	1099 (48)	1361 (50)	1119 (47)	1159 (48)
Not reported	36 (2)	22 (1)	30 (1)	32 (1)	36 (2)

Table 1.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=1912	N=2270	N=2697	N=2396	N=2395
Cocaine	33 (2)	53 (2)	66 (2)	31 (1)	23 (1)
Heroin	593 (31)	781 (34)	917 (34)	808 (34)	802 (33)
Methadone	187 (10)	192 (8)	232 (9)	177 (7)	173 (7)
Methamphetamine	574 (30)	645 (28)	657 (24)	628 (26)	649 (27)
Performance/Image-enhancing drugs	20 (1)	35 (2)	43 (2)	57 (2)	109 (5)
Pharmaceutical opioids	268 (14)	345 (15)	426 (16)	382 (16)	358 (15)
Suboxone	--	--	35 (1)	46 (2)	43 (2)
Subutex/Buprenorphine	99 (5)	104 (5)	134 (5)	100 (4)	94 (4)
More than one	53 (3)	53 (2)	86 (3)	118 (5)	106 (4)
Other drug	51 (3)	21 (1)	34 (1)	37 (2)	33 (1)
Not reported	34 (2)	41 (2)	67 (2)	12 (<1)	5 (<1)
N° Injected last month	N=1721	N=2018	N=2397	N=2109	N=2109
Places injected last month (%)*					
Own home	1488 (89)	1780 (89)	2065 (87)	1738 (82)	1779 (84)
Friend's home	714 (43)	825 (41)	973 (41)	821 (39)	797 (38)
Dealer's home	278 (17)	362 (18)	385 (16)	335 (16)	318 (15)
Street, park, beach	385 (23)	441 (22)	534 (22)	416 (20)	407 (19)
Car	561 (33)	606 (30)	724 (30)	588 (28)	552 (26)
Public toilet	389 (23)	451 (23)	544 (23)	467 (22)	474 (22)
Commercial injecting room	47 (3)	50 (3)	58 (2)	37 (2)	38 (2)
Squat	102 (6)	120 (6)	150 (6)	113 (5)	104 (5)
Injected in a public place	799 (46)	886 (44)	1079 (45)	867 (42)	882 (42)
Use of sterile needles & syringes last month (%)					
All injections	1234 (72)	1429 (71)	1783 (74)	1477 (70)	1569 (74)
Most of the time	374 (22)	475 (24)	503 (21)	398 (19)	383 (18)
Half of the time	41 (2)	48 (2)	39 (2)	38 (2)	41 (2)
Some of the time	25 (1)	28 (1)	35 (1)	28 (1)	26 (1)
Not last month	3 (<1)	13 (<1)	8 (<1)	8 (<1)	4 (<1)
Not reported	44 (3)	25 (1)	29 (1)	160 (8)	86 (4)
Re-used someone else's used needle & syringe last month (%)					
None	1381 (80)	1640 (81)	1963 (82)	1595 (76)	1663 (79)
Once	104 (6)	108 (5)	124 (5)	87 (4)	104 (5)
Twice	53 (3)	101 (5)	93 (4)	70 (3)	80 (4)
3-5 times	70 (4)	70 (3)	86 (4)	58 (3)	74 (4)
>5 times	36 (2)	55 (3)	73 (3)	47 (2)	58 (3)
Not reported	77 (4)	44 (2)	58 (2)	252 (12)	130 (6)
Number of people needle & syringe was re-used after last month (%)					
None	1381 (80)	1640 (81)	1963 (82)	1595 (76)	1663 (79)
One	125 (7)	169 (8)	185 (8)	127 (6)	166 (8)
Two	22 (1)	19 (<1)	26 (1)	21 (1)	23 (1)
Three to five	14 (<1)	17 (<1)	15 (<1)	25 (1)	14 (<1)
More than five	8 (<1)	7 (<1)	10 (<1)	19 (1)	14 (<1)
Don't know	43 (3)	71 (4)	58 (2)	41 (2)	64 (3)
Not reported	128 (7)	95 (5)	140 (6)	281 (13)	165 (8)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	119 (7)	136 (7)	151 (6)	177 (8)	196 (9)
Casual sex partner	12 (<1)	12 (<1)	4 (<1)	16 (<1)	9 (<1)
Close friend	64 (4)	84 (4)	86 (4)	105 (5)	125 (6)
Acquaintance	23 (1)	29 (1)	32 (1)	38 (2)	59 (3)
Other	16 (1)	21 (1)	29 (1)	38 (2)	48 (2)
Equipment used after someone else last month (%)*					
Spoon	379 (24)	436 (24)	541 (25)	446 (21)	481 (22)
Water	274 (17)	314 (17)	358 (16)	316 (15)	310 (15)
Filter	208 (13)	219 (12)	273 (12)	212 (10)	222 (11)
Drug mix	136 (9)	155 (8)	202 (9)	177 (8)	174 (8)
None	1024 (65)	1181 (64)	1409 (64)	1319 (63)	1387 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	1402 (81)	1673 (83)	1958 (82)	1639 (78)	1731 (82)
Yes	235 (14)	281 (14)	387 (16)	242 (11)	283 (13)
Not reported	84 (5)	64 (3)	52 (2)	228 (11)	95 (5)

* More than one option could be selected

Table 1.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=1912	N=2270	N=2697	N=2396	N=2395
Sex with a regular partner last month (%)					
No	813 (43)	1015 (45)	1215 (45)	1082 (45)	1105 (46)
Yes	1026 (54)	1190 (52)	1382 (51)	1210 (51)	1135 (47)
Not reported	73 (4)	65 (3)	100 (4)	104 (4)	157 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=1026	N=1190	N=1382	N=1210	N=1135
Never	756 (74)	828 (70)	999 (72)	840 (69)	800 (71)
Sometimes	131 (13)	144 (12)	179 (13)	154 (13)	133 (12)
Every time	103 (10)	154 (13)	135 (10)	145 (12)	141 (12)
Not reported	36 (4)	64 (5)	69 (5)	71 (6)	59 (5)
Sex with other partner/s last month (%)					
No	1562 (82)	1838 (81)	2186 (81)	1923 (80)	1966 (82)
Yes	279 (15)	345 (15)	378 (14)	327 (14)	330 (14)
Not reported	71 (4)	87 (4)	133 (5)	146 (6)	99 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=279	N=345	N=378	N=327	N=330
Never	91 (33)	85 (25)	129 (34)	116 (35)	108 (33)
Sometimes	69 (25)	101 (29)	96 (25)	72 (22)	80 (24)
Every time	105 (38)	143 (41)	148 (39)	124 (38)	127 (38)
Not reported	14 (5)	16 (5)	5 (1)	15 (5)	15 (5)
Sex work last month (%)					
No	1721 (90)	1991 (88)	2458 (91)	2092 (87)	2169 (91)
Yes	115 (6)	139 (6)	130 (5)	128 (5)	114 (5)
Not reported	76 (4)	140 (6)	109 (4)	176 (7)	112 (5)
Condom used at last sex work last month (%)					
Yes	92 (87)	105 (83)	106 (84)	95 (78)	88 (85)

Table 1.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=1912	N=2270	N=2697	N=2396	N=2395
Previous HIV test (%)					
Yes, last year	1077 (56)	1124 (50)	1360 (50)	1141 (48)	1172 (49)
> 1 year ago	617 (32)	818 (36)	922 (34)	819 (34)	849 (35)
Never tested	187 (10)	215 (9)	310 (11)	282 (12)	287 (12)
Not reported	31 (2)	113 (5)	105 (4)	154 (6)	87 (4)
Previous HCV test (%)					
Yes, last year	1147 (60)	1257 (55)	1549 (57)	1280 (53)	1289 (54)
> 1 year ago	596 (31)	769 (34)	855 (32)	750 (31)	794 (33)
Never tested	141 (7)	154 (7)	196 (7)	190 (8)	169 (7)
Not reported	28 (1)	90 (4)	97 (4)	176 (7)	143 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=848	N=1203	N=1383	N=1274	N=1267
Interferon/Interferon+Ribavirin	43 (5)	107 (9)	126 (9)	136 (11)	121 (10)
Other	17 (2)	21 (2)	17 (1)	17 (1)	18 (1)
No treatment	747 (88)	1039 (86)	1174 (85)	1072 (84)	1054 (83)
Not reported	41 (5)	36 (3)	66 (5)	49 (4)	74 (6)
Current treatment for HCV	N=15	N=27	N=25	N=32	N=36
Interferon/Interferon+Ribavirin	6	18	21	26	28
Other	10	9	4	6	8

Table 1.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=1912	N=2270	N=2697	N=2396	N=2395
Any treatment/therapy for drug use (%)					
No	370 (19)	444 (20)	509 (19)	425 (18)	489 (20)
Yes	1504 (79)	1785 (79)	2144 (80)	1910 (80)	1842 (77)
Not reported	38 (2)	41 (2)	44 (2)	61 (3)	64 (3)
History of methadone maintenance treatment (%)					
Currently	605 (32)	696 (31)	823 (31)	725 (30)	693 (29)
Previously	539 (28)	587 (26)	645 (24)	600 (25)	586 (24)
Never	740 (39)	938 (41)	1167 (43)	946 (39)	1006 (42)
Not reported	28 (1)	49 (2)	62 (2)	125 (5)	110 (5)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	290 (13)	339 (13)	267 (11)	231 (10)
Previously	--	566 (25)	679 (25)	637 (27)	641 (27)
Never	--	1355 (60)	1621 (60)	1461 (61)	1426 (60)
Not reported	--	49 (2)	58 (2)	31 (1)	97 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	142 (6)	211 (8)	200 (8)	224 (9)
Previously	--	270 (12)	411 (15)	413 (17)	438 (18)
Never	--	1787 (79)	2003 (74)	1737 (73)	1640 (68)
Not reported	--	71 (3)	72 (3)	46 (2)	93 (4)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=1399
Yes, in the last month					59 (4)
Yes, 1-6 months ago					54 (4)
Yes, 6-12 months ago					41 (3)
Yes, more than one year ago					136 (10)
No, haven't tried to access OST					1109 (79)

* New variable in 2008

Table 1.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month by survey year

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=1721	N=2018	N=2397	N=2109	N=2109
Needle Syringe Program	1285 (67)	1879 (83)	1569 (65)	2063 (86)	1917 (91)
Chemist/Pharmacy	387 (20)	876 (36)	601 (25)	450 (19)	415 (20)
Personal sources	313 (16)	--	418 (17)	256 (11)	184 (9)
Dispensing/Vending Machine	180 (9)	--	222 (9)	181 (8)	205 (10)
Other sources	64 (3)	--	69 (3)	77 (3)	35 (2)

* More than one option could be selected

Table 1.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=2395
Never	813 (34)
Monthly or less	566 (24)
2-4 times a month	336 (14)
2-3 times a week	293 (12)
4 or more times a week	315 (13)
Not reported	72 (3)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=1510
1 or 2	414 (27)
3 or 4	410 (27)
5 or 6	233 (15)
7, 8 or 9	147 (10)
10 or more	195 (13)
Not reported	111 (7)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
2010	1579	21 (1.3)	759	2 (0.3)	2352	23 (1.0)
2011	1560	21 (1.4)	764	7 (0.9)	2337	29 (1.2)
χ^2 trend p value		0.039		0.142		0.161

* Totals include people whose gender was not reported or reported as transgender

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
p value		<0.001		0.181		<0.001
2009						
Heterosexual	1510	7 (0.5)	682	2 (0.3)	2207	9 (0.4)
Bisexual	78	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	30	18 (37.5)	37	0 (0.0)	87	18 (20.7)
p value		<0.001		1.000		<0.001
2010						
Heterosexual	1390	4 (0.3)	558	2 (0.4)	1954	6 (0.3)
Bisexual	61	3 (4.9)	124	0 (0.0)	188	3 (1.6)
Homosexual	48	14 (29.2)	36	0 (0.0)	85	14 (16.5)
p value		<0.001		1.000		<0.001
2011						
Heterosexual	1393	6 (0.4)	547	5 (0.9)	1943	11 (0.6)
Bisexual	57	3 (5.3)	141	2 (1.4)	203	6 (3.0)
Homosexual	51	12 (23.5)	38	0 (0.0)	91	12 (13.2)
p value		<0.001		0.751		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.3 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
< 25 years	90	0 (0.0)	84	0 (0.0)	175	0 (0.0)
25 – 34	453	6 (1.3)	236	0 (0.0)	693	6 (0.9)
35+ years	650	19 (2.9)	318	2 (0.6)	974	22 (2.3)
p value		0.067		0.364		0.016
2008						
< 25 years	107	0 (0.0)	89	0 (0.0)	196	0 (0.0)
25 – 34	468	7 (1.5)	297	3 (1.0)	767	11 (1.4)
35+ years	816	22 (2.7)	377	0 (0.0)	1201	22 (1.8)
p value		0.102		0.094		0.147
2009						
< 25 years	156	1 (0.6)	117	0 (0.0)	275	1 (0.4)
25 – 34	575	7 (1.2)	346	0 (0.0)	925	7 (0.8)
35+ years	984	20 (1.6)	446	1 (0.2)	1441	22 (1.5)
p value		0.282		0.593		0.100
2010						
< 25 years	105	1 (1.0)	90	0 (0.0)	197	1 (0.5)
25 – 34	502	3 (0.6)	263	0 (0.0)	766	3 (0.4)
35+ years	970	16 (1.7)	405	2 (0.5)	1386	18 (1.3)
p value		0.226		0.629		0.089
2011						
< 25 years	118	1 (0.9)	56	2 (3.6)	176	3 (1.7)
25 – 34	457	1 (0.2)	287	1 (0.4)	748	2 (0.3)
35+ years	979	19 (1.9)	419	4 (1.0)	1404	24 (1.3)
p value		0.015		0.116		0.005

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.4 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
<3 years	61	1 (1.6)	37	0 (0.0)	98	1 (1.0)
3 to 10 years	277	4 (1.4)	190	0 (0.0)	471	4 (0.8)
11 + years	826	19 (2.4)	394	2 (0.5)	1227	22 (1.8)
p value		0.667		0.561		0.331
2008						
<3 years	67	5 (7.4)	43	0 (0.0)	110	5 (4.6)
3 to 10 years	308	4 (1.3)	202	0 (0.0)	511	4 (0.8)
11 + years	986	19 (1.9)	508	3 (0.6)	1502	23 (1.5)
p value		0.005		0.484		0.013
2009						
<3 years	90	2 (2.2)	67	0 (0.0)	158	2 (1.3)
3 to 10 years	317	5 (1.6)	237	0 (0.0)	558	5 (0.9)
11 + years	1279	21 (1.6)	585	1 (0.2)	1875	23 (1.2)
p value		0.909		0.771		0.807
2010						
<3 years	87	2 (2.3)	36	0 (0.0)	124	2 (1.6)
3 to 10 years	253	3 (1.2)	181	0 (0.0)	435	3 (0.7)
11 + years	1202	15 (1.3)	527	2 (0.4)	1740	17 (1.0)
p value		0.562		1.000		0.560
2011						
<3 years	114	2 (1.8)	48	0 (0.0)	163	2 (1.2)
3 to 10 years	251	4 (1.6)	152	2 (1.3)	404	6 (1.5)
11 + years	1148	15 (1.3)	549	5 (0.9)	1707	21 (1.2)
p value		0.731		0.780		0.845

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.5 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Methamphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
Other	475	11 (2.3)	205	1 (0.5)	687	13 (1.9)
p value		0.276		0.586		0.148
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Methamphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
Other	514	8 (1.6)	261	1 (0.4)	779	9 (1.2)
p value		<0.001		0.995		<0.001
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
Other	687	8 (1.2)	337	0 (0.0)	1032	9 (0.9)
p value		0.001		0.507		0.002
2010						
Heroin	522	6 (1.2)	272	2 (0.7)	797	8 (1.0)
Methamphetamine	396	10 (2.5)	210	0 (0.0)	612	10 (1.6)
Other	652	4 (0.6)	273	0 (0.0)	930	4 (0.4)
p value		0.028		0.207		0.052
2011						
Heroin	513	2 (0.4)	267	4 (1.5)	783	7 (0.9)
Methamphetamine	382	12 (3.1)	247	1 (0.4)	632	13 (2.1)
Other	662	7 (1.1)	248	2 (0.8)	917	9 (1.0)
p value		0.002		0.518		0.122

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Less than daily	513	11 (2.1)	276	1 (0.4)	794	13 (1.6)
Daily or more	572	8 (1.4)	292	1 (0.3)	869	9 (1.0)
Not last month	89	5 (5.6)	59	0 (0.0)	149	5 (3.4)
p value		0.032		0.900		0.087
2008						
Less than daily	569	17 (3.0)	309	1 (0.3)	882	18 (2.0)
Daily or more	679	8 (1.2)	363	1 (0.3)	1047	10 (1.0)
Not last month	136	4 (2.9)	83	1 (1.2)	220	5 (2.3)
p value		0.065		0.462		0.100
2009						
Less than daily	645	12 (1.9)	371	2 (0.5)	1023	14 (1.4)
Daily or more	896	12 (1.3)	434	0 (0.0)	1339	13 (1.0)
Not last month	169	4 (2.4)	96	0 (0.0)	266	4 (1.5)
p value		0.535		0.239		0.591
2010						
Less than daily	696	9 (1.3)	351	2 (0.6)	1053	11 (1.0)
Daily or more	705	4 (0.6)	309	0 (0.0)	1018	4 (0.4)
Not last month	156	7 (4.5)	92	0 (0.0)	252	7 (2.8)
p value		0.002		0.616		0.004
2011						
Less than daily	619	11 (1.8)	306	3 (1.0)	929	15 (1.6)
Daily or more	752	5 (0.7)	369	4 (1.1)	1127	9 (0.8)
Not last month	161	4 (2.5)	83	0 (0.0)	246	4 (1.6)
p value		0.047		1.000		0.179

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No receptive sharing	869	15 (1.7)	467	2 (0.4)	1343	18 (1.3)
Receptive sharing	162	4 (2.5)	79	0 (0.0)	244	4 (1.6)
p value		0.522		1.000		0.764
2008						
No receptive sharing	1024	23 (2.3)	544	2 (0.4)	1576	26 (1.7)
Receptive sharing	193	2 (1.0)	118	0 (0.0)	312	2 (0.6)
p value		0.408		1.000		0.300
2009						
No receptive sharing	1268	24 (1.9)	653	2 (0.3)	1936	27 (1.4)
Receptive sharing	238	0 (0.0)	133	0 (0.0)	372	0 (0.0)
p value		0.023		1.000		0.015
2010						
No receptive sharing	1066	14 (1.3)	499	1 (0.2)	1570	15 (1.0)
Receptive sharing	167	1 (0.6)	89	1 (1.1)	257	2 (0.8)
p value		0.708		0.028		1.000
2011						
No receptive sharing	1093	15 (1.4)	529	7 (1.3)	1627	22 (1.4)
Receptive sharing	198	1 (0.5)	105	0 (0.0)	306	1 (0.3)
p value		0.491		0.607		0.158

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No imprisonment	946	23 (2.4)	560	2 (0.4)	1514	25 (1.7)
Imprisonment	190	2 (1.0)	59	0 (0.0)	249	2 (0.8)
p value		0.412		1.000		0.413
2008						
No imprisonment	1079	26 (2.4)	648	0 (0.0)	1735	27 (1.6)
Imprisonment	208	2 (1.0)	65	2 (3.1)	274	4 (1.5)
p value		0.296		0.008		1.000
2009						
No imprisonment	1402	27 (1.9)	794	2 (0.3)	2213	30 (1.4)
Imprisonment	245	1 (0.4)	88	0 (0.0)	333	1 (0.3)
p value		0.108		1.000		0.172
2010						
No imprisonment	1119	18 (1.6)	605	2 (0.3)	1737	20 (1.1)
Imprisonment	167	1 (0.6)	52	0 (0.0)	219	1 (0.5)
p value		0.497		1.000		0.502
2011						
No imprisonment	1303	21 (1.6)	683	6 (0.9)	1997	28 (1.4)
Imprisonment	176	0 (0.0)	56	1 (1.8)	233	1 (0.4)
p value		0.163		0.425		0.356

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No condom use	506	4 (0.8)	344	2 (0.6)	856	7 (0.8)
Condom use	66	1 (1.5)	31	0 (0.0)	98	1 (1.0)
p value		0.460		1.000		0.581
2008						
No condom use	547	4 (0.7)	380	0 (0.0)	930	4 (0.4)
Condom use	93	3 (3.2)	52	1 (1.9)	147	5 (3.4)
p value		0.067		0.120		0.004
2009						
No condom use	671	4 (0.6)	483	1 (0.2)	1162	5 (0.4)
Condom use	91	4 (4.4)	41	0 (0.0)	132	4 (3.0)
p value		0.009		1.000		0.009
2010						
No condom use	506	6 (1.2)	313	0 (0.0)	823	6 (0.7)
Condom use	188	2 (1.1)	102	2 (2.0)	292	4 (1.4)
p value		1.000		0.060		0.299
2011						
No condom use	475	6 (1.3)	308	3 (1.0)	784	9 (1.2)
Condom use	179	4 (2.2)	82	1 (1.2)	263	5 (1.9)
p value		0.473		1.000		0.359

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 1.2.10 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No sex work	1108	23 (2.1)	541	2 (0.4)	1656	25 (1.5)
Sex work	34	1 (2.9)	76	0 (0.0)	114	2 (1.8)
p value		0.519		1.000		0.691
2008						
No sex work	1264	27 (2.1)	633	3 (0.5)	1905	30 (1.6)
Sex work	39	2 (5.1)	91	0 (0.0)	131	3 (2.3)
p value		0.214		1.000		0.467
2009						
No sex work	1612	26 (1.6)	790	2 (0.3)	2425	29 (1.2)
Sex work	36	2 (5.6)	90	0 (0.0)	129	2 (1.6)
p value		0.122		1.000		0.668
2010						
No sex work	1427	18 (1.3)	619	2 (0.3)	2057	20 (1.0)
Sex work	42	2 (4.8)	84	0 (0.0)	127	2 (1.6)
p value		0.110		1.000		0.369
2011						
No sex work	1452	19 (1.3)	666	6 (0.9)	2125	25 (1.2)
Sex work	29	0 (0.0)	75	1 (1.3)	108	2 (1.9)
p value		1.000		0.528		0.378

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Non Indigenous	1045	21 (2.0)	548	2 (0.4)	1602	23 (1.4)
Indigenous	118	3 (2.5)	80	0 (0.0)	200	4 (2.0)
p value		0.728		1.000		0.532
2008						
Non Indigenous	1214	26 (2.1)	631	1 (0.2)	1853	28 (1.5)
Indigenous	130	2 (1.5)	105	2 (1.9)	237	4 (1.7)
p value		1.000		0.055		0.778
2009						
Non Indigenous	1503	26 (1.7)	752	2 (0.3)	2269	28 (1.2)
Indigenous	166	1 (0.6)	145	0 (0.0)	313	2 (0.6)
p value		0.511		1.000		0.571
2010						
Non Indigenous	1388	19 (1.4)	633	2 (0.3)	2033	21 (1.0)
Indigenous	159	2 (1.3)	112	0 (0.0)	273	2 (0.7)
p value		1.000		1.000		1.000
2011						
Non Indigenous	1366	20 (1.5)	641	5 (0.8)	2016	25 (1.2)
Indigenous	158	1 (0.6)	111	2 (1.8)	271	4 (1.5)
p value		0.716		0.277		0.770

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
English speaking	1100	24 (2.2)	609	2 (0.3)	1719	27 (1.6)
Non-English speaking	70	1 (1.4)	27	0 (0.0)	98	1 (1.0)
p value		1.000		1.000		1.000
2008						
English speaking	1299	28 (2.2)	728	3 (0.4)	2037	32 (1.6)
Non-English speaking	73	1 (1.4)	28	0 (0.0)	101	1 (1.0)
p value		1.000		1.000		1.000
2009						
English speaking	1628	27 (1.7)	869	2 (0.2)	2513	30 (1.2)
Non-English speaking	72	1 (1.4)	38	0 (0.0)	111	1 (0.9)
p value		1.000		1.000		1.000
2010						
English speaking	1485	21 (1.4)	736	2 (0.3)	2234	23 (1.0)
Non-English speaking	75	0 (0.0)	15	0 (0.0)	90	0 (0.0)
p value		0.621		1.000		1.000
2011						
English speaking	1444	20 (1.4)	731	7 (1.0)	2187	28 (1.3)
Non-English speaking	100	1 (1.0)	28	0 (0.0)	129	1 (0.8)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and year of survey

	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Australia	1023	22 (2.2)	557	2 (0.4)	1590	25 (1.6)
Other Oceania	25	1 (4.0)	19	0 (0.0)	45	1 (2.2)
Asia	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
UK & Ireland	56	2 (3.6)	28	0 (0.0)	84	2 (2.4)
Other	51	0 (0.0)	19	0 (0.0)	70	0 (0.0)
p value		0.506		1.000		0.640
2008						
Australia	1181	24 (2.0)	650	3 (0.5)	1836	27 (1.5)
Other Oceania	34	3 (8.8)	27	0 (0.0)	63	4 (6.4)
Asia	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
UK & Ireland	68	0 (0.0)	43	0 (0.0)	113	0 (0.0)
Other	71	1 (1.4)	25	0 (0.0)	96	1 (1.0)
p value		0.063		1.000		0.033
2009						
Australia	1480	27 (1.8)	805	2 (0.3)	2298	30 (1.3)
Other Oceania	54	0 (0.0)	30	0 (0.0)	84	0 (0.0)
Asia	19	1 (5.3)	5	0 (0.0)	25	1 (4.0)
UK & Ireland	82	0 (0.0)	37	0 (0.0)	120	0 (0.0)
Other	57	0 (0.0)	30	0 (0.0)	89	0 (0.0)
p value		0.331		1.000		0.312
2010						
Australia	1366	19 (1.4)	673	2 (0.3)	2050	21 (1.0)
Other Oceania	47	1 (2.1)	28	0 (0.0)	76	1 (1.3)
Asia	22	0 (0.0)	5	0 (0.0)	27	0 (0.0)
UK & Ireland	64	0 (0.0)	29	0 (0.0)	93	0 (0.0)
Other	60	1 (1.7)	16	0 (0.0)	76	1 (1.3)
p value		0.834		0.994		0.846
2011						
Australia	1322	20 (1.5)	665	7 (1.1)	1999	28 (1.4)
Other Oceania	46	0 (0.0)	34	0 (0.0)	80	0 (0.0)
Asia	24	1 (4.2)	7	0 (0.0)	31	1 (3.2)
UK & Ireland	73	0 (0.0)	34	0 (0.0)	108	0 (0.0)
Other	77	0 (0.0)	20	0 (0.0)	97	0 (0.0)
p value		0.448		1.000		0.362

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
2010	1567	838 (53)	756	398 (53)	2337	1244 (53)
2011	1530	826 (54)	748	386 (52)	2290	1216 (53)
χ^2 trend p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	1009	627 (62)	431	278 (65)	1441	906 (63)
Bisexual	45	25 (56)	116	77 (66)	165	105 (64)
Homosexual	63	30 (48)	41	21 (51)	107	53 (50)
p value		0.053		0.200		0.023
2008						
Heterosexual	1192	760 (64)	517	317 (61)	1711	1078 (63)
Bisexual	51	30 (59)	147	93 (63)	199	123 (62)
Homosexual	60	26 (43)	47	29 (62)	109	56 (51)
p value		0.006		0.901		0.054
2009						
Heterosexual	1506	751 (50)	681	335 (49)	2193	1090 (50)
Bisexual	79	36 (46)	146	97 (66)	228	133 (58)
Homosexual	48	13 (27)	37	15 (41)	87	28 (32)
p value		0.006		<0.001		<0.001
2010						
Heterosexual	1378	755 (55)	556	293 (53)	1940	1052 (54)
Bisexual	60	33 (55)	123	69 (56)	186	104 (56)
Homosexual	49	11 (22)	36	10 (28)	86	21 (24)
p value		<0.001		0.009		<0.001
2011						
Heterosexual	1369	750 (55)	531	273 (51)	1903	1024 (54)
Bisexual	55	24 (44)	140	71 (51)	200	96 (48)
Homosexual	51	20 (39)	37	15 (41)	90	36 (40)
p value		0.028		0.441		0.014

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	85	27 (32)	77	37 (48)	163	65 (40)
25 – 34	434	237 (55)	223	132 (59)	661	373 (56)
35+ years	619	429 (69)	304	219 (72)	929	651 (70)
p value		<0.001		<0.001		<0.001
2008						
< 25 years	105	31 (30)	89	41 (46)	194	72 (37)
25 – 34	450	249 (55)	291	173 (59)	743	423 (57)
35+ years	792	569 (72)	356	239 (67)	1156	813 (70)
p value		<0.001		0.001		<0.001
2009						
< 25 years	157	32 (20)	117	42 (36)	276	74 (27)
25 – 34	572	246 (43)	348	184 (53)	924	431 (47)
35+ years	983	563 (57)	446	243 (54)	1440	812 (56)
p value		<0.001		0.001		<0.001
2010						
< 25 years	103	17 (17)	90	33 (37)	195	50 (26)
25 – 34	498	228 (46)	262	130 (50)	761	359 (47)
35+ years	965	593 (61)	403	235 (58)	1379	835 (61)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	118	18 (15)	56	16 (29)	176	34 (19)
25 – 34	447	206 (46)	279	136 (49)	730	343 (47)
35+ years	959	599 (62)	411	234 (57)	1375	835 (61)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	59	8 (14)	37	11 (30)	96	19 (20)
3 to 10 years	264	107 (41)	179	97 (54)	447	206 (46)
11 + years	786	558 (71)	372	267 (72)	1165	831 (71)
p value		<0.001		<0.001		<0.001
2008						
<3 years	67	13 (19)	43	17 (40)	110	30 (27)
3 to 10 years	193	122 (63)	200	98 (49)	494	220 (45)
11 + years	960	699 (73)	485	336 (69)	1453	1040 (72)
p value		<0.001		<0.001		<0.001
2009						
<3 years	90	6 (7)	66	15 (23)	157	21 (13)
3 to 10 years	314	106 (34)	236	101 (43)	554	209 (38)
11 + years	1269	716 (56)	584	343 (59)	1864	1063 (57)
p value		<0.001		<0.001		<0.001
2010						
<3 years	87	9 (10)	36	9 (25)	124	18 (15)
3 to 10 years	249	86 (35)	181	77 (43)	431	163 (38)
11 + years	1197	726 (61)	524	306 (58)	1732	1039 (60)
p value		<0.001		<0.001		<0.001
2011						
<3 years	114	12 (11)	47	13 (28)	162	25 (15)
3 to 10 years	249	93 (37)	151	62 (41)	401	155 (39)
11 + years	1120	703 (63)	536	305 (57)	1665	1011 (61)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	21	6 (29)	517	359 (69)	545	371 (68)
Methamphetamine	52	10 (19)	460	244 (53)	524	265 (51)
Other	22	3 (13)	606	415 (68)	656	435 (66)
p value		0.430		<0.001		<0.001
2008						
Heroin	22	9 (41)	688	507 (74)	721	524 (73)
Methamphetamine	43	8 (19)	538	256 (48)	587	265 (45)
Other	43	12 (28)	692	473 (68)	756	496 (66)
p value		0.106		<0.001		<0.001
2009						
Heroin	32	9 (28)	862	512 (59)	902	524 (58)
Methamphetamine	51	4 (8)	585	221 (38)	648	230 (35)
Other	71	8 (11)	929	512 (55)	1030	533 (52)
p value		0.020		<0.001		<0.001
2010						
Heroin	28	8 (29)	747	476 (64)	792	498 (63)
Methamphetamine	33	3 (9)	567	229 (40)	610	237 (39)
Other	63	7 (11)	839	492 (59)	923	504 (55)
p value		0.086		<0.001		<0.001
2011						
Heroin	27	8 (30)	729	452 (62)	773	470 (61)
Methamphetamine	29	5 (17)	577	265 (46)	620	274 (44)
Other	105	12 (11)	756	447 (59)	892	470 (53)
p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	54	8 (15)	687	443 (64)	753	463 (62)
Daily or more	36	8 (22)	768	499 (65)	826	525 (63)
Not last month	6	3 (50)	132	75 (57)	147	81 (55)
p value		0.109		0.188		0.142
2008						
Less than daily	52	9 (17)	792	490 (62)	855	505 (59)
Daily or more	36	15 (42)	951	650 (68)	1010	679 (67)
Not last month	17	3 (18)	188	110 (59)	213	116 (54)
p value		0.026		0.003		<0.001
2009						
Less than daily	63	6 (10)	940	484 (51)	1018	496 (49)
Daily or more	69	13 (19)	1232	655 (53)	1329	683 (51)
Not last month	24	2 (8)	225	119 (53)	265	123 (46)
p value		0.213		0.734		0.220
2010						
Less than daily	57	4 (7)	978	522 (53)	1047	533 (51)
Daily or more	44	12 (27)	942	556 (59)	1010	578 (57)
Not last month	19	2 (11)	222	112 (50)	252	119 (47)
p value		0.015		0.012		0.002
2011						
Less than daily	74	9 (12)	823	431 (52)	912	442 (48)
Daily or more	59	13 (22)	1012	615 (61)	1100	645 (59)
Not last month	26	2 (8)	205	105 (51)	244	110 (45)
p value		0.148		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	73	12 (16)	1176	754 (64)	1271	785 (62)
Receptive sharing	13	4 (31)	215	145 (67)	235	156 (66)
p value		0.405		0.394		0.187
2008						
No receptive sharing	71	17 (24)	1428	918 (64)	1529	952 (62)
Receptive sharing	16	8 (50)	278	196 (71)	296	206 (70)
p value		0.063		0.046		0.018
2009						
No receptive sharing	109	11 (10)	1784	922 (52)	1924	948 (49)
Receptive sharing	19	7 (37)	340	194 (57)	369	205 (56)
p value		0.006		0.075		0.031
2010						
No receptive sharing	84	14 (17)	1449	779 (54)	1563	808 (52)
Receptive sharing	7	2 (29)	243	154 (63)	253	157 (62)
p value		0.602		0.005		0.002
2011						
No receptive sharing	110	15 (14)	1449	811 (56)	1593	840 (53)
Receptive sharing	15	5 (33)	276	171 (62)	297	180 (61)
p value		0.051		0.066		0.012

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 1.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	88	16 (18)	1315	816 (62)	1439	855 (59)
Imprisonment	3	2 (67)	226	170 (75)	238	181 (76)
p value		0.099		<0.001		<0.001
2008						
No imprisonment	96	24 (25)	1555	959 (62)	1680	998 (59)
Imprisonment	7	4 (57)	250	196 (78)	264	204 (77)
p value		0.085		<0.001		<0.001
2009						
No imprisonment	140	14 (10)	2006	1006 (50)	2200	1038 (47)
Imprisonment	12	6 (50)	311	206 (66)	331	216 (65)
p value		0.001		<0.001		<0.001
2010						
No imprisonment	110	12 (11)	1580	806 (51)	1730	835 (48)
Imprisonment	2	1 (50)	211	146 (69)	217	149 (69)
p value		0.220		<0.001		<0.001
2011						
No imprisonment	149	20 (13)	1717	924 (54)	1914	964 (50)
Imprisonment	7	3 (43)	210	157 (75)	226	164 (72)
p value		0.066		<0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 1.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	82	16 (20)	1452	938 (65)	1573	983 (62)
Sex work	7	2 (29)	98	63 (64)	110	68 (62)
p value		0.626		1.000		0.919
2008						
No sex work	99	26 (26)	1715	1104 (64)	1850	1149 (62)
Sex work	4	3 (75)	117	80 (68)	123	83 (67)
p value		0.067		0.424		0.250
2009						
No sex work	153	19 (12)	2200	1149 (52)	2409	1189 (49)
Sex work	3	2 (67)	120	75 (63)	129	79 (61)
p value		0.048		0.031		0.009
2010						
No sex work	109	13 (12)	1893	1053 (56)	2044	1086 (53)
Sex work	9	4 (44)	115	52 (45)	127	57 (45)
p value		0.024		0.033		0.082
2011						
No sex work	150	24 (16)	1886	1055 (56)	2085	1098 (53)
Sex work	2	0 (0)	94	57 (61)	103	60 (58)
p value		1.000		0.370		0.267

* Total includes people who did not report duration of drug injection

Table 1.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	998	599 (60)	523	333 (64)	1530	939 (61)
Indigenous	112	80 (71)	73	48 (66)	187	129 (69)
p value		0.019		0.795		0.046
2008						
Non Indigenous	1177	732 (62)	614	372 (61)	1799	1108 (62)
Indigenous	125	82 (66)	98	67 (68)	225	151 (67)
p value		0.497		0.148		0.109
2009						
Non Indigenous	1490	721 (48)	749	388 (52)	2253	1115 (49)
Indigenous	166	87 (52)	145	76 (52)	313	163 (52)
p value		0.328		0.928		0.399
2010						
Non Indigenous	1377	743 (54)	631	343 (54)	2020	1093 (54)
Indigenous	158	77 (49)	111	50 (45)	271	128 (47)
p value		0.238		0.080		0.038
2011						
Non Indigenous	1341	712 (53)	629	321 (51)	1978	1035 (52)
Indigenous	153	90 (59)	108	58 (54)	263	149 (57)
p value		0.178		0.608		0.186

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	1048	642 (61)	576	369 (64)	1634	1018 (62)
Non-English speaking	68	41 (60)	26	17 (65)	95	59 (62)
p value		0.898		1.000		1.000
2008						
English speaking	1262	788 (62)	704	433 (62)	1976	1227 (62)
Non-English speaking	68	51 (75)	26	14 (54)	94	65 (69)
p value		0.039		0.422		0.191
2009						
English speaking	1615	790 (49)	866	449 (52)	2497	1246 (50)
Non-English speaking	72	39 (54)	38	17 (45)	111	56 (50)
p value		0.401		0.411		0.923
2010						
English speaking	1474	788 (53)	734	383 (52)	2221	1178 (53)
Non-English speaking	75	37 (49)	14	8 (57)	89	45 (51)
p value		0.553		0.792		0.666
2011						
English speaking	1415	746 (53)	716	373 (52)	2142	1122 (52)
Non-English speaking	99	67 (68)	27	11 (41)	127	79 (62)
p value		0.004		0.246		0.031

* Total includes people whose gender was not reported or reported as transgender

Table 1.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	975	592 (61)	526	334 (64)	1511	934 (62)
Other Oceania	24	16 (67)	17	9 (53)	42	25 (60)
Asia	12	9 (75)	8	6 (75)	20	15 (75)
UK & Ireland	53	33 (62)	28	20 (71)	81	53 (65)
Other	50	31 (62)	19	14 (74)	69	45 (65)
p value		0.880		0.631		0.715
2008						
Australia	1145	721 (63)	626	378 (60)	1776	1103 (62)
Other Oceania	34	14 (41)	26	13 (50)	62	27 (44)
Asia	19	17 (89)	6	3 (50)	25	20 (80)
UK & Ireland	66	40 (61)	43	31 (72)	111	72 (65)
Other	68	46 (68)	25	18 (72)	93	64 (69)
p value		0.008		0.259		0.006
2009						
Australia	1467	728 (50)	802	411 (51)	2282	1144 (50)
Other Oceania	54	23 (43)	30	17 (57)	84	40 (48)
Asia	19	9 (47)	5	2 (40)	25	11 (44)
UK & Ireland	82	42 (51)	37	21 (57)	120	64 (53)
Other	57	24 (42)	30	15 (50)	89	40 (45)
p value		0.672		0.904		0.734
2010						
Australia	1357	724 (53)	670	344 (51)	2038	1075 (53)
Other Oceania	46	24 (52)	28	19 (68)	75	43 (57)
Asia	22	13 (59)	5	4 (80)	27	17 (63)
UK & Ireland	64	41 (64)	29	14 (48)	93	55 (59)
Other	58	26 (45)	16	11 (69)	74	37 (50)
p value		0.293		0.170		0.503
2011						
Australia	1296	691 (53)	652	339 (52)	1959	1034 (53)
Other Oceania	44	22 (50)	33	19 (58)	77	41 (53)
Asia	24	16 (67)	7	1 (14)	31	17 (55)
UK & Ireland	73	42 (58)	32	16 (50)	106	58 (55)
Other	76	42 (55)	20	9 (45)	96	51 (53)
p value		0.654		0.309		0.995

* Total includes people whose gender was not reported or reported as transgender

Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	1	1	1	1	1
N° surveyed	N=22	N=31	N=63	N=97	N=100
Response (%)	---	---	67%	83%	56%
Gender (%)					
Male	12 (55)	22 (71)	39 (62)	72 (74)	68 (68)
Female	10 (45)	9 (29)	24 (38)	25 (26)	32 (32)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	19 (86)	22 (71)	52 (83)	81 (83)	83 (83)
Bisexual	1 (5)	3 (10)	7 (11)	5 (5)	5 (5)
Homosexual	2 (9)	3 (10)	1 (2)	1 (1)	5 (5)
Not reported	0 (0)	3 (10)	3 (5)	10 (10)	7 (7)
Age and duration of injection (years)					
<i>Median age</i>	29.5	36	32	35	35
<i>Age range</i>	17-61	22-56	16-60	19-64	22-65
Age group (%)					
<25 years	5 (23)	3 (10)	15 (23)	3 (3)	4 (4)
25+ years	17 (77)	28 (90)	48 (76)	94 (97)	96 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	16	18	17	18	18
<i>Age range</i>	12-33	11-40	12-42	10-40	10-55
Not reported	1	0 (0)	1	2	2
<i>Median years IDU</i>	11	16	13	17	18
<i>Range</i>	2-47	2-38	1-36	2-49	1-49
Duration of drug injection (%)					
<3 years	1 (5)	1 (3)	7 (11)	1 (1)	4 (4)
3+ years	20 (91)	30 (97)	55 (87)	94 (97)	94 (94)
Not reported	1 (5)	0 (0)	1 (2)	2 (2)	2 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	21 (95)	25 (81)	56 (89)	79 (81)	85 (85)
Yes	0 (0)	4 (13)	5 (8)	17 (18)	12 (12)
Not reported	1 (5)	2 (6)	2 (3)	1 (1)	3 (3)
Region/Country of birth (%)					
Australia	18 (82)	25 (81)	50 (79)	89 (92)	90 (90)
Other Oceania	0 (0)	0 (0)	2 (3)	2 (2)	4 (4)
Asia	1 (5)	2 (6)	1 (2)	0 (0)	0 (0)
UK & Ireland	2 (9)	1 (3)	8 (13)	4 (4)	0 (0)
Other	1 (5)	2 (6)	2 (3)	0 (0)	6 (6)
Not reported	0 (0)	1 (3)	0 (0)	2 (2)	0 (0)
Main language spoken at home by parents (%)					
English speaking	20 (91)	30 (97)	61 (97)	95 (98)	95 (95)
Non-English speaking	2 (9)	1 (3)	2 (3)	2 (2)	5 (5)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	19 (86)	26 (84)	51 (81)	67 (69)	89 (89)
Yes	2 (9)	2 (6)	9 (14)	14 (14)	6 (6)
Not reported	1 (5)	3 (10)	3 (5)	16 (16)	5 (5)
Injected in prison (%)	N=2	N=2	N=9	N=14	N=6
Yes	1 (50)	0 (0)	1 (11)	4 (29)	2 (33)
Frequency of injection last month (%)					
Not last month	3 (14)	0 (0)	4 (6)	8 (8)	10 (10)
Less than weekly	1 (5)	3 (10)	10 (16)	15 (15)	16 (16)
Weekly not daily	9 (41)	15 (48)	12 (19)	30 (31)	22 (22)
Daily or more	8 (36)	13 (42)	37 (59)	42 (43)	50 (50)
Not reported	1 (5)	0 (0)	0 (0)	2 (2)	2 (2)

Table 2.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=22	N=31	N=63	N=97	N=100
Cocaine	0 (0)	0 (0)	0 (0)	4 (4)	0 (0)
Heroin	9 (41)	14 (45)	24 (38)	28 (29)	44 (44)
Methadone	0 (0)	2 (6)	2 (3)	16 (16)	12 (12)
Methamphetamine	9 (41)	9 (29)	15 (24)	26 (27)	24 (24)
Performance/Image-enhancing drugs	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Pharmaceutical opioids	1 (5)	2 (6)	6 (10)	3 (3)	3 (3)
Suboxone	--	--	4 (6)	1 (1)	1 (1)
Subutex/Buprenorphine	2 (9)	3 (10)	6 (10)	10 (10)	7 (7)
More than one	1 (5)	0 (0)	2 (3)	7 (7)	5 (5)
Other drug	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)
Not reported	0 (0)	1 (3)	2 (3)	0 (0)	0 (0)
N° Injected last month	N=18	N=31	N=59	N=87	N=88
Places injected last month (%)*					
Own home	16 (94)	27 (87)	50 (86)	77 (89)	81 (92)
Friend's home	11 (65)	11 (35)	30 (52)	45 (52)	40 (45)
Dealer's home	8 (47)	5 (16)	13 (22)	24 (28)	15 (17)
Street, park, beach	8 (47)	12 (39)	16 (28)	19 (22)	18 (20)
Car	8 (47)	12 (39)	18 (31)	20 (23)	17 (19)
Public toilet	9 (53)	12 (39)	17 (29)	32 (37)	33 (38)
Commercial injecting room	1 (6)	2 (6)	0(0)	1(1)	1 (1)
Squat	2 (12)	3 (10)	1(2)	6 (7)	4 (5)
Use of new sterile needles & syringes last month (%)					
All injections	9 (50)	24 (77)	43 (73)	58 (67)	59 (67)
Most of the time	6 (33)	6 (19)	15 (25)	24 (28)	24 (27)
Half of the time	1 (6)	1 (3)	1 (2)	0 (0)	2 (2)
Some of the time	1 (6)	0 (0)	0 (0)	0 (0)	1 (1)
Not last month	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	1 (6)	0 (0)	0 (0)	4 (5)	2 (2)
Re-used another's used needle & syringe last month (%)					
None	9 (50)	25 (81)	51 (86)	62 (71)	75 (85)
Once	3 (17)	2 (6)	1 (2)	3 (3)	4 (5)
Twice	1 (6)	2 (6)	1 (2)	7 (8)	0 (0)
3-5 times	2 (11)	1 (3)	4 (7)	3 (3)	2 (2)
>5 times	2 (11)	1 (3)	1 (2)	2 (2)	3 (3)
Not reported	1 (6)	0 (0)	1 (2)	10 (11)	4 (5)
Number of people needle & syringe was re-used after last month (%)					
None	9 (50)	25 (81)	51 (86)	62 (71)	75 (85)
One	2 (11)	3 (10)	4 (7)	8 (9)	4 (5)
Two	3 (17)	0 (0)	0 (0)	1 (1)	0 (0)
Three to five	0 (0)	0 (0)	2 (3)	2 (2)	0 (0)
More than five	0 (0)	0 (0)	2 (3)	1 (1)	2 (2)
Don't know	2 (11)	1 (3)	0 (0)	3 (3)	3 (3)
Not reported	2 (11)	2 (6)	1 (2)	10 (11)	4 (4)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	2 (11)	2 (6)	4 (7)	8 (9)	8 (9)
Casual sex partner	0 (0)	1 (3)	0 (0)	0 (0)	1 (1)
Close friend	3 (17)	0 (0)	2 (3)	5 (6)	3 (3)
Acquaintance	2 (11)	0 (0)	1 (2)	4 (5)	1 (1)
Other	1 (6)	1 (3)	0 (0)	2 (2)	2 (2)
Equipment used after someone else last month (%)*					
Spoon	6 (35)	11 (37)	20 (38)	18 (21)	12 (14)
Water	9 (53)	8 (27)	14 (26)	16 (18)	14 (16)
Filter	4 (24)	6 (20)	4 (8)	8 (9)	11 (13)
Drug mix	4 (24)	7 (23)	7 (13)	9 (10)	9 (10)
Tourniquet	4 (24)	1 (3)	9 (17)	--	--
None	5 (30)	19 (63)	28 (53)	53 (61)	64 (73)
Injected by someone after that person injected themselves or others last month (%)					
No	10 (56)	28 (90)	49 (83)	66 (76)	80 (91)
Yes	6 (33)	3 (10)	10 (17)	11 (13)	6 (7)
Not reported	2 (11)	0 (0)	0 (0)	10 (11)	2 (2)

* More than one option could be selected

Table 2.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=22	N=31	N=63	N=97	N=100
Sex with a regular partner last month (%)					
No	11 (50)	22 (71)	34 (54)	41 (42)	54 (54)
Yes	9 (41)	8 (26)	28 (44)	50 (52)	44 (44)
Not reported	2 (9)	1 (3)	1 (2)	6 (6)	2 (2)
Condom used with regular partner last month (%)					
N° surveyed	N=9	N=8	N=28	N=41	N=44
Never	7 (78)	3 (38)	20 (71)	23 (56)	31 (70)
Sometimes	2 (22)	2 (25)	4 (14)	7 (17)	9 (20)
Every time	0 (0)	2 (25)	3 (11)	9 (22)	3 (7)
Not reported	0 (0)	1 (12)	1 (4)	2 (5)	1 (2)
Sex with other partner/s last month (%)					
No	14 (64)	26 (84)	59 (94)	82 (85)	91 (91)
Yes	7 (32)	3 (10)	2 (3)	6 (6)	6 (6)
Not reported	1 (5)	2 (6)	2 (3)	9 (9)	3 (3)
Condom used with other partner/s last month (%)					
N° surveyed	N=7	N=3	N=2	N=6	N=6
Never	3 (43)	2 (67)	1 (50)	2 (33)	2 (33)
Sometimes	2 (29)	1 (33)	0 (0)	2 (33)	2 (33)
Every time	2 (29)	0 (0)	1 (50)	1 (17)	2 (33)
Not reported	0 (0)	0 (0)	0 (0)	1 (17)	0 (0)
Sex work last month (%)					
No	20 (91)	29 (94)	60 (95)	85 (88)	91 (91)
Yes	1 (5)	2 (6)	0 (0)	2 (2)	2 (2)
Not reported	1 (5)	0 (0)	3 (5)	10 (10)	7 (7)
Condom used at last sex work last month (%) *					
Yes	1 (100)	0 (0)	0 (0)	2 (100)	1 (100)

Table 2.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=22	N=31	N=63	N=97	N=100
Previous HIV test (%)					
Last year	13 (59)	8 (26)	30 (48)	50 (52)	43 (43)
> 1 year ago	9 (41)	21 (68)	25 (40)	21 (22)	40 (40)
Never tested	0 (0)	1 (3)	5 (8)	15 (15)	14 (14)
Not reported	0 (0)	1 (3)	3 (5)	11 (11)	3 (3)
Previous HCV test (%)					
Last year	12 (55)	11 (35)	34 (54)	49 (51)	53 (53)
> 1 year ago	10 (45)	18 (58)	24 (38)	27 (28)	38 (38)
Never tested	0 (0)	1 (3)	4 (6)	9 (9)	5 (5)
Not reported	0 (0)	1 (3)	1 (2)	12 (12)	4 (4)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=12	N=18	N=31	N=57	N=55
Interferon/Interferon+Ribavirin	1 (8)	2 (11)	2 (6)	4 (7)	6 (11)
Other	0 (0)	1 (6)	0 (0)	1 (2)	1 (2)
No treatment	11 (92)	15 (83)	29 (94)	52 (91)	48 (87)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Current treatment for HCV	N=0	N=0	N=0	N=3	N=1
Interferon/Interferon+Ribavirin	0	0	0	3	1
Other	0	0	0	0	0

Table 2.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=22	N=31	N=63	N=97	N=100
Any treatment/therapy for drug use (%)					
No	5 (23)	3 (10)	10 (16)	11 (11)	14 (14)
Yes	17 (77)	27 (87)	53 (84)	84 (87)	86 (86)
Not reported	0 (0)	1 (3)	0 (0)	2 (2)	0 (0)
History of methadone maintenance treatment (%)					
Currently	5 (23)	11 (35)	23 (37)	45 (46)	43 (43)
Previously	9 (41)	10 (32)	18 (29)	16 (16)	20 (20)
Never	8 (36)	9 (29)	22 (35)	28 (29)	33 (33)
Not reported	0 (0)	1 (3)	0 (0)	8 (8)	4 (4)
History of buprenorphine (Subutex®) treatment (%) *					
Currently	--	6 (19)	4 (6)	7 (7)	7 (7)
Previously	--	5 (16)	11 (17)	25 (26)	34 (34)
Never	--	19 (61)	46 (73)	64 (66)	57 (57)
Not reported	--	1 (3)	2 (3)	1 (1)	2 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	3 (10)	5 (8)	4 (4)	10 (10)
Previously	--	5 (16)	4 (6)	17 (18)	21 (21)
Never	--	22 (71)	51 (81)	75 (77)	66 (66)
Not reported	--	1 (3)	3 (5)	1 (1)	3 (3)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=45
Yes, in the last month					6 (13)
Yes, 1-6 months ago					0 (0)
Yes, 6-12 months ago					3 (7)
Yes, more than one year ago					4 (9)
No, haven't tried to access OST					32 (71)

* New variables in 2008

Table 2.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=18	N=31	N=59	N=87	N=88
Needle Syringe Program	16 (88)	29 (94)	34 (58)	82 (94)	81 (92)
Chemist/Pharmacy	9 (50)	20 (65)	30 (51)	21 (24)	17 (19)
Personal sources	6 (33)	--	21 (36)	12 (14)	8 (9)
Dispensing/Vending Machine	7 (39)	--	15 (25)	20 (23)	14 (16)
Other sources	0 (0)	--	1 (2)	4 (5)	1 (1)

* More than one option could be selected

Table 2.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=100
Never	39 (39)
Monthly or less	27 (27)
2-4 times a month	10 (10)
2-3 times a week	5 (5)
4 or more times a week	14 (14)
Not reported	5 (5)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=56
1 or 2	20 (36)
3 or 4	14 (25)
5 or 6	12 (21)
7, 8 or 9	4 (7)
10 or more	4 (7)
Not reported	2 (4)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
2008	18	0 (0.0)	8	0 (0.0)	26	0 (0.0)
2009	36	0 (0.0)	22	0 (0.0)	58	0 (0.0)
2010	72	0 (0.0)	25	0 (0.0)	97	0 (0.0)
2011	64	0 (0.0)	31	0 (0.0)	95	0 (0.0)
χ^2 trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	10	10 (100)	8	6 (75)	18	16 (89)
2008	18	12 (67)	8	6 (75)	26	18 (69)
2009	36	21 (58)	22	13 (59)	58	34 (59)
2010	70	48 (69)	25	15 (60)	95	63 (66)
2011	62	44 (71)	31	12 (39)	93	56 (60)
χ^2 trend p value		0.639		0.022		0.090

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	9	9 (100)	7	5 (71)	16	14 (88)
Bisexual	0	0 (0)	1	0 (0)	2	0 (0)
Homosexual	1	1 (100)		1 (100)		1 (100)
p value		---		1.000		1.000
2008						
Heterosexual	13	8 (62)	6	4 (67)	19	12 (63)
Bisexual	2	1 (50)	0	0 (0)	2	1 (50)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.779
2009						
Heterosexual	32	19 (59)	18	10 (56)	50	29 (58)
Bisexual	3	1 (33)	2	1 (50)	5	2 (40)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.565		1.000		0.643
2010						
Heterosexual	61	44 (72)	18	12 (67)	79	56 (71)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.439		0.147		0.078
2011						
Heterosexual	56	41 (73)	22	9 (41)	78	50 (64)
Bisexual	2	1 (50)	3	2 (67)	5	3 (60)
Homosexual	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.585		0.777		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	1	1 (100)	4	4 (100)	5	5 (100)
25 – 34	7	7 (100)	2	1 (50)	8	8 (89)
35+ years	2	2 (100)	2	1 (50)	3	3 (75)
p value		--		0.264		0.495
2008						
< 25 years	1	0 (0)	1	1 (100)	2	1 (50)
25 – 34	4	2 (50)	3	3 (100)	7	5 (71)
35+ years	13	10 (77)	4	2 (50)	17	12 (71)
p value		0.211		0.264		0.828
2009						
< 25 years	8	3 (38)	5	4 (80)	13	7 (54)
25 – 34	15	12 (80)	5	3 (60)	20	15 (75)
35+ years	13	6 (46)	12	6 (50)	25	12 (48)
p value		0.077		0.518		0.174
2010						
< 25 years	3	2 (67)	0	0 (0)	3	2 (67)
25 – 34	29	19 (66)	10	6 (60)	39	25 (64)
35+ years	38	27 (71)	15	9 (60)	53	36 (68)
p value		0.905		1.000		0.920
2011						
< 25 years	1	1 (100)	3	0 (0)	4	1 (25)
25 – 34	26	17 (65)	14	5 (36)	40	22 (55)
35+ years	35	26 (74)	14	7 (50)	49	33 (67)
p value		0.696		0.321		0.171

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	3	3 (100)	4	4 (100)	7	7 (100)
11 + years	6	6 (100)	3	1 (33)	9	7 (78)
p value		--		0.053		0.365
2008						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	2 (50)	1	1 (100)	5	3 (60)
11 + years	13	10 (77)	7	5 (71)	20	15 (75)
p value		0.211		0.537		0.251
2009						
<3 years	3	0 (0)	3	2 (67)	6	2 (33)
3 to 10 years	12	9 (75)	3	2 (67)	15	11 (73)
11 + years	20	11 (55)	16	9 (56)	36	20 (56)
p value		0.061		0.907		0.220
2010						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	19	11 (58)	3	0 (0)	22	11 (50)
11 + years	48	35 (73)	22	15 (68)	70	50 (71)
p value		0.140		0.052		0.051
2011						
<3 years	5	2 (100)	2	1 (50)	4	3 (75)
3 to 10 years	11	7 (64)	7	1 (14)	18	8 (44)
11 + years	49	35 (71)	21	10 (48)	70	45 (64)
p value		0.859		0.312		0.307

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	0	0 (0)	7	5 (71)	7	5 (71)
Methamphetamine	1	1 (100)	6	6 (100)	8	8 (100)
Other	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.230		0.171
2008						
Heroin	0	0 (0)	12	10 (83)	12	10 (83)
Methamphetamine	1	0 (0)	7	4 (57)	8	4 (50)
Other	0	0 (0)	6	4 (67)	6	4 (67)
p value		--		0.446		0.283
2009						
Heroin	2	2 (100)	22	13 (59)	24	15 (63)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
Other	4	0 (0)	13	11 (85)	18	12 (67)
p value		0.014		0.041		0.218
2010						
Heroin	0	0 (0)	26	18 (69)	27	19 (70)
Methamphetamine	0	0 (0)	26	13 (50)	26	13 (50)
Other	1	0 (0)	40	30 (75)	42	31 (74)
p value		--		0.105		0.120
2011						
Heroin	4	3 (75)	40	20 (50)	41	20 (49)
Methamphetamine	0	0 (0)	24	14 (58)	24	14 (58)
Other	0	0 (0)	24	19 (79)	28	22 (79)
p value		--		0.063		0.042

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	1	1 (100)	7	6 (86)	8	7 (88)
Daily or more	0	0 (0)	6	5 (83)	7	6 (86)
Not last month	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.831		0.855
2008						
Less than daily	0	0 (0)	14	10 (71)	14	10 (71)
Daily or more	1	1 (100)	11	8 (73)	12	8 (67)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.943		0.793
2009						
Less than daily	1	0 (0)	19	7 (37)	20	7 (35)
Daily or more	5	2 (40)	28	21 (75)	34	24 (71)
Not last month	0	0 (0)	4	3 (75)	4	3 (75)
p value		0.439		0.026		0.029
2010						
Less than daily	1	0 (0)	47	34 (72)	49	35 (71)
Daily or more	0	0 (0)	35	24 (69)	36	25 (69)
Not last month	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.037		0.039
2011						
Less than daily	2	1 (50)	34	22 (65)	36	23 (64)
Daily or more	1	1 (100)	45	28 (62)	45	28 (62)
Not last month	0	0 (0)	8	2 (25)	10	3 (30)
p value		1.000		0.122		0.171

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	1	1 (100)	7	5 (71)	8	6 (75)
Receptive sharing	0	0 (0)	5	5 (100)	6	6 (100)
p value		---		0.470		0.473
2008						
No receptive sharing	1	0 (0)	20	13 (65)	21	13 (62)
Receptive sharing	0	0 (0)	5	5 (100)	5	5 (100)
p value		---		0.274		0.281
2009						
No receptive sharing	5	1 (20)	41	23 (56)	46	24 (52)
Receptive sharing	0	0 (0)	6	5 (83)	7	6 (86)
p value		0.123		1.000		1.000
2010						
No receptive sharing	1	0 (0)	60	39 (65)	62	40 (65)
Receptive sharing	0	0 (0)	13	12 (92)	14	13 (93)
p value		--		0.092		0.052
2011						
No receptive sharing	2	1 (50)	69	47 (68)	71	48 (68)
Receptive sharing	0	0 (0)	8	2 (25)	8	2 (25)
p value		--		0.024		0.046

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 2.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	1	1 (100)	14	12 (86)	16	14 (88)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2008						
No imprisonment	1	0 (0)	20	15 (75)	21	15 (71)
Imprisonment	0	0 (0)	2	1 (50)	2	1 (50)
p value		---		0.481		0.526
2009						
No imprisonment	5	2 (40)	44	27 (61)	49	29 (59)
Imprisonment	1	0 (0)	5	3 (60)	7	4 (57)
p value		1.000		1.000		1.000
2010						
No imprisonment	1	0 (0)	66	43 (65)	67	43 (64)
Imprisonment	0	0 (0)	12	9 (75)	13	10 (77)
p value		--		0.741		0.526
2011						
No imprisonment	2	1 (50)	80	47 (59)	83	48 (58)
Imprisonment	1	1 (100)	5	3 (60)	6	4 (67)
p value		1.000		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 2.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	1	1 (100)	15	13 (87)	17	15 (88)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
No sex work	1	0 (0)	23	16 (70)	24	16 (67)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
No sex work	6	2 (33)	48	30 (63)	55	33 (60)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2010						
No sex work	1	0 (0)	80	53 (66)	83	55 (66)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		1.000		1.000
2011						
No sex work	4	3 (75)	81	48 (59)	86	51 (59)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.515		0.515

* Total includes people who did not report duration of drug injection

Table 2.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	10	10 (100)	7	6 (86)	17	16 (94)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
Non Indigenous	13	8 (62)	7	5 (71)	20	13 (65)
Indigenous	4	3 (75)	0	0 (0)	4	3 (75)
p value		1.000		---		1.000
2009						
Non Indigenous	35	21 (60)	17	10 (59)	52	31 (60)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.417		0.566		0.303
2010						
Non Indigenous	60	43 (72)	17	12 (71)	77	55 (71)
Indigenous	9	5 (56)	8	3 (38)	17	8 (47)
p value		0.439		0.194		0.085
2011						
Non Indigenous	53	37 (70)	27	11 (41)	80	48 (60)
Indigenous	8	6 (75)	3	1 (33)	11	7 (64)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	10	10 (100)	8	6 (75)	18	16 (89)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
English speaking	18	12 (67)	7	5 (71)	25	17 (68)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	35	21 (60)	21	13 (62)	56	34 (61)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.417		0.409		0.167
2010						
English speaking	68	46 (68)	25	15 (60)	93	61 (66)
Non-English speaking	2	2 (100)	0	0 (0)	2	2 (100)
p value		1.000		--		0.548
2011						
English speaking	58	42 (72)	31	12 (39)	89	54 (61)
Non-English speaking	4	2 (50)	0	0 (0)	4	2 (50)
p value		0.573		--		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 2.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	10	10 (100)	6	5 (83)	16	15 (94)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		0.464		0.216
2008						
Australia	16	11 (69)	6	4 (67)	22	15 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.569		1.000		0.704
2009						
Australia	27	18 (67)	18	12 (67)	45	30 (67)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	1 (20)	3	1 (33)	8	2 (25)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.055		0.352		0.015
2010						
Australia	65	45 (69)	23	15 (65)	88	60 (68)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	0 (0)	4	2 (50)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.124		0.071		0.168
2011						
Australia	57	41 (72)	26	11 (42)	83	52 (63)
Other Oceania	2	2 (100)	2	0 (0)	4	2 (50)
Asia	0	0 (0)	0	0 (0)	4	2 (50)
UK & Ireland	1	1 (100)	3	1 (33)	0	0 (0)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.156		0.774		0.258

* Total includes people whose gender was not reported or reported as transgender

New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	22	22	20	22	21
N° surveyed	N=701	N=899	N=830	N=680	N=694
Response (%)	37%	36%	39%	40%	36%
Gender (%)					
Male	450 (64)	582 (65)	500 (60)	427 (63)	463 (67)
Female	247 (35)	310 (34)	322 (39)	247 (36)	228 (33)
Transgender	3 (<1)	4 (<1)	7 (<1)	5 (1)	3 (<1)
Not reported	1 (<1)	3 (<1)	1 (<1)	1 (<1)	0 (0)
Sexual identity (%)					
Heterosexual	575 (82)	715 (80)	669 (81)	545 (80)	563 (81)
Bisexual	64 (9)	93 (10)	77 (9)	76 (11)	61 (9)
Homosexual	45 (6)	56 (6)	40 (5)	25 (4)	38 (5)
Not reported	17 (2)	35 (4)	44 (5)	34 (5)	32 (5)
Age and duration of injection (years)					
<i>Median age</i>	37	37	38	39	38
<i>Age range</i>	16-69	17-70	18-64	18-69	18-63
Age group (%)					
<25 years	59 (8)	81 (9)	66 (8)	54 (8)	51 (7)
25+ years	642 (92)	815 (91)	764 (92)	626 (92)	640 (92)
Not reported	0 (0)	3 (<1)	0 (0)	0 (0)	3 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	19
<i>Age range</i>	10-56	10-60	10-57	10-63	10-47
<i>N° not reported</i>	21	18	17	22	23
<i>Median years IDU</i>	16	17	17	18	17
<i>Range</i>	<1-49	<1-48	<1-45	<1-45	<1-46
Duration of drug injection (%)					
<3 years	23 (3)	46 (5)	47 (6)	48 (7)	64 (9)
<3+ years	657 (94)	835 (93)	766 (92)	610 (90)	606 (87)
Not reported	21 (3)	18 (2)	17 (2)	22 (3)	24 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	575 (82)	736 (82)	682 (82)	565 (83)	582 (84)
Yes	105 (15)	131 (15)	122 (15)	96 (14)	91 (13)
Not reported	21 (3)	32 (4)	26 (3)	19 (3)	21 (3)
Region/Country of birth (%)					
Australia	592 (84)	781 (87)	726 (87)	581 (85)	588 (85)
Other Oceania	18 (3)	31 (3)	18 (2)	24 (4)	21 (3)
Asia	10 (1)	8 (1)	4 (<1)	10 (1)	12 (2)
UK & Ireland	26 (4)	38 (4)	37 (4)	23 (3)	27 (4)
Other	38 (5)	28 (3)	28 (3)	24 (4)	33 (5)
Not reported	17 (2)	13 (1)	17 (2)	18 (3)	13 (2)
Main language spoken at home by parents (%)					
English speaking	648 (92)	844 (94)	787 (95)	645 (95)	643 (93)
Non-English speaking	37 (5)	40 (4)	33 (4)	23 (3)	40 (6)
Not reported	16 (2)	15 (2)	10 (1)	12 (2)	11 (2)
Imprisonment last year (%)*					
No	566 (81)	687 (76)	684 (82)	492 (72)	567 (82)
Yes	103 (15)	137 (15)	103 (12)	77 (11)	82 (12)
Not reported	32 (5)	75 (8)	43 (5)	111 (16)	45 (2)
Injected in prison (%)					
Yes	N=103 37 (36)	N=137 46 (34)	N=103 30 (29)	N=77 20 (26)	N=82 18 (22)
Frequency of injection last month (%)					
Not last month	81 (12)	126 (14)	129 (16)	119 (18)	105 (15)
Less than weekly	136 (19)	146 (16)	150 (18)	128 (19)	119 (17)
Weekly not daily	167 (24)	229 (25)	200 (24)	134 (20)	167 (24)
Daily or more	298 (43)	392 (44)	337 (41)	284 (42)	285 (41)
Not reported	19 (3)	6 (1)	14 (2)	15 (2)	18 (3)

Table 3.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=701	N=899	N=830	N=680	N=694
Cocaine	30 (4)	45 (5)	51 (6)	19 (3)	12 (2)
Heroin	254 (36)	346 (39)	306 (37)	236 (35)	211 (30)
Methadone	88 (13)	107 (12)	116 (14)	59 (9)	79 (11)
Methamphetamine	185 (26)	230 (26)	181 (22)	201 (30)	198 (29)
Performance/Image-enhancing drugs	12 (2)	20 (2)	30 (4)	29 (4)	64 (9)
Pharmaceutical opioids	57 (8)	80 (9)	80 (10)	62 (9)	70 (10)
Suboxone	--	--	6 (<1)	2 (<1)	1 (<1)
Subutex/Buprenorphine	20 (3)	27 (3)	16 (2)	16 (2)	16 (2)
More than one	26 (4)	21 (2)	23 (3)	36 (5)	27 (4)
Other drug	18 (3)	8 (1)	0 (0)	16 (2)	15 (2)
Not reported	11 (2)	15 (2)	21 (3)	4 (<1)	1 (<1)
N° Injected last month	N=601	N=767	N=687	N=548	N=571
Places injected last month (%)*					
Own home	517 (88)	673 (89)	610 (90)	465 (85)	492 (86)
Friend's home	226 (39)	316 (42)	244 (36)	205 (37)	182 (32)
Dealer's home	101 (17)	120 (16)	94 (14)	73 (13)	70 (12)
Street, park, beach	143 (24)	165 (22)	130 (19)	82 (15)	76 (13)
Car	159 (27)	181 (24)	158 (23)	117 (21)	101 (18)
Public toilet	137 (23)	163 (22)	126 (19)	86 (16)	82 (14)
Commercial injecting room	39 (7)	40 (5)	42 (6)	28 (5)	26 (5)
Squat	39 (7)	50 (7)	32 (5)	25 (5)	17 (3)
MSIC	62 (11)	64 (8)	60 (9)	38 (7)	41 (7)
Use of new sterile needles & syringes last month (%)					
All injections	431 (72)	544 (71)	500 (73)	368 (67)	439 (77)
Most of the time	130 (22)	174 (23)	157 (23)	108 (20)	95 (17)
Half of the time	17 (3)	22 (3)	10 (1)	14 (3)	9 (2)
Some of the time	9 (2)	11 (1)	9 (1)	11 (2)	7 (1)
Not last month	---	7 (1)	2 (<1)	6 (1)	1 (<1)
Not reported	14 (2)	9 (1)	9 (1)	41 (7)	20 (4)
Re-used another's used needle & syringe last month (%)					
None	485 (81)	604 (79)	560 (82)	400 (73)	486 (85)
Once	42 (7)	50 (7)	44 (6)	33 (6)	25 (4)
Twice	19 (3)	42 (5)	33 (5)	19 (3)	16 (3)
3-5 times	17 (3)	26 (3)	18 (3)	16 (3)	12 (2)
>5 times	6 (1)	22 (3)	17 (2)	15 (3)	5 (1)
Not reported	32 (5)	23 (3)	15 (2)	65 (12)	27 (5)
Number of people needle & syringe was re-used after last month (%)					
None	485 (81)	604 (79)	560 (82)	400 (73)	486 (85)
One	42 (7)	66 (9)	53 (8)	33 (6)	27 (5)
Two	7 (1)	11 (1)	6 (1)	7 (1)	4 (<1)
Three to five	5 (<1)	10 (1)	3 (<1)	8 (1)	2 (<1)
More than five	2 (<1)	3 (<1)	2 (<1)	4 (<1)	0 (0)
Don't know	12 (2)	30 (4)	18 (3)	11 (2)	16 (3)
Not reported	48 (8)	43 (6)	45 (7)	85 (16)	36 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	36 (6)	56 (7)	39 (6)	53 (10)	48 (8)
Casual sex partner	2 (<1)	7 (1)	3 (<1)	6 (1)	1 (<1)
Close friend	27 (4)	39 (5)	16 (2)	23 (4)	21 (4)
Acquaintance	12 (2)	12 (2)	13 (2)	11 (2)	11 (2)
Other	4 (<1)	8 (1)	11 (2)	13 (2)	12 (2)
Equipment used after someone else last month (%)*					
Spoon	134 (25)	160 (23)	127 (20)	93 (17)	94 (16)
Water	101 (19)	114 (16)	81 (13)	64 (12)	64 (11)
Filter	62 (11)	78 (11)	52 (8)	36 (7)	39 (7)
Drug mix	45 (8)	50 (7)	52 (8)	29 (5)	35 (6)
Tourniquet	58 (11)	74 (11)	57 (9)	--	--
None**	353 (65)	457 (66)	420 (68)	370 (68)	432 (76)
Injected by someone after that person injected themselves or others last month (%)					
No	494 (82)	631 (82)	592 (86)	432 (79)	484 (85)
Yes	77 (13)	110 (14)	76 (11)	52 (9)	66 (12)
Not reported	30 (5)	26 (3)	19 (3)	64 (12)	21 (4)

* More than one option could be selected

Table 3.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=701	N=899	N=830	N=680	N=694
Sex with a regular partner last month (%)					
No	300 (43)	392 (44)	369 (44)	280 (41)	307 (44)
Yes	375 (54)	481 (54)	439 (53)	370 (54)	334 (48)
Not reported	26 (4)	26 (3)	22 (3)	30 (4)	53 (8)
Condom used with regular partner last month (%)					
N° surveyed	N=375	N=481	N=439	N=370	N=334
Never	275 (73)	330 (69)	378 (86)	273 (74)	238 (71)
Sometimes	38 (10)	61 (13)	43 (10)	42 (11)	32 (10)
Every time	49 (13)	69 (14)	2 (<1)	35 (9)	46 (14)
Not reported	13 (3)	21 (4)	16 (4)	20 (5)	18 (5)
Sex with other partner/s last month (%)					
No	570 (81)	705 (78)	665 (80)	532 (78)	557 (80)
Yes	100 (14)	165 (18)	126 (15)	103 (15)	102 (15)
Not reported	31 (4)	29 (3)	39 (5)	45 (7)	35 (5)
Condom used with other partner/s last month (%)					
N° surveyed	N=100	N=165	N=126	N=103	N=102
Never	28 (28)	38 (23)	47 (37)	44 (43)	27 (26)
Sometimes	17 (17)	39 (24)	22 (17)	17 (17)	28 (27)
Every time	47 (47)	79 (48)	55 (44)	39 (38)	46 (45)
Not reported	8 (8)	9 (5)	2 (2)	3 (3)	1 (1)
Sex work last month (%)					
No	618 (88)	771 (86)	740 (89)	568 (84)	618 (89)
Yes	50 (7)	78 (9)	57 (7)	51 (8)	38 (5)
Not reported	33 (5)	50 (6)	33 (4)	61 (9)	38 (5)
Condom used at last sex work last month (%)					
Yes	47 (98)	57 (84)	52 (91)	39 (80)	30 (83)

Table 3.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=701	N=899	N=830	N=680	N=694
Previous HIV test (%)					
Yes, last year	392 (56)	443 (49)	423 (51)	337 (50)	331 (48)
> 1 year ago	228 (33)	334 (37)	304 (37)	227 (33)	244 (35)
Never tested	65 (9)	73 (8)	69 (8)	69 (10)	92 (13)
Not reported	16 (2)	49 (5)	34 (4)	47 (7)	27 (4)
Previous HCV test (%)					
Yes, last year	420 (60)	494 (55)	497 (60)	357 (53)	354 (51)
> 1 year ago	215 (31)	327 (36)	265 (32)	216 (32)	229 (33)
Never tested	52 (7)	45 (5)	39 (5)	59 (9)	67 (10)
Not reported	14 (2)	33 (4)	29 (3)	48 (7)	44 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=344	N=546	N=508	N=368	N=364
Interferon/Interferon+Ribavirin	12 (3)	53 (10)	50 (10)	47 (13)	36 (10)
Other	4 (1)	5 (1)	3 (<1)	5 (1)	4 (1)
No treatment	312 (91)	470 (86)	432 (85)	301 (82)	296 (81)
Not reported	16 (5)	18 (3)	23 (5)	15 (4)	28 (8)
Current treatment for HCV	N=3	N=13	N=6	N=14	N=13
Interferon/Interferon+Ribavirin	2	9	5	11	7
Other	1	4	1	3	3

Table 3.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=701	N=899	N=830	N=680	N=694
Any treatment/therapy for drug use (%)					
No	106 (15)	128 (14)	112 (13)	111 (16)	525 (76)
Yes	578 (82)	754 (84)	704 (85)	551 (81)	138 (20)
Not reported	17 (2)	17 (2)	14 (2)	18 (3)	31 (4)
History of methadone maintenance treatment (%)					
Currently	286 (41)	379 (42)	396 (48)	279 (41)	273 (39)
Previously	182 (26)	219 (24)	177 (21)	143 (21)	128 (18)
Never	218 (31)	281 (31)	236 (28)	218 (32)	245 (35)
Not reported	15 (2)	20 (2)	21 (3)	40 (6)	48 (7)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	120 (13)	91 (11)	60 (9)	60 (9)
Previously	--	193 (21)	213 (26)	176 (26)	156 (22)
Never	--	564 (63)	500 (60)	435 (64)	443 (64)
Not reported	--	22 (2)	26 (3)	7 (1)	35 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	26 (3)	37 (4)	30 (4)	39 (6)
Previously	--	59 (7)	76 (9)	68 (10)	82 (12)
Never	--	782 (87)	687 (87)	567 (83)	535 (77)
Not reported	--	32 (4)	1 (1)	15 (2)	38 (5)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=352
Yes, in the last month					14 (4)
Yes, 1-6 months ago					5 (1)
Yes, 6-12 months ago					4 (1)
Yes, more than one year ago					25 (7)
No, haven't tried to access OST					304 (86)

* New variable in 2008

Table 3.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=601	N=767	N=687	N=548	N=571
Needle Syringe Program	435 (72)	687 (90)	474 (69)	491 (69)	521 (91)
Chemist/Pharmacy	130 (22)	334 (44)	139 (20)	139 (20)	96 (17)
Personal sources	82 (14)	--	79 (12)	79 (12)	39 (7)
Dispensing/Vending Machine	125 (21)	--	129 (19)	129 (19)	95 (17)
Other sources	28 (5)	--	22 (3)	22 (3)	18 (3)

* More than one option could be selected

Table 3.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=694
Never	260 (37)
Monthly or less	166 (24)
2-4 times a month	88 (13)
2-3 times a week	81 (12)
4 or more times a week	75 (11)
Not reported	24 (3)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	
N=410	
1 or 2	128 (31)
3 or 4	112 (27)
5 or 6	58 (14)
7, 8 or 9	34 (8)
10 or more	50 (12)
Not reported	28 (7)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
2008	563	15 (2.7)	297	3 (1.0)	867	19 (2.2)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
2010	422	8 (1.9)	243	0 (0.0)	671	8 (1.2)
2011	455	5 (1.1)	224	1 (0.5)	682	7 (1.0)
χ^2 trend p value		0.060		0.160		0.027

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
p value		<0.001		0.207		<0.001
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
p value		<0.001		---		<0.001
2010						
Heterosexual	371	1 (0.3)	166	0 (0.0)	539	1 (0.2)
Bisexual	14	0 (0.0)	58	0 (0.0)	74	0 (0.0)
Homosexual	15	7 (46.7)	8	0 (0.0)	24	7 (29.2)
p value		<0.001		--		<0.001
2011						
Heterosexual	397	1 (0.3)	158	0 (0.0)	555	1 (0.2)
Bisexual	17	1 (5.6)	40	1 (2.5)	59	3 (5.1)
Homosexual	21	3 (14.3)	15	0 (0.0)	37	3 (8.1)
p value		<0.001		0.258		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.3 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
< 25 years	28	0 (0.0)	28	0 (0.0)	56	0 (0.0)
25 – 34	142	4 (2.8)	74	0 (0.0)	217	4 (1.8)
35+ years	269	8 (3.0)	138	2 (1.5)	410	11 (2.7)
p value		0.654		0.475		0.399
2008						
< 25 years	45	0 (0.0)	34	0 (0.0)	79	0 (0.0)
25 – 34	167	4 (2.4)	101	3 (3.0)	270	8 (3.0)
35+ years	348	11 (3.2)	162	0 (0.0)	515	11 (2.1)
p value		0.449		0.053		0.284
2009						
< 25 years	26	0 (0.0)	38	0 (0.0)	64	0 (0.0)
25 – 34	135	2 (1.5)	109	0 (0.0)	244	2 (0.8)
35+ years	324	10 (3.1)	173	0 (0.0)	505	11 (2.2)
p value		0.425		--		0.217
2010						
< 25 years	27	1 (3.7)	25	0 (0.0)	53	1 (1.9)
25 – 34	107	1 (0.9)	85	0 (0.0)	192	1 (0.5)
35+ years	286	4 (1.4)	133	0 (0.0)	424	4 (0.9)
p value		0.556		--		0.504
2011						
< 25 years	40	1 (2.5)	10	0 (0.0)	50	1 (2.0)
25 – 34	123	0 (0.0)	88	1 (1.1)	212	1 (0.5)
35+ years	290	3 (8.1)	125	0 (0.0)	417	5 (1.2)
p value		<0.001		0.439		0.444

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.4 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3 to 10 years	92	1 (1.1)	61	0 (0.0)	155	1 (0.6)
11 + years	326	11 (3.4)	158	2 (1.3)	486	14 (2.9)
p value		0.426		0.631		0.204
2008						
<3 years	33	3 (9.1)	15	0 (0.0)	48	3 (6.3)
3 to 10 years	114	2 (1.8)	64	0 (0.0)	179	2 (3.4)
11 + years	400	10 (2.5)	217	3 (1.4)	622	14 (2.3)
p value		0.056		0.580		0.087
2009						
<3 years	30	2 (6.7)	16	0 (0.0)	46	2 (4.4)
3 to 10 years	66	2 (3.0)	68	0 (0.0)	135	2 (1.5)
11 + years	382	8 (2.1)	229	0 (0.0)	618	9 (1.5)
p value		0.292		--		0.323
2010						
<3 years	30	1 (3.3)	16	0 (0.0)	47	1 (2.1)
3 to 10 years	59	0 (0.0)	50	0 (0.0)	109	0 (0.0)
11 + years	317	5 (1.6)	170	0 (0.0)	492	5 (1.0)
p value		0.521		--		0.290
2011						
<3 years	51	0 (0.0)	10	0 (0.0)	61	0 (0.0)
3 to 10 years	78	3 (3.9)	34	0 (0.0)	112	2 (2.7)
11 + years	306	2 (0.7)	177	1 (0.6)	486	4 (0.8)
p value		0.064		1.000		0.224

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.5 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Methamphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
Other	168	4 (2.4)	76	1 (1.3)	246	6 (2.4)
p value		0.772		0.538		0.712
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Methamphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
Other	197	2 (1.0)	101	1 (1.0)	300	3 (1.0)
p value		<0.001		0.947		<0.001
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.7)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
Other	198	3 (1.5)	113	0 (0.0)	315	4 (1.3)
p value		0.004		--		0.016
2010						
Heroin	136	1 (0.7)	93	0 (0.0)	231	1 (0.4)
Methamphetamine	120	3 (2.5)	75	0 (0.0)	197	3 (1.5)
Other	162	2 (1.2)	73	0 (0.0)	237	2 (0.8)
p value		0.589		--		0.523
2011						
Heroin	123	0 (0.0)	82	0 (0.0)	207	1 (0.5)
Methamphetamine	118	4 (3.4)	76	0 (0.0)	195	4 (2.1)
Other	213	1 (0.5)	66	1 (1.5)	279	2 (0.7)
p value		0.026		0.295		0.308

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Less than daily	186	4 (2.2)	106	1 (0.9)	295	6 (2.0)
Daily or more	196	6 (3.1)	96	1 (1.0)	292	7 (2.4)
Not last month	47	2 (4.3)	32	0 (0.0)	80	2 (2.5)
p value		0.703		0.850		0.944
2008						
Less than daily	244	8 (3.3)	114	1 (0.9)	362	9 (2.5)
Daily or more	239	4 (1.7)	135	1 (0.7)	376	6 (1.6)
Not last month	77	3 (3.9)	45	1 (2.2)	123	4 (3.3)
p value		0.427		0.680		0.496
2009						
Less than daily	194	5 (2.6)	146	0 (0.0)	341	5 (1.5)
Daily or more	207	4 (1.9)	121	0 (0.0)	332	5 (1.5)
Not last month	78	3 (3.9)	48	0 (0.0)	127	3 (2.4)
p value		0.652		--		0.770
2010						
Less than daily	179	3 (1.7)	100	0 (0.0)	281	3 (1.1)
Daily or more	171	3 (1.8)	84	0 (0.0)	257	3 (1.2)
Not last month	59	0 (0.0)	56	0 (0.0)	117	0 (0)
p value		0.871		--		0.749
2011						
Less than daily	192	2 (1.0)	87	0 (0.0)	281	3 (1.1)
Daily or more	188	1 (0.5)	91	1 (1.1)	280	2 (0.7)
Not last month	60	1 (1.7)	43	0 (0.0)	103	1 (1.0)
p value		0.513		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 3 HIV antibody prevalence by re-use of someone else's used needle & syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No receptive sharing	306	6 (2.0)	165	2 (1.2)	474	9 (1.9)
Receptive sharing	56	4 (7.1)	26	0 (0.0)	82	4 (4.9)
p value		0.053		1.000		0.110
2008						
No receptive sharing	388	11 (2.8)	190	2 (1.1)	584	14 (2.4)
Receptive sharing	79	1 (1.3)	52	0 (0.0)	131	1 (0.8)
p value		0.700		1.000		0.328
2009						
No receptive sharing	337	9 (2.7)	210	0 (0.0)	554	10 (1.8)
Receptive sharing	56	0 (0.0)	53	0 (0.0)	109	0 (0.0)
p value		0.370		---		0.381
2010						
No receptive sharing	259	8 (3.1)	133	0 (0.0)	394	8 (2.0)
Receptive sharing	50	0 (0.0)	32	0 (0.0)	83	0 (0.0)
p value		0.363		--		0.361
2011						
No receptive sharing	322	2 (0.6)	154	1 (0.7)	477	3 (0.6)
Receptive sharing	39	1 (2.6)	19	0 (0.0)	58	1 (1.7)
p value		0.291		1.000		0.369

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no injection last month

Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No imprisonment	342	10 (2.9)	205	2 (1.0)	550	12 (2.2)
Imprisonment	76	2 (2.6)	26	0 (0.0)	102	2 (2.0)
p value		1.000		1.000		1.000
2008						
No imprisonment	416	14 (3.4)	240	0 (0.0)	662	15 (2.3)
Imprisonment	98	1 (1.0)	32	2 (6.3)	131	3 (2.3)
p value		0.323		0.013		1.000
2009						
No imprisonment	394	12 (3.1)	273	0 (0.0)	675	13 (1.9)
Imprisonment	70	0 (0.0)	32	0 (0.0)	102	0 (0.0)
p value		0.228		---		0.236
2010						
No imprisonment	291	7 (2.4)	190	0 (0.0)	486	7 (1.4)
Imprisonment	54	0 (0.0)	22	0 (0.0)	76	0 (0.0)
p value		0.602		--		0.602
2011						
No imprisonment	385	5 (1.3)	185	0 (0.0)	572	6 (1.1)
Imprisonment	53	0 (0.0)	26	1 (3.9)	80	1 (1.3)
p value		1.000		0.123		0.602

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.9 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No condom use	181	2 (1.1)	119	2 (1.7)	303	5 (1.7)
Condom use	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.361		1.000		0.589
2008						
No condom use	226	1 (0.4)	150	0 (0.0)	378	1 (0.3)
Condom use	43	1 (2.3)	22	1 (4.6)	67	3 (1.5)
p value		0.295		0.128		0.012
2009						
No condom use	197	1 (0.5)	175	0 (0.0)	374	1 (0.3)
Condom use	31	2 (6.5)	10	0 (0.0)	41	2 (4.9)
p value		0.049		---		0.027
2010						
No condom use	163	3 (1.8)	106	0 (0.0)	270	3 (1.1)
Condom use	48	0 (0.0)	27	0 (0.0)	76	0 (0.0)
p value		1.000		--		1.000
2011						
No condom use	152	3 (2.0)	83	0 (0.0)	235	3 (1.3)
Condom use	51	2 (3.9)	24	1 (4.2)	76	3 (4.0)
p value		0.601		0.224		0.159

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 3.2.10 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No sex work	407	11 (2.7)	190	2 (1.1)	600	13 (2.2)
Sex work	9	1 (11.1)	40	0 (0.0)	50	2 (4.0)
p value		0.234		1.000		0.323
2008						
No sex work	511	13 (2.5)	229	3 (1.3)	745	16 (2.2)
Sex work	23	2 (8.7)	49	0 (0.0)	73	3 (4.1)
p value		0.133		1.000		0.236
2009						
No sex work	462	10 (2.2)	261	0 (0.0)	729	11 (1.5)
Sex work	7	2 (28.6)	48	0 (0.0)	57	2 (3.5)
p value		0.012		---		0.243
2010						
No sex work	374	6 (1.6)	183	0 (0.0)	561	6 (1.1)
Sex work	9	1 (11.1)	41	0 (0.0)	51	1 (2.0)
p value		0.154		--		0.458
2011						
No sex work	416	4 (1.0)	192	0 (0.0)	609	4 (0.7)
Sex work	6	0 (0.0)	28	1 (3.6)	36	2 (5.6)
p value		1.000		0.127		0.039

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Non Indigenous	366	10 (2.8)	190	2 (1.1)	559	12 (2.2)
Indigenous	56	1 (1.8)	47	0 (0.0)	104	2 (1.9)
p value		1.000		1.000		1.000
2008						
Non Indigenous	469	13 (2.8)	234	1 (0.4)	709	15 (2.1)
Indigenous	71	1 (1.4)	54	2 (3.7)	126	3 (2.4)
p value		1.000		0.091		0.744
2009						
Non Indigenous	422	11 (2.6)	245	0 (0.0)	672	11 (1.6)
Indigenous	48	1 (2.1)	70	0 (0.0)	120	2 (1.7)
p value		1.000		---		1.000
2010						
Non Indigenous	357	7 (2.0)	197	0 (0.0)	558	5 (1.3)
Indigenous	52	1 (1.9)	42	0 (0.0)	96	1 (1.0)
p value		1.000		--		1.000
2011						
Non Indigenous	395	5 (1.3)	178	0 (0.0)	574	5 (0.9)
Indigenous	47	0 (0.0)	40	1 (2.5)	88	2 (2.3)
p value		1.000		0.183		0.236

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
English speaking	403	12 (3.0)	225	2 (0.9)	632	15 (2.4)
Non-English speaking	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
2008						
English speaking	525	15 (2.9)	284	3 (1.1)	816	19 (2.3)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		1.000		1.000		1.000
2009						
English speaking	461	12 (2.6)	307	0 (0.0)	776	13 (1.7)
Non-English speaking	21	0 (0.0)	11	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	398	8 (2.0)	234	0 (0.0)	638	8 (1.3)
Non-English speaking	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		1.000		--		1.000
2011						
English speaking	67	0 (0.0)	23	0 (0.0)	91	0 (0.0)
Non-English speaking	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
p value		1.000		1.000		0.602

* Total includes people whose gender was not reported or reported as transgender

Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Australia	365	11 (3.0)	208	2 (1.0)	576	14 (2.4)
Other Oceania	9	1 (11.1)	8	0 (0.0)	18	1 (5.6)
Asia	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	9	0 (0.0)	37	0 (0.0)
p value		0.461		1.000		0.643
2008						
Australia	485	12 (2.5)	266	3 (1.1)	755	15 (2.0)
Other Oceania	14	2 (14.3)	10	0 (0.0)	26	3 (11.2)
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
UK & Ireland	25	0 (0.0)	9	0 (0.0)	35	0 (0.0)
Other	27	1 (3.7)	7	0 (0.0)	34	1 (2.9)
p value		0.135		1.000		0.063
2009						
Australia	417	12 (2.9)	292	0 (0.0)	714	13 (1.8)
Other Oceania	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other	17	0 (0.0)	9	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2010						
Australia	355	7 (2.0)	216	0 (0.0)	575	7 (1.2)
Other Oceania	12	1 (8.3)	11	0 (0.0)	24	1 (4.2)
Asia	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
UK & Ireland	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
Other	22	0 (0.0)	4	0 (0.0)	26	0 (0.0)
p value		0.483		--		0.654
2011						
Australia	378	5 (1.3)	199	1 (0.5)	579	7 (1.2)
Other Oceania	10	0 (0.0)	11	0 (0.0)	21	0 (0.0)
Asia	10	0 (0.0)	2	0 (0.0)	12	0 (0.0)
UK & Ireland	19	0 (0.0)	6	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	4	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	428	289 (68)	231	169 (73)	663	460 (69)
2008	539	379 (70)	281	208 (74)	827	591 (71)
2009	485	272 (56)	320	193 (60)	813	468 (58)
2010	422	228 (54)	243	135 (56)	671	365 (54)
2011	448	220 (49)	219	129 (59)	670	350 (52)
χ^2 trend p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	374	264 (71)	166	121 (73)	541	386 (71)
Bisexual	20	11 (55)	41	34 (83)	62	45 (73)
Homosexual	24	8 (33)	19	9 (47)	43	17 (40)
p value		<0.001		0.020		<0.001
2008						
Heterosexual	468	337 (72)	191	144 (75)	660	481 (73)
Bisexual	24	17 (71)	59	45 (76)	84	62 (74)
Homosexual	29	12 (41)	20	13 (65)	51	26 (51)
p value		0.003		0.564		0.005
2009						
Heterosexual	421	238 (57)	232	134 (58)	655	373 (57)
Bisexual	21	13 (62)	53	41 (77)	76	54 (71)
Homosexual	22	5 (23)	15	7 (47)	39	12 (31)
p value		0.004		0.012		<0.001
2010						
Heterosexual	371	209 (56)	166	91 (55)	539	301 (56)
Bisexual	14	8 (57)	58	35 (60)	74	44 (59)
Homosexual	15	2 (13)	8	3 (38)	24	5 (21)
p value		0.003		0.422		0.002
2011						
Heterosexual	391	192 (49)	154	91 (59)	545	283 (52)
Bisexual	17	9 (53)	40	23 (58)	59	32 (54)
Homosexual	21	7 (33)	14	8 (57)	36	16 (44)
p value		0.340		0.969		0.641

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	25	6 (24)	27	16 (59)	52	22 (42)
25 – 34	139	85 (61)	72	51 (71)	212	137 (65)
35+ years	264	198 (75)	132	102 (77)	399	301 (75)
p value		<0.001		0.136		<0.001
2008						
< 25 years	43	15 (35)	34	22 (65)	77	37 (48)
25 – 34	157	99 (63)	98	70 (71)	257	170 (66)
35+ years	336	264 (79)	149	116 (78)	490	383 (78)
p value		<0.001		0.222		<0.001
2009						
< 25 years	26	2 (8)	38	17 (45)	64	19 (30)
25 – 34	135	66 (49)	109	66 (61)	244	132 (54)
35+ years	324	202 (62)	173	109 (63)	505	314 (62)
p value		<0.001		0.109		<0.001
2010						
< 25 years	27	4 (15)	25	16 (64)	53	20 (38)
25 – 34	107	49 (46)	85	39 (46)	192	88 (46)
35+ years	288	175 (61)	133	80 (60)	426	257 (60)
p value		<0.001		0.078		<0.001
2011						
< 25 years	40	4 (10)	10	5 (50)	50	9 (18)
25 – 34	120	49 (41)	86	46 (53)	207	95 (46)
35+ years	286	167 (58)	122	78 (64)	410	246 (60)
p value		<0.001		0.261		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	11	1 (9)	11	4 (36)	22	5 (23)
3 to 10 years	88	35 (40)	58	39 (67)	148	75 (51)
11 + years	319	247 (77)	153	119 (78)	474	367 (77)
p value		<0.001		0.006		<0.001
2008						
<3 years	32	7 (22)	13	6 (46)	45	13 (29)
3 to 10 years	106	55 (52)	63	40 (63)	170	95 (56)
11 + years	386	309 (80)	203	161 (79)	594	473 (80)
p value		<0.001		0.003		<0.001
2009						
<3 years	30	1 (3)	16	6 (38)	46	7 (15)
3 to 10 years	65	20 (31)	68	37 (54)	134	58 (43)
11 + years	380	249 (66)	229	147 (64)	616	398 (65)
p value		<0.001		0.052		<0.001
2010						
<3 years	30	3 (10)	16	5 (31)	47	8 (17)
3 to 10 years	59	20 (34)	50	28 (56)	109	48 (44)
11 + years	319	200 (63)	170	100 (59)	494	302 (61)
p value		<0.001		0.114		<0.001
2011						
<3 years	51	5 (10)	10	3 (30)	61	8 (13)
3 to 10 years	78	27 (35)	33	19 (58)	111	46 (41)
11 + years	299	183 (61)	173	107 (62)	475	291 (61)
p value		<0.001		0.156		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	10	2 (20)	229	163 (71)	241	167 (69)
Methamphetamine	6	3 (50)	162	110 (68)	172	116 (67)
Other	5	0 (0)	221	161 (73)	239	169 (71)
p value		0.114		0.526		0.763
2008						
Heroin	10	3 (30)	305	240 (79)	319	245 (77)
Methamphetamine	10	2 (20)	195	123 (63)	209	126 (60)
Other	25	8 (32)	252	195 (77)	286	209 (73)
p value		0.776		<0.001		<0.001
2009						
Heroin	10	3 (30)	289	187 (65)	301	190 (63)
Methamphetamine	10	3 (30)	164	85 (52)	177	90 (51)
Other	26	7 (15)	283	173 (61)	316	180 (57)
p value		0.050		0.023		0.025
2010						
Heroin	10	3 (30)	214	137 (64)	231	144 (62)
Methamphetamine	11	2 (18)	184	89 (48)	198	93 (47)
Other	26	3 (12)	201	122 (61)	238	126 (53)
p value		0.381		0.005		0.005
2011						
Heroin	5	3 (60)	196	104 (53)	206	109 (53)
Methamphetamine	7	2 (29)	178	98 (55)	190	100 (53)
Other	48	3 (6)	212	135 (64)	273	141 (52)
p value		0.004		0.068		0.961

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	11	2 (18)	272	202 (74)	287	208 (72)
Daily or more	10	3 (30)	265	180 (68)	282	189 (67)
Not last month	1	0 (0)	73	50 (68)	79	52 (66)
p value		0.696		0.243		0.287
2008						
Less than daily	22	2 (9)	318	224 (70)	344	229 (67)
Daily or more	15	8 (53)	332	263 (79)	357	277 (78)
Not last month	7	2 (29)	109	77 (71)	120	80 (67)
p value		0.012		0.024		0.003
2009						
Less than daily	17	3 (18)	321	196 (61)	342	200 (58)
Daily or more	20	2 (10)	305	184 (60)	330	190 (58)
Not last month	8	2 (25)	115	69 (60)	127	71 (56)
p value		0.586		0.973		0.880
2010						
Less than daily	25	2 (8)	253	135 (53)	282	138 (49)
Daily or more	13	4 (31)	235	149 (63)	258	155 (60)
Not last month	7	2 (29)	105	59 (56)	117	64 (55)
p value		0.131		0.073		0.033
2011						
Less than daily	28	4 (14)	242	127 (52)	275	132 (48)
Daily or more	18	3 (17)	247	155 (63)	275	160 (58)
Not last month	15	1 (7)	84	47 (56)	103	48 (47)
p value		0.793		0.069		0.029

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	14	4 (29)	439	309 (70)	460	320 (70)
Receptive sharing	5	1 (20)	72	53 (74)	79	56 (71)
p value		1.000		0.675		0.895
2008						
No receptive sharing	30	7 (23)	515	379 (74)	558	394 (71)
Receptive sharing	6	4 (67)	114	89 (78)	120	93 (78)
p value		0.057		0.345		0.146
2009						
No receptive sharing	34	3 (9)	510	307 (60)	551	314 (57)
Receptive sharing	3	2 (67)	105	66 (63)	109	68 (62)
p value		0.042		0.742		0.341
2010						
No receptive sharing	30	5 (17)	352	195 (55)	394	203 (52)
Receptive sharing	4	1 (25)	78	52 (67)	83	53 (64)
p value		0.559		0.077		0.052
2011						
No receptive sharing	42	6 (14)	414	234 (57)	468	243 (52)
Receptive sharing	1	1 (100)	55	41 (75)	56	42 (75)
p value		0.163		0.013		0.001

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 3.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	20	5 (25)	499	350 (70)	533	363 (68)
Imprisonment	0	0 (0)	95	72 (76)	99	76 (77)
p value		---		0.323		0.096
2008						
No imprisonment	39	11 (28)	582	412 (71)	632	428 (68)
Imprisonment	4	2 (50)	118	100 (85)	125	104 (83)
p value		0.572		0.001		<0.001
2009						
No imprisonment	41	4 (10)	615	360 (59)	673	369 (55)
Imprisonment	3	2 (67)	98	70 (71)	101	72 (71)
p value		0.045		0.020		0.002
2010						
No imprisonment	41	5 (12)	427	228 (53)	486	238 (49)
Imprisonment	1	0 (0)	74	55 (74)	76	56 (74)
p value		1.000		0.001		<0.001
2011						
No imprisonment	59	7 (12)	475	260 (55)	550	269 (49)
Imprisonment	1	1 (100)	73	55 (75)	77	58 (75)
p value		0.133		0.001		<0.001

* Total includes people who did not report duration of drug injection

Table 3.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	19	5 (26)	548	393 (72)	581	408 (70)
Sex work	1	0 (0)	45	32 (71)	49	33 (67)
p value		--		1.000		0.746
2008						
No sex work	41	12 (29)	659	483 (73)	714	502 (70)
Sex work	3	2 (67)	64	50 (78)	68	52 (76)
p value		0.234		0.459		0.330
2009						
No sex work	45	6 (13)	666	399 (60)	726	410 (56)
Sex work	1	1 (100)	55	40 (73)	57	41 (72)
p value		0.152		0.084		0.036
2010						
No sex work	39	4 (10)	504	293 (58)	561	303 (54)
Sex work	5	3 (60)	45	23 (51)	51	26 (51)
p value		0.023		0.432		0.770
2011						
No sex work	55	7 (13)	527	305 (58)	600	315 (53)
Sex work	0	0 (0)	32	18 (56)	34	19 (56)
p value		--		0.856		0.728

* Total includes people who did not report duration of drug injection

Table 3.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non-Indigenous	358	239 (67)	184	135 (73)	545	376 (69)
Indigenous	54	42 (78)	44	31 (70)	99	73 (74)
p value		0.118		0.708		0.405
2008						
Non-Indigenous	449	314 (70)	225	163 (72)	680	480 (71)
Indigenous	67	50 (75)	48	40 (83)	116	91 (78)
p value		0.475		0.146		0.094
2009						
Non-Indigenous	419	231 (55)	245	152 (62)	669	385 (58)
Indigenous	48	27 (56)	70	37 (53)	120	64 (53)
p value		1.000		0.269		0.484
2010						
Non-Indigenous	357	191 (54)	197	113 (57)	558	305 (55)
Indigenous	52	31 (60)	42	21 (50)	96	53 (55)
p value		0.458		0.397		1.000
2011						
Non-Indigenous	390	187 (48)	174	102 (59)	565	289 (51)
Indigenous	45	21 (47)	39	24 (62)	85	45 (53)
p value		1.000		0.857		0.816

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	392	266 (68)	216	158 (73)	612	426 (70)
Non-English speaking	23	16 (70)	14	10 (71)	37	26 (70)
p value		1.000		1.000		1.000
2008						
English speaking	503	352 (70)	268	197 (74)	778	553 (71)
Non-English speaking	27	21 (78)	8	7 (88)	35	28 (80)
p value		0.517		0.685		0.339
2009						
English speaking	458	258 (56)	307	183 (60)	773	444 (57)
Non-English speaking	21	10 (48)	11	8 (73)	32	18 (56)
p value		0.823		0.536		1.000
2010						
English speaking	398	220 (55)	234	128 (55)	638	350 (55)
Non-English speaking	17	6 (35)	6	4 (67)	23	10 (43)
p value		0.136		0.693		0.295
2011						
English speaking	413	197 (48)	206	125 (61)	622	323 (52)
Non-English speaking	28	17 (61)	10	4 (40)	38	21 (55)
p value		0.241		0.207		0.740

* Total includes people whose gender was not reported or reported as transgender

Table 3.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	356	237 (67)	200	145 (73)	559	384 (69)
Other Oceania	9	7 (78)	7	5 (71)	17	12 (71)
Asia	5	3 (60)	5	3 (60)	10	6 (60)
UK & Ireland	17	14 (82)	7	7 (100)	24	21 (88)
Other	28	21 (75)	9	7 (78)	37	28 (76)
p value		0.568		0.516		0.273
2008						
Australia	464	324 (70)	251	187 (75)	719	514 (71)
Other Oceania	14	10 (71)	9	5 (56)	25	15 (60)
Asia	5	5 (100)	1	0 (0)	6	5 (83)
UK & Ireland	24	17 (71)	9	7 (78)	34	25 (74)
Other	25	18 (72)	7	5 (71)	32	23 (72)
p value		0.796		0.356		0.761
2009						
Australia	414	234 (57)	292	171 (59)	711	406 (57)
Other Oceania	11	8 (73)	7	5 (71)	18	13 (72)
Asia	3	1 (33)	1	1 (100)	4	2 (50)
UK & Ireland	28	16 (57)	8	6 (75)	37	23 (62)
Other	17	9 (53)	9	8 (89)	28	18 (64)
p value		0.771		0.280		0.649
2010						
Australia	355	195 (55)	216	119 (55)	575	316 (55)
Other Oceania	12	8 (67)	11	8 (73)	24	16 (67)
Asia	9	4 (44)	1	1 (100)	10	5 (50)
UK & Ireland	14	10 (71)	8	2 (25)	22	12 (55)
Other	22	7 (32)	4	3 (75)	26	10 (38)
p value		0.122		0.217		0.372
2011						
Australia	373	177 (47)	194	118 (61)	569	296 (52)
Other Oceania	8	6 (75)	11	7 (64)	19	13 (68)
Asia	10	6 (60)	2	0 (0)	12	6 (50)
UK & Ireland	20	10 (50)	6	2 (33)	27	12 (44)
Other	28	14 (50)	4	2 (50)	32	16 (50)
p value		0.571		0.296		0.609

* Total includes people whose gender was not reported or reported as transgender

Northern Territory

Table 4.1.1 Number (percentage) of respondents by graphic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	3	3	3	3	3
N° surveyed	N=31	N=75	N=77	N=83	N=70
Response (%)	31%	43%	29%	31%	33%
Gender (%)					
Male	22 (71)	48 (64)	52 (68)	59 (71)	46 (66)
Female	9 (29)	27 (36)	25 (32)	24 (29)	23 (33)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	28 (90)	62 (83)	66 (86)	67 (81)	56 (80)
Bisexual	1 (3)	4 (5)	5 (6)	10 (12)	12 (17)
Homosexual	2 (6)	5 (7)	2 (3)	5 (6)	1 (1)
Not reported	0 (0)	4 (5)	4 (5)	1 (1)	1 (1)
Age and duration of injection (years)					
<i>Median age</i>	38	39	40	41	40
Age range	25-59	17-66	22-60	17-63	17-64
<i>Age group (%)</i>					
<25 years	0 (0)	3 (4)	4 (5)	6 (7)	4 (6)
25+ years	31 (100)	72 (96)	73 (95)	77 (93)	66 (94)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1stIDU</i>	17	18	18	18	19
Age range	12-42	13-58	12-42	12-46	12-44
Not reported	1	2	4	0	3
<i>Median years IDU</i>	18	16	18	19	16
Range	3-36	<1-35	1-37	<1-43	1-46
<i>Duration of drug injection (%)</i>					
<3 years	0 (0)	1 (1)	4 (5)	7 (8)	7 (10)
3+ years	30 (97)	72 (96)	69 (90)	76 (92)	60 (86)
Not reported	1 (3)	2 (3)	4 (5)	0 (0)	3 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	0 (0)	61 (81)	65 (84)	64 (77)	56 (80)
Yes	30 (97)	13 (17)	10 (13)	18 (22)	13 (19)
Not reported	1 (3)	1 (1)	2 (3)	1 (1)	1 (1)
Region/Country of birth (%)					
Australia	28 (90)	65 (87)	65 (84)	71 (86)	60 (86)
Other Oceania	1 (3)	2 (3)	2 (3)	3 (4)	0 (0)
Asia	0 (0)	0 (0)	2 (3)	0 (0)	2 (3)
UK & Ireland	1 (3)	3 (4)	2 (3)	6 (7)	8 (11)
Other	0 (0)	2 (3)	4 (5)	2 (2)	0 (0)
Not reported	1 (3)	3 (4)	2 (3)	1 (1)	0 (0)
Main language spoken at home by parents (%)					
English speaking	29 (94)	75 (100)	70 (91)	77 (93)	65 (93)
Non-English speaking	1 (3)	0 (0)	6 (7)	6 (7)	5 (7)
Not reported	1 (3)	0 (0)	1 (1)	0 (0)	0 (0)
Imprisonment last year (%)					
No	29 (94)	69 (92)	72 (94)	65 (78)	65 (93)
Yes	1 (3)	3 (4)	2 (3)	2 (2)	3 (4)
Not reported	1 (3)	3 (4)	3 (4)	16 (19)	2 (3)
Injected in prison (%)	N=1	N=3	N=2	N=2	N=3
Yes	1 (100)	0 (0)	1 (50)	1 (50)	1 (33)
Frequency of injection last month (%)					
Not last month	2 (6)	4 (5)	7 (9)	10 (12)	10 (14)
Less than weekly	3 (10)	8 (11)	13 (17)	13 (16)	7 (10)
Weekly not daily	6 (19)	11 (15)	15 (19)	13 (16)	7 (10)
Daily or more	20 (65)	52 (69)	42 (55)	45 (54)	46 (66)
Not reported	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)

Table 4.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=31	N=75	N=77	N=83	N=70
Cocaine	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Heroin	0 (0)	2 (3)	2 (3)	3 (4)	2 (3)
Methadone	5 (16)	4 (5)	7 (9)	3 (4)	2 (3)
Methamphetamine	5 (16)	13 (17)	20 (26)	21 (25)	16 (23)
Performance/Image-enhancing drugs	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
Pharmaceutical opioids	16 (52)	47 (63)	38 (49)	50 (60)	44 (63)
Suboxone	--	--	1 (1)	4 (5)	2 (3)
Subutex/Buprenorphine	4 (13)	1 (1)	1 (1)	1 (1)	0 (0)
More than one	0 (0)	2 (3)	1 (1)	0 (0)	1 (1)
Other drug	0 (0)	4 (5)	1 (1)	0 (0)	2 (3)
Not reported	1 (3)	2 (3)	4 (5)	0 (0)	0 (0)
N° Injected last month	N=29	N=71	N=70	N=71	N=60
Places injected last month (%)*					
Own home	26 (93)	67 (94)	62 (89)	54 (76)	48 (80)
Friend's home	8 (29)	27 (38)	34 (49)	40 (56)	30 (50)
Dealer's home	1 (4)	9 (13)	13 (19)	16 (23)	17 (28)
Street, park, beach	1 (4)	7 (10)	11 (16)	12 (17)	10 (17)
Car	3 (11)	8 (11)	18 (26)	14 (20)	12 (20)
Public toilet	6 (21)	9 (13)	9 (13)	15 (21)	11 (18)
Commercial injecting room	0 (0)	0 (0)	1 (1)	0 (0)	2 (3)
Squat	0 (0)	1 (1)	3 (4)	3 (4)	3 (5)
Use of new sterile needles & syringes last month (%)					
All injections	26 (90)	61 (86)	59 (84)	57 (80)	49 (82)
Most of the time	2 (7)	9 (13)	9 (13)	10 (14)	9 (15)
Half of the time	1 (3)	0 (0)	1 (1)	2 (3)	0 (0)
Some of the time	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)
Re-used another's used needle & syringe last month (%)					
None	26 (90)	65 (92)	62 (89)	62 (87)	48 (80)
Once	0 (0)	1 (1)	5 (7)	1 (1)	3 (5)
Twice	0 (0)	2 (3)	0 (0)	1 (1)	4 (7)
3-5 times	1 (3)	3 (4)	1 (1)	1 (1)	1 (2)
>5 times	0 (0)	0 (0)	1 (1)	0 (0)	1 (2)
Not reported	2 (7)	0 (0)	1 (1)	6 (8)	3 (5)
Number of people needle & syringe was re-used after last month (%)					
None	26 (90)	65 (92)	62 (89)	62 (87)	48 (80)
One	0 (0)	2 (3)	2 (3)	2 (3)	6 (10)
Two	0 (0)	1 (1)	0 (0)	1 (1)	1 (2)
Three to five	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
More than five	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	1 (1)	2 (3)	0 (0)	2 (5)
Not reported	3 (10)	0 (0)	4 (6)	6 (8)	2 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	0 (0)	3 (4)	1 (1)	1 (1)	8 (13)
Casual sex partner	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Close friend	0 (0)	2 (3)	0 (0)	2 (3)	5 (8)
Acquaintance	0 (0)	2 (3)	0 (0)	0 (0)	2 (3)
Other	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	4 (17)	18 (26)	12 (18)	19 (27)	17 (28)
Water	1 (4)	5 (7)	4 (6)	4 (6)	8 (13)
Filter	1 (4)	6 (9)	8 (12)	7 (10)	4 (7)
Drug mix	1 (4)	5 (7)	4 (6)	8 (11)	4 (7)
Tourniquet	1 (4)	14 (21)	10 (15)	--	--
None**	16 (67)	38 (56)	47 (71)	45 (63)	38 (63)
Injected by someone after that person injected themselves or others last month (%)					
No	22 (76)	59 (83)	58 (83)	61 (86)	4 (7)
Yes	4 (14)	11 (15)	11 (16)	4 (6)	54 (90)
Not reported	3 (10)	1 (1)	1 (1)	6 (8)	2 (3)

* More than one option could be selected

Table 4.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=31	N=75	N=77	N=83	N=70
Sex with a regular partner last month (%)					
No	16 (52)	42 (56)	47 (61)	53 (64)	35 (50)
Yes	13 (42)	33 (44)	26 (34)	26 (31)	34 (49)
Not reported	2 (6)	0 (0)	4 (5)	4 (5)	1 (1)
Condom used with regular partner last month (%)					
N° surveyed	N=13	N=33	N=26	N=26	N=34
Never	10 (77)	24 (73)	19 (73)	20 (77)	23 (68)
Sometimes	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Every time	3 (23)	8 (24)	3 (12)	4 (15)	8 (24)
Not reported	0 (0)	1 (3)	3 (12)	2 (8)	3 (9)
Sex with other partner/s last month (%)					
No	24 (77)	66 (88)	65 (84)	65 (78)	64 (91)
Yes	6 (19)	7 (9)	6 (8)	12 (14)	6 (9)
Not reported	1 (3)	2 (3)	6 (8)	6 (7)	0 (0)
Condom used with other partner/s last month (%)					
N° surveyed	N=6	N=7	N=6	N=12	N=6
Never	2 (33)	2 (29)	2 (33)	5 (42)	1 (17)
Sometimes	0 (0)	3 (43)	1 (17)	2 (17)	1 (17)
Every time	4 (67)	2 (29)	3 (50)	4 (33)	3 (50)
Not reported	0 (0)	0 (0)	0 (0)	1 (8)	1 (17)
Sex work last month (%)					
No	28 (90)	69 (92)	71 (92)	72 (87)	66 (94)
Yes	1 (3)	4 (5)	3 (4)	5 (6)	4 (6)
Not reported	2 (6)	2 (3)	3 (4)	6 (7)	0 (0)
Condom used at last sex work last month (%)					
Yes	1 (100)	4 (100)	3 (100)	4 (80)	4 (100)

Table 4.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=31	N=75	N=77	N=83	N=70
Previous HIV test (%)					
Yes, last year	16 (52)	36 (48)	32 (42)	38 (46)	32 (46)
> 1 year ago	12 (39)	25 (33)	33 (43)	28 (34)	32 (46)
Never tested	2 (6)	9 (12)	9 (12)	12 (14)	6 (9)
Not reported	1 (3)	5 (7)	3 (4)	5 (6)	0 (0)
Previous HCV test (%)					
Yes, last year	19 (61)	38 (51)	40 (52)	46 (55)	37 (53)
> 1 year ago	10 (32)	27 (36)	32 (42)	23 (28)	30 (43)
Never tested	1 (3)	5 (7)	3 (4)	8 (10)	2 (3)
Not reported	1 (3)	5 (7)	2 (3)	6 (7)	1 (1)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=17	N=36	N=32	N=46	N=33
Interferon/Interferon+Ribavirin	0 (0)	3 (9)	2 (6)	2 (4)	1 (3)
Other	2 (12)	2 (6)	0 (0)	1 (2)	2 (6)
No treatment	12 (71)	31 (86)	30 (94)	44 (96)	29 (88)
Not reported	3 (18)	0 (0)	0 (0)	0 (0)	1 (3)
Current treatment for HCV	N=1	N=2	N=0	N=2	N=1
Interferon/Interferon+Ribavirin	1	1	0	1	0
Other	0	1	0	1	1

Table 4.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=31	N=75	N=77	N=83	N=70
Any treatment/therapy for drug use (%)					
No	13 (42)	22 (29)	21 (27)	24 (29)	22 (31)
Yes	17 (55)	53 (71)	55 (71)	56 (67)	47 (67)
Not reported	1 (3)	0 (0)	1 (1)	3 (4)	1 (1)
History of methadone maintenance treatment					
Currently	4 (13)	12 (16)	12 (16)	7 (8)	7 (10)
Previously	10 (32)	18 (24)	14 (18)	25 (30)	22 (31)
Never	16 (52)	45 (60)	49 (64)	46 (55)	39 (56)
Not reported	1 (3)	0 (0)	2 (3)	5 (6)	2 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	13 (17)	3 (4)	5 (6)	3 (4)
Previously	--	20 (27)	18 (23)	17 (20)	21 (30)
Never	--	42 (56)	55 (71)	59 (71)	45 (64)
Not reported	--	0 (0)	1 (1)	2 (2)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	5 (7)	3 (9)	9 (11)	6 (9)
Previously	--	15 (20)	6 (8)	9 (11)	13 (19)
Never	--	54 (72)	67 (87)	64 (77)	51 (73)
Not reported	--	1 (1)	1 (1)	1 (1)	0 (0)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=58
Yes, in the last month					4 (7)
Yes, 1-6 months ago					3 (5)
Yes, 6-12 months ago					4 (7)
Yes, more than one year ago					7 (12)
No, haven't tried to access OST					40 (69)

* New variable in 2008

Table 4.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=29	N=71	N=70	N=71	N=60
Needle Syringe Program	20 (69)	60 (85)	46 (66)	59 (83)	58 (97)
Chemist/Pharmacy	0 (0)	16 (23)	7 (10)	9 (13)	8 (13)
Personal sources	8 (28)	--	21 (30)	14 (19)	8 (13)
Dispensing/Vending Machine	0 (0)	--	0 (0)	0 (0)	0 (0)
Other sources	0 (0)	--	0 (0)	4 (6)	0 (0)

* More than one option could be selected

Table 4.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=70
Never	21 (30)
Monthly or less	17 (24)
2-4 times a month	12 (17)
2-3 times a week	7 (10)
4 or more times a week	13 (19)
Not reported	0 (0)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	
N=49	
1 or 2	14 (29)
3 or 4	13 (27)
5 or 6	10 (20)
7, 8 or 9	3 (6)
10 or more	7 (14)
Not reported	2 (4)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
2010	55	0 (0.0)	23	0 (0.0)	78	0 (0.0)
2011	46	1 (2.2)	21	0 (0.0)	68	1 (1.5)
χ^2 trend p value		0.804		---		0.784

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	20	13 (65)	9	5 (56)	29	18 (62)
2008	46	23 (50)	26	15 (58)	72	38 (53)
2009	50	20 (40)	25	9 (36)	75	29 (39)
2010	55	29 (53)	23	8 (35)	78	37 (47)
2011	40	22 (50)	21	10 (48)	61	32 (52)
χ^2 trend p value		0.926		0.310		0.516

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	18	13 (72)	9	5 (56)	27	18 (67)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.316		---		0.357
2008						
Heterosexual	40	22 (55)	19	11 (58)	59	33 (56)
Bisexual	1	0 (0)	3	2 (67)	4	2 (50)
Homosexual	2	0 (0)	3	2 (67)	5	2 (40)
p value		0.108		1.000		0.867
2009						
Heterosexual	46	19 (41)	18	7 (39)	64	26 (41)
Bisexual	2	1 (50)	3	1 (33)	5	2 (40)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.826
2010						
Heterosexual	48	28 (58)	15	7 (47)	63	35 (56)
Bisexual	5	1 (20)	4	1 (25)	9	2 (22)
Homosexual	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.104		0.320		0.007
2011						
Heterosexual	35	21 (60)	14	7 (50)	49	28 (57)
Bisexual	4	1 (25)	7	3 (43)	11	4 (36)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.195		1.000		0.247

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	0	0 (0)	0	0 (0)	0	0 (0)
25 – 34	7	3 (43)	3	2 (67)	10	5 (50)
35+ years	13	10 (77)	6	3 (50)	19	13 (68)
p value		0.128		0.635		0.331
2008						
< 25 years	1	0 (0)	2	1 (50)	3	1 (33)
25 – 34	13	4 (31)	8	3 (38)	21	7 (33)
35+ years	32	19 (59)	16	11 (69)	48	30 (63)
p value		0.132		0.335		0.065
2009						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	7	1 (14)	7	2 (29)	14	3 (21)
35+ years	41	19 (46)	16	6 (38)	57	25 (44)
p value		0.139		0.838		0.257
2010						
< 25 years	4	1 (25)	2	0 (0)	6	1 (17)
25 – 34	5	0 (0)	7	2 (29)	12	2 (17)
35+ years	46	28 (61)	14	6 (43)	60	34 (57)
p value		0.009		0.543		0.011
2011						
< 25 years	1	1 (100)	2	0 (0)	3	1 (33)
25 – 34	9	3 (33)	7	4 (57)	16	7 (44)
35+ years	30	18 (60)	12	6 (50)	42	24 (57)
p value		0.253		0.565		0.478

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	1 (33)	3	2 (67)	6	3 (50)
11 + years	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.243		0.635		0.544
2008						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	10	1 (10)	5	4 (80)	15	5 (33)
11 + years	34	22 (65)	20	11 (55)	54	33 (61)
p value		0.002		0.295		0.088
2009						
<3 years	2	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	1 (25)	5	1 (20)	9	2 (22)
11 + years	42	19 (45)	16	7 (44)	58	26 (45)
p value		0.349		0.603		0.352
2010						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3 to 10 years	7	3 (43)	3	3 (100)	10	6 (60)
11 + years	44	26 (59)	17	5 (29)	61	31 (51)
p value		0.042		0.034		0.020
2011						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	3	3 (100)	4	3 (75)	7	6 (86)
11 + years	30	16 (53)	15	6 (40)	45	22 (49)
p value		0.117		0.285		0.050

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Pharmaceutical opioids	0	0 (0)	15	10 (67)	15	10 (67)
Methamphetamine	0	0 (0)	4	1 (25)	5	2 (40)
Other	0	0 (0)	9	6 (67)	9	6 (67)
p value		--		0.287		0.535
2008						
Pharmaceutical opioids	0	0 (0)	45	29 (64)	46	29 (63)
Methamphetamine	1	0 (0)	11	2 (18)	12	2 (17)
Other	0	0 (0)	13	7 (54)	13	7 (54)
p value		--		0.022		0.016
2009						
Pharmaceutical opioids	2	1 (50)	36	19 (53)	38	20 (53)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
Other	0	0 (0)	12	4 (33)	14	4 (29)
p value		0.248		0.053		0.023
2010						
Pharmaceutical opioids	2	0 (0)	46	25 (54)	48	25 (52)
Methamphetamine	3	0 (0)	15	7 (47)	18	7 (39)
Other	2	0 (0)	10	5 (50)	12	5 (42)
p value		--		0.866		0.618
2011						
Pharmaceutical opioids	1	0 (0)	33	21 (64)	36	23 (64)
Methamphetamine	2	0 (0)	13	5 (38)	15	5 (33)
Other	3	1 (33)	6	2 (33)	10	4 (40)
p value		1.000		0.203		0.103

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	0	0 (0)	9	5 (56)	9	5 (56)
Daily or more	0	0 (0)	17	11 (65)	18	12 (67)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.856		0.800
2008						
Less than daily	1	0 (0)	17	7 (41)	18	7 (39)
Daily or more	0	0 (0)	49	30 (61)	51	30 (59)
Not last month	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.266		0.273
2009						
Less than daily	1	0 (0)	26	14 (54)	28	14 (50)
Daily or more	2	1 (50)	38	14 (37)	41	15 (37)
Not last month	1	0 (0)	3	0 (0)	6	0 (0)
p value		0.513		0.129		0.068
2010						
Less than daily	2	0 (0)	26	15 (58)	28	15 (54)
Daily or more	3	0 (0)	37	18 (49)	40	18 (45)
Not last month	2	0 (0)	6	2 (33)	8	2 (25)
p value		--		0.549		0.377
2011						
Less than daily	3	0 (0)	10	3 (30)	13	3 (28)
Daily or more	2	1 (50)	36	21 (58)	40	24 (60)
Not last month	1	0 (0)	6	4 (67)	8	5 (63)
p value		0.500		0.239		0.062

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	0	0 (0)	23	14 (61)	24	15 (63)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
p value		---		1.000		1.000
2008						
No receptive sharing	0	0 (0)	61	33 (54)	63	33 (52)
Receptive sharing	1	1 (100)	5	4 (80)	6	4 (67)
p value		---		0.375		0.679
2009						
No receptive sharing	3	1 (33)	57	23 (40)	61	24 (39)
Receptive sharing	0	0 (0)	6	4 (67)	7	4 (57)
p value		--		0.388		0.435
2010						
No receptive sharing	3	0 (0)	56	30 (54)	59	30 (51)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.112		0.238
2011						
No receptive sharing	4	0 (0)	35	19 (54)	41	21 (51)
Receptive sharing	1	1 (100)	8	2 (25)	9	3 (33)
p value		0.200		0.240		0.467

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 4.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	0	0 (0)	27	17 (63)	27	17 (63)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
No imprisonment	1	0 (0)	65	35 (54)	66	35 (53)
Imprisonment	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No imprisonment	4	1 (25)	62	24 (39)	70	25 (36)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.161		0.137
2010						
No imprisonment	5	0 (0)	57	30 (53)	62	30 (48)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.237		0.494
2011						
No imprisonment	5	0 (0)	49	26 (53)	57	29 (51)
Imprisonment	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.167		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 4.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	0	0 (0)	25	17 (68)	26	18 (69)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.346		0.333
2008						
No sex work	1	0 (0)	65	35 (54)	66	35 (53)
Sex work	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No sex work	4	1 (25)	61	26 (43)	69	27 (39)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
p value		---		0.265		0.287
2010						
No sex work	5	0 (0)	63	35 (56)	68	35 (51)
Sex work	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.023		0.055
2011						
No sex work	5	1 (20)	49	27 (55)	57	31 (54)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		1.000		0.590		0.338

* Total includes people who did not report duration of drug injection

Table 4.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	19	13 (68)	9	5 (56)	28	18 (64)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
Non Indigenous	39	21 (54)	20	12 (60)	59	33 (56)
Indigenous	7	2 (29)	6	3 (50)	13	5 (38)
p value		0.414		1.000		0.359
2009						
Non Indigenous	40	17 (43)	23	9 (39)	63	26 (41)
Indigenous	8	1 (13)	2	0 (0)	10	1 (10)
p value		0.229		0.520		0.080
2010						
Non Indigenous	43	24 (56)	18	6 (33)	61	30 (49)
Indigenous	12	5 (42)	5	2 (40)	17	7 (41)
p value		0.517		1.000		0.595
2011						
Non Indigenous	32	18 (56)	16	7 (44)	48	25 (52)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		0.682		0.635		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	18	12 (67)	9	5 (56)	27	17 (63)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		---		1.000
2008						
English speaking	46	23 (50)	26	15 (58)	72	38 (53)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	44	16 (36)	24	9 (38)	68	25 (37)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		0.363		1.000		0.667
2010						
English speaking	49	27 (55)	23	8 (35)	72	35 (49)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.406		--		0.678
2011						
English speaking	36	19 (53)	20	10 (50)	56	29 (52)
Non-English speaking	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.613		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 4.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	17	12 (71)	9	5 (56)	26	17 (65)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.544		---		0.595
2008						
Australia	39	20 (51)	23	13 (57)	62	33 (53)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		0.697		0.747
2009						
Australia	40	14 (35)	23	8 (35)	63	22 (35)
Other Oceania	1	1 (100)	1	1 (100)	2	2 (100)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.283		0.600		0.109
2010						
Australia	46	24 (52)	20	6 (30)	66	30 (45)
Other Oceania	2	1 (50)	1	1 (100)	3	2 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	3 (60)	1	1 (100)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.802		0.214		0.698
2011						
Australia	35	18 (51)	18	9 (50)	53	27 (50)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	2	0 (0)	2	2 (100)
UK & Ireland	5	4 (80)	1	1 (100)	6	5 (83)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.355		0.476		0.111

* Total includes people whose gender was not reported or reported as transgender

Queensland

Table 5.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	7	8	8	8	8
N° surveyed	N=417	N=508	N=801	N=550	N=552
Response (%)	36%	37%	59%	34%	40%
Gender (%)					
Male	282 (68)	341 (67)	585 (73)	419 (76)	394 (71)
Female	131 (31)	165 (32)	211 (26)	126 (23)	154 (28)
Transgender	3 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)
Not reported	1 (<1)	1 (<1)	4 (<1)	4 (<1)	2 (<1)
Sexual identity (%)					
Heterosexual	350 (84)	436 (86)	868 (86)	457 (83)	467 (85)
Bisexual	32 (8)	40 (8)	63 (8)	39 (7)	44 (8)
Homosexual	25 (6)	21 (4)	10 (1)	28 (5)	20 (4)
Not reported	10 (2)	11 (2)	42 (5)	26 (5)	21 (4)
Age and duration of injection (years)					
<i>Median age</i>	35	34	34	35	35
<i>Age range</i>	17-60	16-60	15-66	15-73	17-62
<i>Age group (%)</i>					
<25 years	49 (12)	68 (13)	117 (15)	61 (11)	59 (11)
25+ years	367 (88)	438 (86)	684 (85)	487 (86)	492 (89)
Not reported	1 (<1)	2 (<1)	0 (0)	2 (<1)	1 (<1)
<i>Median age 1st IDU</i>	18	18	18	18	18
<i>Age range</i>	11-44	10-57	10-58	10-59	11-56
Not reported	12	7	19	13	12
<i>Median years IDU</i>	14	14	14	15	11
<i>Range</i>	<1-38	<1-40	<1-46	<1-60	<1-47
<i>Duration of drug injection</i>					
<3 years	32 (8)	29 (6)	58 (7)	40 (7)	55 (10)
3+ years	373 (89)	471 (93)	724 (90)	496 (90)	486 (88)
Not reported	12 (3)	8 (2)	19 (2)	14 (3)	11 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	375 (90)	459 (90)	675 (84)	479 (87)	481 (87)
Yes	38 (10)	32 (6)	105 (13)	62 (11)	55 (10)
Not reported	4 (<1)	17 (3)	21 (3)	9 (2)	16 (3)
Region/Country of birth (%)					
Australia	374 (90)	431 (85)	698 (87)	490 (89)	465 (84)
Other Oceania	15 (4)	25 (5)	40 (5)	20 (4)	29 (5)
Asia	1 (<1)	5 (1)	5 (<1)	5 (1)	4 (1)
UK & Ireland	14 (3)	22 (4)	24 (3)	17 (3)	22 (4)
Other	10 (2)	14 (3)	21 (3)	15 (3)	22 (4)
Not reported	3 (<1)	11 (2)	13 (2)	3 (<1)	10 (2)
Main language spoken at home by parents (%)					
English speaking	395 (95)	489 (96)	768 (96)	535 (97)	530 (96)
Non-English speaking	17 (4)	13 (3)	24 (3)	9 (2)	15 (3)
Not reported	5 (1)	6 (1)	9 (1)	6 (1)	7 (1)
Imprisonment last year (%)					
No	363 (87)	418 (82)	656 (82)	410 (75)	474 (86)
Yes	43 (10)	56 (11)	111 (14)	51 (9)	49 (9)
Not reported	11 (3)	34 (7)	34 (4)	89 (16)	29 (5)
Injected in prison (%)	N=43	N=56	N=111	N=51	N=49
Yes	22 (51)	20 (36)	51 (46)	25 (49)	26 (53)
Frequency of injection last month (%)					
Not last month	32 (8)	50 (10)	74 (9)	59 (11)	51 (9)
Less than weekly	70 (17)	80 (16)	123 (15)	103 (19)	99 (18)
Weekly not daily	119 (29)	137 (27)	173 (22)	131 (24)	136 (25)
Daily or more	188 (45)	234 (46)	426 (53)	252 (46)	260 (47)
Not reported	8 (2)	7 (1)	5 (<1)	5 (1)	6 (1)

Table 5.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=417	N=508	N=801	N=550	N=552
Cocaine	1 (<1)	2 (<1)	7 (<1)	2 (<1)	6 (1)
Heroin	106 (25)	124 (24)	218 (27)	123 (22)	112 (20)
Methadone	19 (5)	32 (6)	38 (5)	36 (7)	22 (4)
Methamphetamine	145 (35)	171 (34)	232 (29)	149 (27)	162 (29)
Performance/Image-enhancing drugs	5 (1)	11 (2)	9 (1)	24 (4)	41 (7)
Pharmaceutical opioids	96 (23)	120 (24)	177 (22)	141 (26)	130 (24)
Suboxone	--	--	10 (1)	13 (2)	10 (2)
Subutex/Buprenorphine	28 (7)	26 (5)	53 (7)	32 (6)	39 (7)
More than one	2 (<1)	11 (2)	30 (4)	19 (3)	24 (4)
Other drug	6 (1)	6 (1)	10 (1)	9 (2)	6 (1)
Not reported	9 (2)	5 (1)	17 (2)	2 (<1)	0 (0)
N° Injected last month	N=377	N=451	N=722	N=487	N=495
Places injected last month (%)*					
Own home	328 (88)	410 (91)	591 (83)	406 (83)	427 (86)
Friend's home	159 (43)	172 (38)	309 (43)	155 (32)	179 (36)
Dealer's home	53 (14)	66 (15)	131 (18)	59 (12)	70 (14)
Street, park, beach	65 (17)	73 (16)	186 (26)	78 (16)	72 (15)
Car	134 (36)	137 (31)	218 (31)	118 (24)	125 (25)
Public toilet	73 (20)	71 (16)	184 (26)	86 (18)	76 (15)
Commercial injecting room	3 (<1)	2 (<1)	7 (1)	4 (1)	6 (1)
Squat	17 (5)	13 (3)	62 (9)	22 (5)	21 (4)
Use of new sterile needles & syringes last month (%)					
All injections	282 (75)	329 (73)	532 (74)	348 (71)	368 (74)
Most of the time	71 (19)	107 (24)	151 (21)	91 (19)	92 (19)
Half of the time	9 (2)	7 (2)	10 (1)	8 (2)	12 (2)
Some of the time	2 (<1)	2 (<1)	14 (2)	5 (1)	6 (1)
Not last month	3 (<1)	2 (<1)	5 (<1)	1 (<1)	2 (<1)
Not reported	10 (3)	4 (1)	10 (1)	34 (7)	15 (3)
Re-used another's used needle & syringe last month (%)					
None	316 (84)	388 (86)	579 (80)	377 (77)	379 (77)
Once	16 (4)	24 (5)	37 (5)	13 (3)	29 (6)
Twice	12 (3)	14 (3)	23 (5)	9 (2)	15 (3)
3-5 times	16 (4)	7 (2)	32 (4)	11 (2)	19 (4)
>5 times	9 (2)	13 (3)	31 (4)	10 (2)	18 (4)
Not reported	8 (2)	5 (1)	20 (3)	67 (14)	35 (7)
Number of people needle & syringe was re-used after last month (%)					
None	316 (84)	388 (86)	579 (80)	377 (77)	379 (77)
One	28 (7)	35 (8)	63 (9)	26 (5)	43 (9)
Two	5 (1)	0 (0)	11 (2)	1 (<1)	6 (1)
Three to five	2 (<1)	3 (1)	7 (1)	7 (1)	3 (<1)
More than five	1 (<1)	3 (1)	5 (<1)	3 (<1)	4 (1)
Don't know	8 (2)	9 (2)	16 (2)	10 (2)	9 (2)
Not reported	17 (5)	13 (3)	41 (6)	63 (13)	51 (10)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	26 (7)	26 (6)	52 (7)	29 (6)	45 (9)
Casual sex partner	2 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)
Close friend	13 (3)	13 (3)	43 (6)	17 (3)	28 (6)
Acquaintance	0 (0)	7 (2)	8 (1)	7 (1)	11 (2)
Other	5 (1)	3 (1)	6 (<1)	6 (1)	10 (2)
Equipment used after someone else last month (%)*					
Spoon	80 (23)	85 (21)	187 (28)	97 (20)	111 (22)
Water	50 (15)	61 (15)	132 (20)	74 (15)	77 (16)
Filter	53 (15)	48 (12)	100 (15)	56 (12)	54 (11)
Drug mix	33 (10)	32 (8)	65 (10)	41 (8)	42 (8)
Tourniquet	27 (8)	39 (9)	56 (9)	--	--
None**	239 (69)	280 (68)	389 (59)	317 (65)	318 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	314 (83)	381 (84)	575 (80)	382 (78)	69 (14)
Yes	52 (14)	62 (14)	133 (18)	49 (10)	404 (81)
Not reported	11 (3)	8 (2)	14 (2)	56 (12)	25 (5)

* More than one option could be selected

Table 5.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=417	N=508	N=801	N=487	N=552
Sex with a regular partner last month (%)					
No	178 (43)	228 (45)	358 (45)	241 (44)	250 (45)
Yes	224 (54)	261 (51)	414 (52)	284 (52)	280 (51)
Not reported	15 (4)	19 (4)	29 (4)	25 (5)	22 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=224	N=261	N=414	N=284	N=280
Never	165 (74)	191 (73)	293 (71)	194 (68)	199 (71)
Sometimes	31 (14)	25 (10)	58 (14)	42 (15)	34 (12)
Every time	21 (9)	27 (10)	41 (10)	33 (12)	30 (11)
Not reported	7 (3)	18 (7)	22 (5)	15 (5)	17 (6)
Sex with other partner/s last month (%)					
No	347 (83)	417 (82)	653 (82)	440 (80)	449 (81)
Yes	61 (15)	68 (13)	117 (15)	79 (14)	81 (15)
Not reported	9 (2)	23 (5)	31 (4)	31 (6)	22 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=61	N=68	N=117	N=79	N=81
Never	20 (33)	21 (31)	40 (34)	25 (32)	30 (37)
Sometimes	22 (36)	16 (24)	40 (34)	20 (25)	20 (25)
Every time	16 (26)	28 (41)	36 (31)	31 (39)	24 (30)
Not reported	3 (5)	3 (4)	1 (<1)	3 (4)	7 (9)
Sex work last month (%)					
No	387 (93)	455 (90)	740 (92)	489 (89)	509 (92)
Yes	20 (5)	14 (3)	30 (4)	14 (3)	19 (3)
Not reported	10 (2)	39 (8)	31 (4)	47 (9)	24 (4)
Condom used at last sex work last month (%)					
Yes	11 (65)	12 (86)	18 (69)	10 (83)	12 (80)

Table 5.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=417	N=508	N=801	N=550	N=552
Previous HIV test (%)					
Yes, last year	239 (57)	258 (51)	410 (51)	239 (43)	281 (51)
> 1 year ago	135 (32)	176 (35)	239 (30)	205 (37)	193 (35)
Never tested	40 (10)	49 (10)	126 (16)	73 (13)	63 (11)
Not reported	3 (<1)	25 (5)	26 (3)	33 (6)	15 (3)
Previous HCV test (%)					
Yes, last year	258 (62)	289 (57)	446 (56)	281 (51)	290 (53)
> 1 year ago	123 (30)	160 (32)	249 (31)	187 (34)	182 (33)
Never tested	32 (8)	36 (7)	85 (11)	44 (8)	47 (9)
Not reported	4 (1)	23 (5)	21 (9)	38 (7)	33 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=188	N=238	N=351	N=263	N=255
Interferon/Interferon+Ribavirin	8 (4)	11 (5)	18 (5)	27 (10)	20 (8)
Other	5 (3)	2 (1)	6 (2)	2 (1)	5 (2)
No treatment	163 (87)	211 (89)	300 (85)	222 (84)	217 (85)
Not reported	8 (4)	7 (3)	20 (6)	12 (5)	13 (5)
Current treatment for HCV	N=4	N=1	N=8	N=2	N=4
Interferon/Interferon+Ribavirin	4	1	6	2	2
Other	0	0	2	0	2

Table 5.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=417	N=508	N=801	N=550	N=552
Any treatment/therapy for drug use (%)					
No	86 (21)	124 (24)	182 (23)	119 (22)	152 (28)
Yes	323 (77)	374 (74)	606 (76)	410 (75)	380 (69)
Not reported	8 (2)	10 (2)	13 (2)	21 (4)	20 (4)
History of methadone maintenance treatment (%)					
Currently	94 (23)	92 (18)	143 (18)	98 (18)	92 (17)
Previously	132 (32)	129 (25)	189 (24)	133 (24)	121 (22)
Never	189 (45)	272 (54)	453 (57)	292 (53)	322 (58)
Not reported	2 (<1)	15 (3)	16 (2)	27 (5)	17 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	60 (12)	115 (14)	77 (14)	67 (12)
Previously	--	125 (25)	173 (22)	121 (22)	120 (22)
Never	--	309 (61)	497 (62)	345 (63)	343 (62)
Not reported	--	14 (3)	16 (2)	7 (1)	22 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	43 (8)	70 (9)	47 (9)	46 (8)
Previously	--	75 (15)	153 (19)	109 (20)	110 (20)
Never	--	376 (74)	560 (70)	379 (69)	376 (68)
Not reported	--	14 (3)	18 (2)	15 (3)	20 (4)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=378
Yes, in the last month					8 (2)
Yes, 1-6 months ago					15 (4)
Yes, 6-12 months ago					5 (1)
Yes, more than one year ago					29 (8)
No, haven't tried to access OST					321 (85)

* New variable in 2008

Table 5.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=377	N=451	N=722	N=487	N=495
Needle Syringe Program	263 (70)	411 (91)	461 (64)	430 (88)	444 (90)
Chemist/Pharmacy	95 (25)	187 (41)	234 (32)	112 (23)	118 (24)
Personal sources	59 (16)	--	133 (18)	47 (10)	38 (7)
Dispensing/Vending Machine	36 (10)	--	71 (10)	56 (12)	72 (15)
Other sources	13 (3)	--	18 (2)	4 (6)	5 (1)

* More than one option could be selected

Table 5.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=552
Never	181 (33)
Monthly or less	125 (23)
2-4 times a month	89 (16)
2-3 times a week	73 (13)
4 or more times a week	72 (13)
Not reported	12 (2)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=359
1 or 2	92 (26)
3 or 4	95 (26)
5 or 6	51 (14)
7, 8 or 9	38 (11)
10 or more	54 (15)
Not reported	29 (8)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
2010	407	11 (2.1)	123	0 (0.0)	535	11 (2.1)
2011	376	8 (2.1)	148	0 (0.0)	528	8 (1.5)
χ^2 trend p value		0.341		---		0.467

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
p value		<0.001		---		<0.001
2008						
Heterosexual	302	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	7 (41)	4	0 (0.0)	21	7 (33)
p value		<0.001		---		<0.001
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.2)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
p value		<0.001		---		<0.001
2010						
Heterosexual	345	2 (0.6)	97	0 (0.0)	445	2 (0.5)
Bisexual	21	2 (9.5)	16	0 (0.0)	37	2 (5.4)
Homosexual	21	7 (33)	6	0 (0.0)	27	87(25.9)
p value		<0.001		---		<0.001
2011						
Heterosexual	340	2 (0.6)	109	0 (0.0)	451	2 (0.4)
Bisexual	13	0 (0.0)	29	0 (0.0)	43	0 (0.0)
Homosexual	11	6 (54.6)	6	0 (0.0)	17	6 (35.3)
p value		<0.001		---		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.3 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
< 25 years	34	0 (0.0)	15	0 (0.0)	49	0 (0.0)
25 – 34	107	1(0.9)	45	0 (0.0)	154	1 (0.7)
35+ years	137	9 (6.6)	70	0 (0.0)	209	9 (4.3)
p value		0.031		--		0.041
2008						
< 25 years	38	0 (0.0)	26	0 (0.0)	64	0 (0.0)
25 – 34	127	2 (1.6)	60	0 (0.0)	187	2 (1.1)
35+ years	169	7 (4.1)	74	0 (0.0)	245	7 (2.9)
p value		0.222		--		0.196
2009						
< 25 years	75	0 (0.0)	39	0 (0.0)	116	0 (0.0)
25 – 34	220	3 (1.4)	82	0 (0.0)	304	3 (1.0)
35+ years	283	7 (2.5)	85	0 (0.0)	369	7 (1.9)
p value		0.305		--		0.242
2010						
< 25 years	44	0 (0.0)	13	0 (0.0)	58	0 (0.0)
25 – 34	155	2 (1.3)	50	0 (0.0)	205	2 (1.0)
35+ years	208	10 (4.8)	59	0 (0.0)	271	10 (3.7)
p value		0.090		--		0.092
2011						
< 25 years	45	0 (0.0)	9	0 (0.0)	56	0 (0.0)
25 – 34	129	0 (0.0)	67	0 (0.0)	197	0 (0.0)
35+ years	201	8 (4.0)	72	0 (0.0)	274	8 (2.9)
p value		0.039		---		0.023

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.4 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
<3 years	23	1 (4.4)	9	0 (0.0)	32	1 (3.1)
3 to 10 years	77	1 (1.3)	34	0 (0.0)	111	1 (0.9)
11 + years	169	7 (4.1)	85	0 (0.0)	258	7 (2.7)
p value		0.496		--		0.526
2008						
<3 years	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
3 to 10 years	95	1 (1.1)	61	0 (0.0)	156	1 (0.6)
11 + years	215	7 (3.3)	88	0 (0.0)	305	7 (2.3)
p value		0.430		--		0.366
2009						
<3 years	36	0 (0.0)	20	0 (0.0)	57	0 (0.0)
3 to 10 years	128	1 (0.8)	67	0 (0.0)	197	1 (0.5)
11 + years	404	9 (2.2)	116	0 (0.0)	522	9 (1.7)
p value		0.394		--		0.291
2010						
<3 years	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
3 to 10 years	82	3 (3.7)	28	0 (0.0)	111	3 (2.7)
11 + years	288	9 (3.1)	83	0 (0.0)	375	9 (2.4)
p value		0.782		--		0.891
2011						
<3 years	41	1 (2.4)	12	0 (0.0)	84	1 (1.9)
3 to 10 years	71	1 (1.4)	36	0 (0.0)	108	1 (0.9)
11 + years	254	6 (2.4)	99	0 (0.0)	355	6 (1.7)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.5 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Methamphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
Other	112	6 (5.4)	40	0 (0.0)	155	6 (3.9)
p value		0.199		--		0.151
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Methamphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
Other	142	4 (2.8)	62	0 (0.0)	206	4 (1.9)
p value		0.562		--		0.579
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
Other	242	2 (0.8)	84	0 (0.0)	328	2 (0.6)
p value		0.016		--		0.016
2010						
Heroin	93	3 (3.2)	30	0 (0.0)	123	3 (2.4)
Methamphetamine	107	7 (6.6)	33	0 (0.0)	143	7 (4.9)
Other	207	2 (1.0)	59	0 (0.0)	268	2 (0.8)
p value		0.014		--		0.019
2011						
Heroin	75	0 (0.0)	32	0 (0.0)	107	0 (0.0)
Methamphetamine	102	4 (3.9)	54	0 (0.0)	156	4 (2.6)
Other	199	4 (2.0)	62	0 (0.0)	265	4 (1.5)
p value		0.267		---		0.284

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Less than daily	125	7 (5.6)	59	0 (0.0)	186	7 (3.8)
Daily or more	123	0 (0.0)	62	0 (0.0)	187	0 (0.0)
Not last month	24	2 (8.3)	8	0 (0.0)	32	2 (6.3)
p value		0.017		--		0.013
2008						
Less than daily	145	7 (4.8)	69	0 (0.0)	214	7 (3.3)
Daily or more	154	2 (1.3)	73	0 (0.0)	229	2 (0.9)
Not last month	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
p value		0.107		--		0.104
2009						
Less than daily	218	6 (2.8)	76	0 (0.0)	296	6 (2.0)
Daily or more	305	3 (1.0)	112	0 (0.0)	420	3 (0.7)
Not last month	56	1 (1.8)	18	0 (0.0)	74	1 (1.4)
p value		0.310		--		0.301
2010						
Less than daily	181	4 (2.2)	58	0 (0.0)	242	4 (1.7)
Daily or more	174	1 (0.6)	57	0 (0.0)	232	1 (0.4)
Not last month	49	7 (14.3)	8	0 (0.0)	58	7 (12.1)
p value		<0.001		--		<0.001
2011						
Less than daily	162	4 (2.5)	61	0 (0.0)	224	4 (1.8)
Daily or more	169	2 (1.2)	76	0 (0.0)	247	2 (0.8)
Not last month	41	2 (4.9)	10	0 (0.0)	51	2 (3.9)
p value		0.196		---		0.176

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No receptive sharing	207	7 (3.4)	104	0 (0.0)	314	7 (2.2)
Receptive sharing	34	0 (0.0)	16	0 (0.0)	51	0 (0.0)
p value		0.598		---		0.600
2008						
No receptive sharing	255	8 (3.1)	123	0 (0.0)	380	8 (2.1)
Receptive sharing	40	1 (2.5)	18	0 (0.0)	58	1 (1.7)
p value		1.000		---		1.000
2009						
No receptive sharing	418	9 (2.2)	152	0 (0.0)	574	9 (1.6)
Receptive sharing	94	0 (0.0)	28	0 (0.0)	123	0 (0.0)
p value		0.377		---		0.373
2010						
No receptive sharing	279	4 (1.4)	88	0 (0.0)	369	4 (1.1)
Receptive sharing	28	1 (2.6)	13	0 (0.0)	41	1 (2.4)
p value		0.382		--		0.411
2011						
No receptive sharing	260	6 (2.3)	101	0 (0.0)	363	6 (1.7)
Receptive sharing	48	0 (0.0)	28	0 (0.0)	77	0 (0.0)
p value		0.595		---		0.596

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No imprisonment	238	10 (4.2)	118	0 (0.0)	359	10 (2.8)
Imprisonment	32	0 (0.0)	11	0 (0.0)	43	0 (0.0)
p value		0.613		---		0.609
2008						
No imprisonment	276	7 (2.5)	134	0 (0.0)	411	7 (1.7)
Imprisonment	36	1 (2.8)	47	0 (0.0)	53	1 (1.9)
p value		1.000		---		1.000
2009						
No imprisonment	465	10 (2.2)	182	0 (0.0)	652	10 (1.5)
Imprisonment	86	0 (0.0)	24	0 (0.0)	110	0 (0.0)
p value		0.375		---		0.372
2010						
No imprisonment	302	10 (3.3)	94	0 (0.0)	401	10 (2.5)
Imprisonment	38	0 (0.0)	10	0 (0.0)	48	0 (0.0)
p value		0.610		---		0.609
2011						
No imprisonment	325	8 (2.5)	135	0 (0.0)	463	8 (1.7)
Imprisonment	40	0 (0.0)	8	0 (0.0)	48	0 (0.0)
p value		0.606		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.9 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No condom use	117	1 (0.9)	75	0 (0.0)	194	1 (0.5)
Condom use	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
No condom use	133	2 (1.5)	78	0 (0.0)	212	2 (0.9)
Condom use	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2009						
No condom use	224	3 (1.3)	118	0 (0.0)	347	3 (0.9)
Condom use	33	2 (6.1)	8	0 (0.0)	41	2 (4.9)
p value		0.125		---		0.089
2010						
No condom use	131	3 (2.3)	56	0 (0.0)	189	3 (1.6)
Condom use	56	2 (3.8)	15	0 (0.0)	71	2 (2.8)
p value		0.637		--		0.616
2011						
No condom use	121	2 (1.7)	70	0 (0.0)	192	2 (1.0)
Condom use	44	1 (2.3)	14	0 (0.0)	59	1 (1.7)
p value		1.000		---		0.554

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 5.2.10 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
No sex work	263	10 (3.8)	118	0 (0.0)	383	10 (2.6)
Sex work	8	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value				---		1.000
2008						
No sex work	300	9 (3.0)	144	0 (0.0)	446	9 (2.0)
Sex work	2	0 (0.0)	11	0 (0.0)	13	0 (0.0)
p value		1.000		---		1.000
2009						
No sex work	545	10 (1.8)	188	0 (0.0)	737	10 (1.4)
Sex work	13	0 (0.0)	16	0 (0.0)	30	0 (0.0)
p value		1.000		---		1.000
2010						
No sex work	370	11 (3.0)	103	0 (0.0)	477	11 (2.3)
Sex work	4	0 (0.0)	9	0 (0.0)	13	0 (0.0)
p value		1.000		--		1.000
2011						
No sex work	355	7 (2.0)	135	0 (0.0)	492	7 (1.4)
Sex work	4	0 (0.0)	11	0 (0.0)	16	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Non Indigenous	250	8 (3.2)	119	0 (0.0)	372	8 (2.2)
Indigenous	26	2 (7.7)	10	0 (0.0)	37	2 (5.4)
p value		0.240		---		0.226
2008						
Non Indigenous	316	9 (2.9)	136	0 (0.0)	453	9 (1.9)
Indigenous	7	0 (0.0)	20	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2009						
Non Indigenous	495	10 (2.0)	172	0 (0.0)	672	10 (1.5)
Indigenous	67	0 (0.0)	35	0 (0.0)	102	0 (0.0)
p value		0.617		---		0.375
2010						
Non Indigenous	358	10 (2.8)	103	0 (0.0)	466	10 (2.2)
Indigenous	42	1 (2.4)	19	0 (0.0)	61	1 (1.6)
p value		1.000		--		1.000
2011						
Non Indigenous	329	8 (2.4)	128	0 (0.0)	460	8 (1.8)
Indigenous	36	0 (0.0)	18	0 (0.0)	54	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
English speaking	261	9 (3.5)	126	0 (0.0)	391	9 (2.3)
Non-English speaking	13	1 (7.7)	4	0 (0.0)	17	1 (5.9)
p value		0.390		---		0.351
2008						
English speaking	321	8 (2.5)	156	0 (0.0)	479	8 (1.7)
Non-English speaking	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
p value		0.223		---		0.216
2009						
English speaking	558	10 (1.8)	199	0 (0.0)	762	10 (1.3)
Non-English speaking	14	0 (0.0)	10	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2010						
English speaking	396	11 (2.8)	120	0 (0.0)	521	11 (2.1)
Non-English speaking	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)
p value		1.000		---	0	1.000
2011						
English speaking	360	8 (2.2)	145	0 (0.0)	509	8 (1.6)
Non-English speaking	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007						
Australia	248	9 (3.6)	118	0 (0.0)	370	9 (2.4)
Other Oceania	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
UK & Ireland	11	1 (9.1)	3	0 (0.0)	14	1 (7.1)
Other	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
p value		0.663		---		0.499
2008						
Australia	283	8 (2.8)	138	0 (0.0)	422	8 (1.9)
Other Oceania	8	1 (12.5)	6	0 (0.0)	14	1 (7.1)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	27	0 (0.0)
p value		0.459		---		0.455
2009						
Australia	504	10 (2.0)	183	0 (0.0)	692	10 (1.5)
Other Oceania	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
p value		1.000		---		0.455
2010						
Australia	361	10 (2.8)	110	0 (0.0)	476	10 (2.1)
Other Oceania	16	0 (0.0)	4	0 (0.0)	20	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	2	0 (0.0)	17	0 (0.0)
Other	11	1 (9.1)	5	0 (0.0)	16	1 (6.3)
p value		0.618		--		0.689
2011						
Australia	316	8 (2.5)	126	0 (0.0)	446	8 (1.8)
Other Oceania	18	0 (0.0)	11	0 (0.0)	29	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
Other	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
p value		1.000		---		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	278	158 (57)	129	85 (66)	411	247 (60)
2008	333	182 (55)	159	91 (57)	494	275 (56)
2009	576	244 (42)	209	94 (45)	790	339 (43)
2010	403	180 (45)	121	58 (48)	529	241 (46)
2011	368	158 (43)	146	63 (43)	518	221 (43)
χ^2 trend p value		<0.001		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	248	140 (56)	97	62 (64)	345	202 (59)
Bisexual	7	4 (57)	22	16 (73)	31	22 (71)
Homosexual	18	11 (61)	6	3 (50)	25	15 (60)
p value		0.943		0.553		0.414
2008						
Heterosexual	300	164 (55)	126	67 (53)	427	232 (54)
Bisexual	10	5 (50)	26	18 (69)	36	23 (64)
Homosexual	17	8 (47)	4	3 (75)	21	11 (52)
p value		0.819		0.292		0.556
2009						
Heterosexual	514	222 (43)	162	67 (41)	677	289 (43)
Bisexual	24	7 (29)	37	22 (59)	62	29 (47)
Homosexual	9	3 (33)	1	1 (100)	10	4 (40)
p value		0.375		0.054		0.808
2010						
Heterosexual	340	150 (44)	96	45 (47)	439	197 (45)
Bisexual	21	10 (48)	15	9 (60)	36	19 (53)
Homosexual	22	7 (32)	6	2 (33)	28	9 (32)
p value		0.486		0.490		0.267
2011						
Heterosexual	334	145 (43)	107	45 (42)	443	190 (43)
Bisexual	12	4 (33)	28	13 (46)	41	17 (41)
Homosexual	10	3 (30)	6	1 (17)	16	4 (25)
p value		0.620		0.440		0.403

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	34	9 (26)	14	6 (43)	48	15 (31)
25 – 34	107	55 (51)	45	23 (51)	154	80 (52)
35+ years	136	93 (68)	70	56 (80)	208	151 (73)
p value		<0.001		0.001		<0.001
2008						
< 25 years	38	10 (26)	26	13 (50)	64	23 (36)
25 – 34	125	56 (45)	58	32 (55)	183	88 (48)
35+ years	169	115 (68)	74	46 (62)	245	163 (67)
p value		<0.001		0.500		<0.001
2009						
< 25 years	75	17 (23)	39	15 (38)	116	32 (28)
25 – 34	218	75 (34)	85	39 (46)	305	114 (37)
35+ years	283	152 (54)	85	40 (47)	369	193 (52)
p value		<0.001		0.655		<0.001
2010						
< 25 years	43	7 (16)	13	3 (23)	57	10 (18)
25 – 34	154	55 (36)	50	25 (50)	204	80 (39)
35+ years	205	118 (58)	57	30 (53)	266	151 (57)
p value		<0.001		0.166		<0.001
2011						
< 25 years	45	3 (7)	9	3 (33)	56	6 (11)
25 – 34	128	44 (34)	65	24 (37)	194	68 (35)
35+ years	194	110 (57)	72	36 (50)	267	146 (55)
p value		<0.001		0.248		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	23	4 (17)	9	2 (22)	32	6 (19)
3 to 10 years	77	30 (39)	33	16 (48)	110	46 (42)
11 + years	168	117 (70)	85	66 (78)	257	187 (73)
p value		<0.001		<0.001		<0.001
2008						
<3 years	19	2 (11)	10	4 (40)	29	6 (21)
3 to 10 years	94	28 (30)	61	29 (48)	155	57 (37)
11 + years	214	149 (70)	86	58 (67)	302	209 (69)
p value		<0.001		0.027		<0.001
2009						
<3 years	36	3 (8)	20	3 (15)	57	6 (11)
3 to 10 years	127	41 (32)	67	27 (40)	196	68 (35)
11 + years	400	196 (49)	116	63 (54)	518	260 (50)
p value		<0.001		0.003		<0.001
2010						
<3 years	29	2 (7)	7	0 (0)	36	2 (6)
3 to 10 years	80	25 (31)	28	9 (32)	109	34 (31)
11 + years	285	149 (52)	81	47 (58)	370	199 (54)
p value		<0.001		0.001		<0.001
2011						
<3 years	41	3 (7)	11	2 (18)	53	5 (9)
3 to 10 years	70	18 (26)	36	11 (31)	107	29 (27)
11 + years	247	136 (55)	98	50 (51)	347	186 (54)
p value		<0.001		0.023		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	4	0 (0)	100	66 (66)	106	67 (63)
Methamphetamine	24	5 (21)	119	63 (53)	143	68 (48)
Other	4	1 (25)	140	99 (71)	153	106 (69)
p value		0.579		0.012		<0.001
2008						
Heroin	2	1 (50)	120	82 (68)	123	84 (68)
Methamphetamine	15	2 (13)	146	62 (42)	162	65 (40)
Other	11	3 (27)	187	118 (63)	204	122 (60)
p value		0.432		<0.001		<0.001
2009						
Heroin	12	3 (25)	202	114 (56)	216	117 (54)
Methamphetamine	22	0 (0)	206	65 (32)	231	65 (28)
Other	11	3 (14)	296	143 (48)	327	151 (46)
p value		0.067		<0.001		<0.001
2010						
Heroin	5	0 (0)	113	66 (58)	122	70 (57)
Methamphetamine	11	1 (9)	128	46 (36)	142	47 (33)
Other	20	1 (5)	237	121 (51)	263	124 (47)
p value		1.000		0.001		<0.001
2011						
Heroin	7	2 (29)	98	53 (54)	106	55 (52)
Methamphetamine	11	1 (9)	139	50 (36)	152	52 (34)
Other	35	2 (6)	217	112 (52)	260	114 (44)
p value		0.178		0.005		0.015

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	20	3 (15)	163	92 (56)	186	98 (53)
Daily or more	10	2 (20)	170	124 (73)	185	130 (70)
Not last month	2	1 (50)	28	14 (50)	32	15 (47)
p value		0.478		0.002		0.001
2008						
Less than daily	14	4 (29)	199	106 (53)	214	110 (51)
Daily or more	9	2 (22)	213	140 (66)	225	143 (64)
Not last month	6	0 (0)	39	16 (41)	48	18 (38)
p value		0.349		0.003		0.001
2009						
Less than daily	22	1 (5)	268	105 (39)	294	107 (36)
Daily or more	26	5 (19)	383	186 (49)	417	194 (47)
Not last month	9	0 (0)	59	34 (58)	74	35 (47)
p value		0.136		0.010		0.019
2010						
Less than daily	19	0 (0)	216	89 (41)	237	90 (38)
Daily or more	10	2 (20)	212	116 (55)	230	122 (53)
Not last month	5	0 (0)	50	28 (56)	58	28 (48)
p value		0.098		0.011		0.004
2011						
Less than daily	29	2 (7)	187	80 (43)	220	82 (37)
Daily or more	16	3 (19)	221	118 (53)	241	122 (51)
Not last month	7	0 (0)	41	16 (39)	51	16 (31)
p value		0.396		0.055		0.003

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	27	4 (15)	280	175 (63)	313	184 (59)
Receptive sharing	3	1 (33)	46	37 (80)	50	39 (78)
p value		0.433		0.019		0.012
2008						
No receptive sharing	17	3 (18)	356	209 (59)	376	213 (57)
Receptive sharing	6	3 (50)	52	34 (65)	58	37 (64)
p value		0.279		0.450		0.322
2009						
No receptive sharing	33	1 (3)	529	225 (43)	569	228 (40)
Receptive sharing	13	5 (38)	106	57 (54)	123	63 (51)
p value		0.005		0.042		0.027
2010						
No receptive sharing	25	2 (8)	331	149 (45)	365	156 (43)
Receptive sharing	1	0 (0)	38	24 (63)	40	24 (60)
p value		1.000		0.040		0.044
2011						
No receptive sharing	38	4 (11)	311	141 (45)	356	146 (41)
Receptive sharing	5	0 (0)	68	39 (57)	74	39 (53)
p value		1.000		0.082		0.071

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 5.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	31	5 (16)	317	188 (59)	358	199 (56)
Imprisonment	1	1 (100)	39	34 (87)	42	37 (88)
p value		0.188		<0.001		<0.001
2008						
No imprisonment	26	4 (15)	375	207 (55)	407	213 (52)
Imprisonment	2	2 (100)	50	40 (80)	53	43 (81)
p value		0.040		0.001		<0.001
2009						
No imprisonment	48	2 (4)	587	250 (43)	648	254 (39)
Imprisonment	7	4 (57)	99	58 (59)	110	64 (58)
p value		0.001		0.004		<0.001
2010						
No imprisonment	35	2 (0)	351	154 (44)	397	160 (40)
Imprisonment	0	0 (0)	47	29 (62)	48	29 (60)
p value		--		0.028		0.009
2011						
No imprisonment	51	5 (10)	385	170 (44)	446	176 (39)
Imprisonment	0	0 (0)	46	31 (67)	47	31 (66)
p value		--		0.004		0.001

* Total includes people who did not report duration of drug injection

Table 5.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	29	6 (21)	341	211 (62)	381	224 (59)
Sex work	1	0 (0)	18	16 (89)	20	17 (85)
p value		1.000		0.023		0.020
2008						
No sex work	27	5 (19)	408	238 (58)	442	246 (56)
Sex work	1	1 (100)	12	6 (50)	13	7 (54)
p value		0.214		0.568		1.000
2009						
No sex work	55	5 (9)	663	294 (44)	732	302 (41)
Sex work	1	1 (100)	26	19 (73)	30	21 (70)
p value		0.107		0.005		0.002
2010						
No sex work	36	2 (6)	426	200 (47)	472	206 (44)
Sex work	0	0 (0)	12	7 (58)	13	7 (54)
p value		--		0.561		0.574
2011						
No sex work	50	5 (10)	422	199 (47)	482	205 (43)
Sex work	1	0 (0)	14	7 (50)	16	7 (44)
p value		1.000		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 5.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	249	142 (57)	118	76 (64)	370	221 (60)
Indigenous	26	14 (54)	10	8 (80)	37	23 (62)
p value		0.836		0.492		0.861
2008						
Non Indigenous	314	168 (54)	135	72 (53)	450	241 (54)
Indigenous	7	3 (43)	20	16 (80)	28	20 (71)
p value		0.709		0.030		0.079
2008						
Non Indigenous	490	203 (41)	172	78 (45)	667	282 (42)
Indigenous	67	33 (49)	35	16 (46)	102	49 (48)
p value		0.237		1.000		0.284
2010						
Non Indigenous	354	159 (45)	101	52 (51)	460	214 (47)
Indigenous	42	17 (40)	19	6 (32)	61	23 (38)
p value		0.625		0.137		0.219
2011						
Non Indigenous	323	133 (41)	126	51 (40)	452	184 (41)
Indigenous	34	19 (56)	19	11 (58)	53	30 (57)
p value		0.105		0.213		0.028

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	260	150 (58)	125	83 (66)	389	237 (61)
Non-English speaking	13	6 (46)	4	2 (50)	17	8 (47)
p value		0.567		0.605		0.313
2008						
English speaking	319	174 (55)	155	89 (57)	476	265 (56)
Non-English speaking	9	5 (56)	4	2 (50)	13	7 (54)
p value		1.000		1.000		1.000
2009						
English speaking	553	231 (42)	199	90 (45)	757	322 (43)
Non-English speaking	14	9 (64)	10	4 (40)	24	13 (54)
p value		0.106		1.000		0.297
2010						
English speaking	392	173 (44)	118	57 (48)	515	233 (45)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
p value		1.000		0.497		0.523
2011						
English speaking	352	147 (42)	144	62 (43)	500	209 (42)
Non-English speaking	11	7 (64)	2	1 (50)	13	8 (62)
p value		0.215		1.000		0.167

* Total includes people whose gender was not reported or reported as transgender

Table 5.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	247	141 (57)	117	77 (66)	368	222 (60)
Other Oceania	9	4 (44)	6	3 (50)	15	7 (47)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	11	7 (64)	3	2 (67)	14	9 (64)
Other	8	4 (50)	2	2 (100)	10	6 (60)
p value		0.818		0.816		0.821
2008						
Australia	281	154 (55)	137	75 (55)	419	230 (55)
Other Oceania	8	1 (13)	6	5 (83)	14	6 (43)
Asia	4	4 (100)	1	0 (0)	5	4 (80)
UK & Ireland	12	6 (50)	7	3 (43)	19	9 (47)
Other	21	12 (57)	6	6 (100)	27	18 (67)
p value		0.054		0.053		0.425
2009						
Australia	499	215 (43)	183	85 (46)	687	301 (44)
Other Oceania	28	6 (21)	12	5 (42)	40	11 (28)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	19	10 (53)	5	2 (40)	24	12 (50)
Other	14	4 (29)	7	1 (14)	21	5 (24)
p value		0.057		0.459		0.071
2010						
Australia	358	157 (44)	108	49 (45)	471	209 (44)
Other Oceania	16	6 (38)	4	3 (75)	20	9 (45)
Asia	3	1 (33)	1	0 (0)	4	1 (25)
UK & Ireland	15	8 (53)	2	1 (50)	17	9 (53)
Other	10	7 (70)	5	4 (80)	15	11 (73)
p value		0.458		0.350		0.200
2011						
Australia	308	131 (43)	125	55 (44)	437	186 (43)
Other Oceania	18	5 (28)	10	4 (40)	28	9 (32)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	15	8 (53)	6	2 (33)	21	10 (48)
Other	18	9 (50)	2	1 (50)	20	10 (50)
p value		0.428		0.877		0.335

* Total includes people whose gender was not reported or reported as transgender

South Australia

Table 6.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	7	7	7	7	7
N° surveyed	N=220	N=196	N=248	N=216	N=213
Response (%)	41%	45%	53%	41%	51%
Gender (%)					
Male	127 (58)	101 (52)	156 (63)	129 (60)	133 (62)
Female	91 (41)	93 (47)	92 (37)	86 (40)	78 (37)
Transgender	2 (1)	1 (1)	0 (0)	1 (<1)	2 (1)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	175 (80)	146 (74)	204 (82)	185 (86)	178 (84)
Bisexual	23 (10)	29 (15)	23 (9)	11 (5)	22 (10)
Homosexual	15 (7)	13 (7)	13 (5)	12 (6)	6 (3)
Not reported	7 (3)	8 (4)	8 (3)	8 (4)	7 (3)
Age and duration of injection (years)					
<i>Median age</i>	34	36	38	38	39
<i>Age range</i>	19-58	17-56	16-61	18-62	17-61
<i>Age group (%)</i>					
<25 years	25 (11)	19 (10)	25 (10)	18 (8)	13 (6)
25+ years	193 (88)	177 (90)	222 (90)	198 (92)	200 (94)
Not reported	2 (1)	0 (0)	1 (<1)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	18	18	19
<i>Age range</i>	10-47	11-45	12-46	12-44	11-45
Not reported	5	4	5	2	4
<i>Median years IDU</i>	13	15	17	17	20
<i>Range</i>	<1-41	1-41	<1-44	<1-45	<1-37
<i>Duration of drug injection (%)</i>					
<3 years	16 (7)	13 (7)	15 (6)	5 (2)	12 (6)
3+ years	199 (90)	179 (91)	228 (92)	209 (97)	197 (92)
Not reported	5 (2)	4 (2)	5 (2)	2 (1)	4 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	202 (92)	158 (81)	206 (83)	185 (86)	183 (86)
Yes	16 (7)	28 (14)	31 (13)	23 (11)	29 (14)
Not reported	2 (1)	10 (5)	11 (4)	8 (4)	1 (<1)
Region/Country of birth (%)					
Australia	186 (85)	160 (82)	219 (88)	191 (88)	185 (87)
Other Oceania	3 (1)	4 (2)	5 (2)	3 (1)	4 (2)
Asia	2 (<1)	5 (3)	1 (<1)	4 (2)	4 (2)
UK & Ireland	18 (8)	17 (9)	17 (7)	11 (5)	9 (4)
Other	8 (4)	7 (4)	5 (2)	4 (2)	9 (4)
Not reported	3 (1)	3 (2)	1 (<1)	3 (1)	2 (1)
Main language spoken at home by parents (%)					
English speaking	195 (89)	179 (91)	224 (90)	198 (92)	193 (91)
Non-English speaking	23 (10)	12 (6)	19 (8)	16 (7)	18 (8)
Not reported	2 (1)	5 (3)	5 (2)	2 (1)	2 (1)
Imprisonment last year (%)					
No	173 (79)	158 (81)	199 (80)	168 (78)	175 (82)
Yes	32 (15)	21 (11)	37 (15)	16 (7)	19 (9)
Not reported	15 (7)	17 (9)	12 (5)	32 (15)	19 (9)
Injected in prison (%)	N=32	N=21	N=37	N=16	N=19
Yes	8 (25)	7 (33)	5 (14)	1 (6)	4 (21)
Frequency of injection last month (%)					
Not last month	14 (6)	20 (10)	22 (9)	13 (6)	12 (6)
Less than weekly	40 (18)	30 (15)	38 (15)	42 (19)	41 (19)
Weekly not daily	54 (25)	51 (26)	59 (24)	61 (28)	49 (23)
Daily or more	112 (51)	93 (47)	127 (51)	99 (46)	108 (51)
Not reported	0 (0)	2 (1)	2 (1)	1 (<1)	3 (1)

Table 6.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=220	N=196	N=248	N=216	N=213
Cocaine	2 (1)	4 (2)	3 (1)	2 (1)	2 (1)
Heroin	62 (28)	49 (25)	84 (34)	86 (40)	77 (36)
Methadone	11 (5)	10 (5)	8 (3)	7 (3)	13 (6)
Methamphetamine	95 (43)	100 (51)	91 (37)	87 (40)	75 (35)
Performance/Image-enhancing drugs	2 (1)	1 (1)	0 (0)	0 (0)	1 (<1)
Pharmaceutical opioids	24 (11)	20 (10)	34 (14)	26 (12)	28 (13)
Suboxone	--	--			2 (1)
Subutex/Buprenorphine	10 (5)	7 (4)	14 (6)	2 (1)	3 (1)
More than one	6 (3)	2 (1)	5 (2)	3 (1)	8 (4)
Other drug	6 (3)	0 (0)	3 (1)	3 (1)	4 (2)
Not reported	2 (1)	3 (2)	6 (2)	0 (0)	0 (0)
N° Injected last month	N=206	N=174	N=224	N=202	N=198
Places injected last month (%)*					
Own home	176 (88)	151 (88)	198 (89)	170 (84)	171 (86)
Friend's home	90 (45)	74 (43)	92 (41)	82 (41)	81 (41)
Dealer's home	32 (16)	35 (20)	24 (11)	31 (15)	27 (14)
Street, park, beach	45 (23)	34 (20)	24 (11)	39 (19)	45 (23)
Car	84 (42)	66 (38)	70 (31)	83 (41)	73 (37)
Public toilet	44 (22)	36 (21)	29 (13)	38 (19)	34 (17)
Commercial injecting room	1 (<1)	1 (1)	0 (0)	1 (<1)	1 (<1)
Squat	10 (5)	5 (3)	3 (1)	6 (3)	8 (4)
Use of new sterile needles & syringes last month (%)					
All injections	147 (71)	126 (72)	184 (82)	151 (75)	146 (74)
Most of the time	45 (22)	34 (20)	31 (14)	32 (16)	36 (18)
Half of the time	4 (2)	6 (3)	4 (2)	4 (2)	3 (2)
Some of the time	3 (1)	5 (3)	3 (1)	4 (2)	1 (<1)
Not last month	0 (0)	1 (1)	0 (0)	0 (0)	1 (<1)
Not reported	7 (3)	2 (1)	2 (1)	11 (5)	11 (6)
Re-used another's used needle & syringe last month (%)					
None	166 (81)	138 (79)	197 (88)	154 (76)	163 (82)
Once	11 (5)	7 (4)	7 (3)	8 (4)	5 (3)
Twice	8 (4)	10 (6)	7 (3)	4 (2)	6 (3)
3-5 times	8 (4)	11 (6)	3 (1)	7 (3)	6 (3)
>5 times	4 (2)	2 (1)	4 (2)	5 (2)	5 (3)
Not reported	9 (4)	6 (3)	6 (3)	24 (12)	13 (7)
Number of people needle & syringe was re-used after last month (%)					
None	166 (81)	138 (79)	197 (88)	154 (76)	163 (82)
One	10 (5)	17 (10)	11 (5)	7 (3)	14 (7)
Two	5 (2)	3 (2)	3 (1)	3 (1)	2 (1)
Three to five	3 (1)	0 (0)	0 (0)	3 (1)	1 (<1)
More than five	1 (<1)	0 (0)	0 (0)	3 (1)	0 (0)
Don't know	5 (2)	8 (5)	4 (2)	4 (2)	4 (2)
Not reported	16 (8)	8 (5)	9 (4)	28 (14)	14 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	15 (7)	10 (6)	9 (4)	19 (9)	18 (9)
Casual sex partner	4 (2)	0 (0)	0 (0)	2 (1)	0 (0)
Close friend	2 (1)	7 (4)	3 (1)	13 (6)	7 (4)
Acquaintance	1 (<1)	3 (2)	2 (1)	2 (1)	3 (2)
Other	2 (1)	4 (2)	0 (0)	6 (3)	4 (2)
Equipment used after someone else last month (%)*					
Spoon	47 (24)	25 (16)	36 (18)	46 (23)	33 (17)
Water	39 (20)	36 (23)	28 (14)	42 (21)	27 (14)
Filter	29 (15)	16 (10)	19 (9)	24 (12)	19 (10)
Drug mix	15 (8)	9 (6)	20 (10)	16 (8)	17 (9)
Tourniquet	30 (15)	17 (11)	14 (7)	--	--
None**	118 (60)	100 (63)	141 (69)	121 (60)	131 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	167 (81)	143 (82)	183 (82)	148 (73)	32 (16)
Yes	30 (15)	24 (14)	34 (15)	31 (15)	156 (79)
Not reported	9 (4)	7 (4)	7 (3)	23 (11)	10 (5)

* More than one option could be selected

Table 6.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=220	N=196	N=248	N=216	N=213
Sex with a regular partner last month (%)					
No	88 (40)	81 (41)	112 (45)	100 (46)	96 (45)
Yes	122 (55)	107 (55)	124 (50)	106 (49)	102 (48)
Not reported	10 (5)	8 (4)	12 (5)	10 (5)	15 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=122	N=107	N=124	N=106	N=102
Never	97 (80)	78 (73)	80 (64)	71 (67)	69 (68)
Sometimes	17 (14)	17 (16)	23 (19)	13 (12)	10 (10)
Every time	6 (5)	8 (7)	12 (10)	10 (9)	15 (15)
Not reported	2 (2)	4 (4)	9 (7)	12 (11)	8 (8)
Sex with other partner/s last month (%)					
No	171 (78)	153 (78)	205 (83)	170 (79)	179 (84)
Yes	42 (19)	31 (16)	31 (13)	33 (15)	22 (10)
Not reported	7 (3)	12 (6)	12 (5)	13 (6)	12 (6)
Condom used with other partner/s last month (%)					
N° surveyed	N=42	N=31	N=31	N=33	N=22
Never	21 (50)	5 (16)	9 (29)	7 (21)	6 (27)
Sometimes	6 (14)	12 (39)	9 (29)	7 (21)	6 (27)
Every time	14 (33)	14 (45)	13 (42)	16 (48)	10 (45)
Not reported	1 (2)	0 (0)	0 (0)	3 (9)	0 (0)
Sex work last month (%)					
No	194 (88)	170 (87)	229 (92)	184 (85)	194 (91)
Yes	21 (10)	13 (7)	10 (4)	20 (9)	9 (4)
Not reported	5 (2)	13 (7)	9 (4)	12 (6)	9 (4)
Condom used at last sex work last month (%)					
Yes	13 (72)	11 (85)	9 (90)	13 (68)	8 (89)

Table.6.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=220	N=196	N=248	N=216	N=213
Previous HIV test (%)					
Yes, last year	116 (53)	94 (48)	130 (52)	88 (41)	93 (44)
> 1 year ago	76 (35)	62 (32)	81 (33)	92 (43)	81 (38)
Never tested	27 (12)	30 (15)	28 (11)	25 (12)	29 (14)
Not reported	1 (<1)	10 (5)	9 (4)	11 (5)	10 (5)
Previous HCV test (%)					
Yes, last year	123 (56)	104 (53)	139 (56)	99 (46)	105 (49)
> 1 year ago	73 (33)	57 (29)	67 (27)	73 (34)	77 (36)
Never tested	23 (10)	29 (15)	28 (11)	23 (11)	15 (7)
Not reported	1 (<1)	6 (3)	14 (6)	21 (10)	16 (8)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=59	N=59	N=102	N=92	N=101
Interferon/Interferon+Ribavirin	2 (3)	7 (12)	14 (14)	6 (7)	12 (12)
Other	1 (2)	0 (0)	1 (1)	0 (0)	1 (1)
No treatment	53 (90)	50 (85)	81 (79)	83 (90)	80 (79)
Not reported	3 (5)	2 (3)	6 (6)	3 (3)	8 (8)
Current treatment for HCV	N=2	N=1	N=3	N=2	N=2
Interferon/Interferon+Ribavirin	2	1	2	2	2
Other	0	0	1	0	0

Table 6.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=220	N=196	N=248	N=216	N=213
Any treatment/therapy for drug use (%)					
No	60 (27)	66 (34)	67 (27)	46 (21)	49 (23)
Yes	158 (72)	123 (63)	176 (71)	163 (75)	163 (77)
Not reported	2 (1)	7 (4)	5 (2)	7 (3)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	51 (23)	39 (20)	61 (25)	57 (26)	48 (22)
Previously	57 (26)	40 (20)	46 (19)	53 (25)	61 (29)
Never	109 (50)	112 (57)	135 (54)	92 (42)	96 (45)
Not reported	3 (1)	5 (3)	6 (2)	14 (6)	8 (4)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	26 (13)	40 (16)	23 (11)	13 (6)
Previously	--	33 (17)	58 (23)	60 (28)	55 (26)
Never	--	130 (66)	148 (60)	131 (61)	138 (65)
Not reported	--	7 (4)	2 (1)	2 (1)	7 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	7 (4)	12 (5)	7 (4)	21 (10)
Previously	--	21 (11)	36 (15)	21 (11)	37 (17)
Never	--	160 (82)	194 (78)	160 (82)	149 (70)
Not reported	--	8 (4)	6 (2)	8 (4)	6 (3)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=142
Yes, in the last month					9 (6)
Yes, 1-6 months ago					9 (6)
Yes, 6-12 months ago					3 (2)
Yes, more than one year ago					19 (13)
No, haven't tried to access OST					102 (72)

* New variable in 2008

Table 6.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=206	N=174	N=224	N=202	N=198
Needle Syringe Program	139 (67)	144 (83)	150 (67)	183 (91)	176 (89)
Chemist/Pharmacy	37 (18)	66 (38)	36 (16)	26 (13)	30 (15)
Personal sources	49 (24)	--	39 (17)	24 (12)	19 (10)
Dispensing/Vending Machine	0 (0)	--	0 (0)	0 (0)	17 (9)
Other sources	6 (3)	--	9 (4)	5 (2)	3 (2)

* More than one option could be selected

Table 6.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=213
Never	76 (36)
Monthly or less	59 (28)
2-4 times a month	27 (13)
2-3 times a week	27 (13)
4 or more times a week	17 (8)
Not reported	7 (3)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=130
1 or 2	41 (32)
3 or 4	29 (22)
5 or 6	25 (19)
7, 8 or 9	13 (10)
10 or more	15 (12)
Not reported	7 (5)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
2010	129	0 (0.0)	84	1 (1.2)	214	1 (0.5)
2011	129	2 (1.6)	76	3 (4.0)	207	5 (2.4)
χ^2 trend p value		0.886		0.017		0.138

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.2 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heterosexual	118	2 (1.7)	56	2 (3.6)	174	4 (2.3)
Bisexual	6	0 (0.0)	14	1 (7.1)	21	1 (4.8)
Homosexual	1	0 (0.0)	4	0 (0.0)	6	0 (0.0)
p value		1.000		0.572		0.518

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.3 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
< 25 years	5	0 (0.0)	8	2 (25.0)	13	2 (15.4)
25 – 34	25	0 (0.0)	13	0 (0.0)	39	0 (0.0)
35+ years	99	2 (2.0)	55	1 (1.8)	155	3 (1.9)
p value		1.000		0.041		0.044

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.4 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	14	0 (0.0)	12	2 (16.7)	26	2 (7.7)
11 + years	107	2 (1.9)	56	1 (1.8)	165	3 (1.8)
p value		1.000		0.087		0.235

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.5 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Heroin	51	0 (0.0)	24	1 (4.2)	75	1 (1.3)
Methamphetamine	43	0 (0.0)	28	1 (3.6)	72	1 (1.4)
Other	35	2 (5.7)	24	1 (4.2)	60	3 (5.0)
p value		0.072		1.000		0.444

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.6 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Less than daily	61	0 (0.0)	28	2 (7.1)	89	2 (2.3)
Daily or more	60	2 (3.3)	42	1 (2.4)	104	3 (2.9)
Not last month	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
p value		0.325		0.643		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.7 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No receptive sharing	103	2 (1.9)	56	3 (5.4)	160	5 (3.1)
Receptive sharing	11	0 (0.0)	9	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender ** Excludes people who did not inject last month

Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No imprisonment	106	2 (1.9)	69	3 (4.4)	177	5 (2.8)
Imprisonment	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.9 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No condom use	40	0 (0.0)	27	1 (3.7)	67	1 (1.5)
Condom use	16	0 (0.0)	8	0 (0.0)	24	0 (0.0)
p value		---		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender ** Excludes people with no sexual activity last month

Table 6.2.10 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
No sex work	124	2 (1.6)	65	3 (4.6)	191	5 (2.6)
Sex work	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Non Indigenous	112	2 (1.8)	63	2 (3.2)	177	4 (2.3)
Indigenous	17	0 (0.0)	12	1 (8.3)	29	1 (3.5)
p value		1.000		0.412		0.535

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
English speaking	117	2 (1.7)	69	3 (4.4)	188	5 (2.7)
Non-English speaking	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2011						
Australia	112	2 (1.8)	66	3 (4.6)	180	5 (2.8)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
UK & Ireland	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 6.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	120	50 (42)	89	31 (35)	211	82 (39)
2008	95	30 (32)	90	24 (27)	186	54 (29)
2009	155	65 (42)	91	36 (40)	246	101 (41)
2010	127	54 (43)	84	38 (45)	212	93 (44)
2011	128	67 (52)	75	31 (41)	205	98 (48)
χ^2 trend p value		0.029		0.055		0.003

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	103	41 (40)	64	26 (41)	167	67 (40)
Bisexual	5	3 (60)	16	3 (19)	22	7 (32)
Homosexual	8	4 (50)	6	2 (33)	15	6 (40)
p value		0.542		0.304		0.759
2008						
Heterosexual	84	29(35)	55	17 (31)	139	46 (33)
Bisexual	5	1 (20)	23	4 (17)	28	5 (18)
Homosexual	3	0 (0)	10	3 (30)	13	3 (23)
p value		0.592		0.462		0.238
2009						
Heterosexual	134	59 (44)	68	27 (40)	202	86 (43)
Bisexual	11	3 (27)	12	6 (50)	23	9 (36)
Homosexual	4	0 (0)	9	3 (33)	13	3 (23)
p value		0.138		0.756		0.410
2010						
Heterosexual	113	51 (45)	69	31 (45)	182	82 (45)
Bisexual	1	1 (100)	8	4 (50)	10	6 (60)
Homosexual	7	0 (0)	5	1 (20)	12	1 (8)
p value		0.10		0.661		0.019
2011						
Heterosexual	117	60 (51)	55	23 (42)	172	83 (48)
Bisexual	6	4 (67)	14	5 (36)	21	9 (43)
Homosexual	1	0 (0)	4	1 (25)	6	1 (17)
p value		0.553		0.756		0.325

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	7	4 (57)	14	4 (29)	22	9 (41)
25 – 34	45	14 (31)	37	10 (27)	82	24 (29)
35+ years	67	31 (46)	37	17 (46)	105	48 (46)
p value		0.189		0.199		0.071
2008						
< 25 years	6	0 (0)	11	2 (18)	17	2 (12)
25 – 34	23	5 (22)	37	7 (19)	60	12 (20)
35+ years	66	25 (38)	42	15 (36)	109	40 (37)
p value		0.082		0.192		0.019
2009						
< 25 years	14	1 (7)	10	4 (40)	24	5 (21)
25 – 34	37	13 (35)	30	11 (37)	67	24 (36)
35+ years	104	51 (49)	50	21 (42)	154	72 (47)
p value		0.007		0.895		0.032
2010						
< 25 years	8	0 (0)	10	2 (20)	18	2 (11)
25 – 34	30	8 (27)	23	11 (48)	53	19 (36)
35+ years	89	46 (52)	51	25 (49)	141	72 (51)
p value		0.001		0.266		0.002
2011						
< 25 years	5	0 (0)	8	1 (13)	13	1 (8)
25 – 34	25	9 (36)	13	3 (23)	39	12 (31)
35+ years	98	58 (59)	54	27 (50)	153	85 (56)
p value		0.005		0.045		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	8	0 (0)	7	4 (57)	15	4 (27)
3 to 10 years	27	9 (33)	33	9 (27)	61	18 (30)
11 + years	82	39 (48)	47	17 (36)	130	57 (44)
p value		0.022		0.300		0.103
2008						
<3 years	5	0 (0)	7	1 (14)	12	1 (8)
3 to 10 years	16	4 (25)	24	3 (13)	40	7 (18)
11 + years	74	26 (35)	57	20 (35)	132	46 (35)
p value		0.216		0.082		0.027
2009						
<3 years	4	0 (0)	10	1 (10)	14	1 (7)
3 to 10 years	26	4 (15)	20	8 (40)	46	12 (26)
11 + years	122	59 (48)	59	27 (46)	181	86 (48)
p value		0.002		0.103		0.001
2010						
<3 years	3	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	18	0 (0)	20	7 (35)	38	7 (18)
11 + years	105	54 (51)	61	31 (51)	167	86 (52)
p value		<0.001		0.242		<0.001
2011						
<3 years	5	0 (0)	7	0 (0)	12	0 (0)
3 to 10 years	14	3 (21)	12	1 (8)	26	4 (15)
11 + years	106	63 (59)	55	29 (53)	163	92 (56)
p value		0.001		0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	3	2 (67)	57	29 (51)	60	31 (52)
Methamphetamine	9	1 (11)	78	19 (24)	90	23 (26)
Other	3	1 (33)	54	26 (48)	59	27 (46)
p value		0.162		0.002		0.002
2008						
Heroin	3	1 (33)	45	22 (49)	48	23 (48)
Methamphetamine	7	0 (0)	85	12 (14)	92	12 (13)
Other	2	0 (0)	41	19 (46)	43	19 (44)
p value		0.195		<0.001		<0.001
2009						
Heroin	3	0 (0)	79	40 (51)	83	41 (49)
Methamphetamine	6	1 (17)	83	28 (34)	90	29 (32)
Other	5	0 (0)	61	29 (48)	67	30 (44)
p value		0.488		0.080		0.069
2010						
Heroin	2	0 (0)	83	41 (49)	85	41 (48)
Methamphetamine	3	0 (0)	82	26 (32)	86	26 (30)
Other	0	0 (0)	40	26 (65)	41	26 (63)
p value		--		0.002		0.001
2011						
Heroin	4	0 (0)	68	46 (68)	74	47 (64)
Methamphetamine	3	0 (0)	66	20 (30)	71	21 (30)
Other	5	0 (0)	55	30 (55)	60	30 (50)
p value		--		<0.001		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	10	1 (10)	77	33 (43)	88	35 (40)
Daily or more	4	2 (50)	103	40 (39)	111	44 (40)
Not last month	1	1 (100)	11	2 (18)	12	3 (25)
p value		0.071		0.290		0.598
2008						
Less than daily	6	0 (0)	68	19 (28)	74	19 (26)
Daily or more	4	1 (25)	87	30 (34)	91	31 (34)
Not last month	2	0 (0)	16	4 (25)	19	4 (21)
p value		0.336		0.589		0.352
2009						
Less than daily	6	1 (17)	89	43 (48)	96	44 (46)
Daily or more	5	0 (0)	118	51 (43)	126	53 (42)
Not last month	3	0 (0)	18	3 (17)	22	3 (14)
p value		0.488		0.047		0.020
2010						
Less than daily	3	0 (0)	100	46 (46)	104	46 (44)
Daily or more	1	0 (0)	92	43 (47)	94	43 (46)
Not last month	1	0 (0)	12	4 (33)	13	4 (31)
p value		--		0.763		0.613
2011						
Less than daily	3	0 (0)	83	43 (52)	88	44 (50)
Daily or more	7	0 (0)	96	49 (51)	103	49 (48)
Not last month	1	0 (0)	10	4 (40)	12	4 (33)
p value		--		0.812		0.568

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	13	2 (15)	145	61 (42)	161	64 (40)
Receptive sharing	1	1 (100)	27	9 (33)	29	11 (38)
p value		0.214		0.523		1.000
2008						
No receptive sharing	7	0 (0)	125	40 (32)	132	40 (30)
Receptive sharing	3	1 (33)	26	8 (31)	29	9 (31)
p value		0.300		1.000		1.000
2009						
No receptive sharing	10	1 (10)	181	85 (47)	195	88 (45)
Receptive sharing	0	0 (0)	21	7 (33)	21	7 (33)
p value		1.000		0.484		0.588
2010						
No receptive sharing	4	0 (0)	146	66 (45)	151	66 (44)
Receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
p value		--		0.515		0.660
2011						
No receptive sharing	8	0 (0)	149	79 (53)	159	80 (50)
Receptive sharing	1	0 (0)	19	9 (47)	20	9 (45)
p value		--		0.808		0.813

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 6.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	12	3 (25)	150	51 (34)	165	55 (33)
Imprisonment	1	0 (0)	30	20 (67)	32	21 (66)
p value		1.000		0.002		0.001
2008						
No imprisonment	11	1 (9)	139	42 (30)	151	43 (28)
Imprisonment	0	0 (0)	21	8 (38)	21	8 (38)
p value		---		0.460		0.445
2009						
No imprisonment	13	1 (8)	180	72 (40)	197	74 (38)
Imprisonment	1	0 (0)	35	20 (57)	37	21 (57)
p value		1.000		0.065		0.044
2010						
No imprisonment	5	0 (0)	159	62 (39)	166	62 (37)
Imprisonment	0	0 (0)	16	10 (63)	16	10 (63)
p value		--		0.107		0.062
2011						
No imprisonment	10	0 (0)	156	78 (50)	170	80 (47)
Imprisonment	1	0 (0)	16	13 (81)	17	13 (76)
p value		--		0.019		0.023

* Total includes people who did not report duration of drug injection

Table 6.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	12	3 (25)	169	70 (41)	185	75 (41)
Sex work	2	0 (0)	18	4 (22)	21	5 (24)
p value		1.000		0.134		0.161
2008						
No sex work	11	1 (9)	150	48 (32)	162	49 (30)
Sex work	0	0 (0)	13	5 (38)	13	5 (38)
p value		---		0.759		0.543
2009						
No sex work	14	1 (7)	208	93 (45)	227	96 (42)
Sex work	0	0 (0)	10	2 (20)	10	2 (20)
p value		---		0.192		0.202
2010						
No sex work	5	0 (0)	174	80 (46)	181	80 (44)
Sex work	0	0 (0)	20	5 (25)	20	5 (25)
p value		--		0.096		0.151
2011						
No sex work	10	0 (0)	176	91 (52)	189	92 (49)
Sex work	0	0 (0)	7	2 (29)	8	3 (38)
p value		--		0.273		0.722

* Total includes people who did not report duration of drug injection

Table 6.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	110	43 (39)	82	29 (35)	194	73 (38)
Indigenous	9	6 (67)	6	2 (33)	15	8 (53)
p value		0.159		1.000		0.275
2008						
Non Indigenous	75	23 (31)	77	23 (30)	153	46 (30)
Indigenous	17	6 (35)	8	0 (0)	25	6 (24)
p value		0.775		0.101		0.640
2009						
Non Indigenous	128	50 (39)	76	28 (37)	204	78 (38)
Indigenous	20	12 (60)	11	7 (64)	31	19 (61)
p value		0.091		0.109		0.019
2010						
Non Indigenous	108	46 (43)	72	33 (46)	181	80 (44)
Indigenous	15	5 (33)	8	3 (38)	23	8 (35)
p value		0.584		0.724		0.504
2011						
Non Indigenous	112	56 (50)	62	25 (40)	176	81 (46)
Indigenous	16	11 (69)	12	5 (42)	28	16 (57)
p value		0.189		1.000		0.312

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	102	40 (39)	85	30 (35)	188	70 (37)
Non-English speaking	17	9 (53)	3	1 (33)	21	11 (52)
p value		0.301		1.000		0.237
2008						
English speaking	87	26 (30)	83	21 (25)	171	47 (27)
Non-English speaking	5	4 (80)	6	2 (33)	11	6 (55)
p value		0.037		0.646		0.083
2009						
English speaking	140	63 (45)	83	33 (40)	223	96 (43)
Non-English speaking	11	1 (9)	7	2 (29)	18	3 (17)
p value		0.025		0.701		0.044
2010						
English speaking	112	46 (41)	81	37 (46)	194	84 (43)
Non-English speaking	13	6 (46)	3	1 (33)	16	7 (44)
p value		0.772		1.000		1.000
2011						
English speaking	116	59 (51)	68	28 (41)	186	87 (47)
Non-English speaking	11	7 (64)	6	2 (33)	17	9 (53)
p value		0.534		1.000		0.801

* Total includes people whose gender was not reported or reported as transgender

Table 6.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	102	41 (40)	73	23 (32)	177	65 (37)
Other Oceania	1	0 (0)	2	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	7	4 (57)	11	7 (64)	18	11 (61)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.361		0.087		0.041
2008						
Australia	79	24 (30)	73	15 (21)	152	39 (26)
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)
Asia	2	2 (100)	3	2 (67)	5	4 (80)
UK & Ireland	7	1 (14)	8	4 (50)	16	5 (31)
Other	3	2 (67)	2	2 (100)	5	4 (80)
p value		0.091		0.010		0.009
2009						
Australia	137	60 (44)	80	29 (36)	217	89 (41)
Other Oceania	3	2 (67)	2	1 (50)	5	3 (60)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	11	3 (27)	6	5 (83)	17	8 (47)
Other	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.345		0.057		0.255
2010						
Australia	113	45 (40)	74	32 (43)	188	78 (41)
Other Oceania	0	0 (0)	3	3 (100)	3	3 (100)
Asia	3	3 (100)	1	1 (100)	4	4 (100)
UK & Ireland	6	4 (67)	5	2 (40)	11	6 (55)
Other	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.090		0.172		0.033
2011						
Australia	111	57 (51)	66	23 (35)	179	80 (45)
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)
Asia	4	4 (100)	0	0 (0)	4	4 (100)
UK & Ireland	5	2 (40)	3	3 (100)	8	5 (63)
Other	6	4 (67)	3	2 (67)	9	6 (67)
p value		0.164		0.008		0.124

* Total includes people whose gender was not reported or reported as transgender

Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	5	4	4	4	4
N° surveyed	N=168	N=57	N=122	N=106	N=68
Response (%)	45%	25%	22%	39%	28%
Gender (%)					
Male	111 (66)	33 (58)	74 (61)	68 (64)	43 (63)
Female	57 (34)	24 (42)	47 (39)	38 (36)	25 (37)
Transgender	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	138 (82)	46 (81)	101 (83)	96 (91)	61 (90)
Bisexual	12 (7)	6 (11)	12 (10)	4 (4)	2 (3)
Homosexual	13 (8)	3 (5)	5 (4)	1 (1)	3 (4)
Not reported	5 (3)	2 (4)	4 (3)	5 (5)	2 (3)
Age and duration of injection (years)					
<i>Median age</i>	34	36	33	35	38
Age range	15-57	21-58	17-59	20-60	17-58
<i>Age group (%)</i>					
<25 years	26 (10)	3 (5)	13 (11)	7 (7)	4 (6)
25+ years	152 (90)	54 (95)	109 (89)	99 (93)	64 (94)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st IDU</i>	18	18	19	19	19
Age range	10-44	11-38	11-44	12-42	13-49
Not reported	3	1	5	0	3
<i>Median years IDU</i>	14	16.5	13	14	15
Range	<1-40	1-41	<1-39	<1-42	1-40
<i>Duration of drug injection (%)</i>					
<3 years	10 (6)	1 (2)	9 (7)	4 (4)	7 (10)
3+ years	155 (92)	55 (96)	108 (89)	102 (96)	58 (85)
Not reported	3 (2)	1 (2)	5 (4)	0 (0)	3 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	141 (84)	50 (88)	100 (82)	94 (89)	59 (87)
Yes	25 (15)	5 (9)	15 (12)	12 (11)	8 (12)
Not reported	2 (1)	2 (4)	7 (6)	0 (0)	1 (1)
Region/Country of birth (%)					
Australia	159 (95)	48 (84)	111 (91)	98 (92)	64 (94)
Other Oceania	3 (2)	0 (0)	2 (2)	2 (2)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	3 (2)	6 (11)	2 (2)	4 (4)	2 (3)
Other	0 (0)	0 (0)	2 (2)	2 (2)	2 (3)
Not reported	3 (2)	3 (5)	5 (4)	0 (0)	0 (0)
Main language spoken at home by parents (%)					
English speaking	165 (98)	55 (96)	119 (98)	105 (99)	68 (100)
Non-English speaking	3 (2)	2 (4)	1 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Imprisonment last year (%)					
No	139 (83)	45 (79)	98 (80)	81 (76)	63 (93)
Yes	25 (15)	7 (12)	17 (14)	5 (5)	4 (6)
Not reported	4 (2)	5 (9)	7 (6)	20 (19)	1 (1)
Injected in prison (%)					
Yes	11 (44)	3 (43)	6 (35)	0 (0)	1 (25)
Frequency of injection last month (%)					
Not last month	6 (4)	2 (4)	7 (6)	9 (8)	5 (7)
Less than weekly	48 (29)	8 (14)	18 (15)	21 (20)	10 (15)
Weekly not daily	55 (33)	23 (40)	47 (39)	45 (42)	27 (40)
Daily or more	58 (35)	24 (42)	46 (38)	31 (29)	26 (38)
Not reported	1 (<1)	0 (0)	4 (3)	0 (0)	0 (0)

Table 7.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=168	N=57	N=122	N=106	N=68
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	3 (2)	4 (7)	4 (3)	1 (1)	1 (1)
Methadone	54 (32)	24 (42)	40 (33)	30 (28)	21 (31)
Methamphetamine	50 (30)	13 (23)	30 (25)	29 (27)	18 (26)
Performance/Image-enhancing drugs	0 (0)	0 (0)	1 (<1)	1(1)	0 (0)
Pharmaceutical opioids	43 (26)	12 (21)	33 (27)	35 (33)	23 (34)
Suboxone	--	--			
Subutex/Buprenorphine	1 (<1)	1 (2)	2 (2)	0 (0)	1 (1)
More than one	5 (3)	1 (2)	4 (3)	8 (8)	3 (4)
Other drug	9 (5)	1 (2)	5 (4)	2 (2)	1 (1)
Not reported	3 (2)	1 (2)	3 (2)	0 (0)	0 (0)
N° Injected last month	N=161	N=55	N=111	N=97	N=63
Places injected last month (%)*					
Own home	147 (91)	50 (94)	102 (93)	78 (80)	61 (97)
Friend's home	72 (45)	13 (25)	40 (36)	27 (28)	21 (33)
Dealer's home	17 (11)	6 (11)	5 (5)	6 (6)	2 (3)
Street, park, beach	18 (11)	4 (8)	2 (2)	8 (8)	2 (3)
Car	51 (32)	15 (28)	37 (34)	27 (28)	18 (29)
Public toilet	24 (15)	9 (17)	13 (12)	11 (11)	11 (17)
Commercial injecting room	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
Squat	5 (3)	0 (0)	2 (2)	1 (1)	0 (0)
Use of new sterile needles & syringes last month (%)					
All injections	131 (81)	40 (73)	93 (84)	75 (77)	55 (87)
Most of the time	27 (17)	13 (24)	15 (14)	10 (10)	7 (11)
Half of the time	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Some of the time	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	2 (1)	2 (4)	1 (1)	12 (12)	1 (1)
Re-used another's used needle & syringe last month (%)					
None	132 (82)	44 (80)	94 (85)	82 (85)	51 (81)
One	8 (5)	2 (4)	1 (1)	1 (1)	5 (8)
Twice	3 (2)	2 (4)	4 (4)	1 (1)	1 (1)
3-5 times	6 (4)	3 (5)	7 (6)	0 (0)	4 (6)
>5 times	2 (1)	2 (4)	2 (2)	0 (0)	0 (0)
Not reported	10 (6)	2 (4)	3 (3)	13 (13)	2 (3)
Number of people needle & syringe was re-used after last month (%)					
None	132 (82)	44 (80)	94 (85)	82 (85)	51 (81)
One	6 (4)	3 (5)	3 (3)	2 (2)	3 (5)
Two	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Three to five	0 (0)	1 (2)	1 (1)	0 (0)	0 (0)
More than five	1 (<1)	0 (0)	1 (1)	0 (0)	0 (0)
Don't know	4 (2)	1 (2)	3 (3)	0 (0)	6 (10)
Not reported	18 (11)	6 (11)	9 (8)	13 (13)	3 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	7 (4)	4 (7)	4 (4)	5 (5)	3 (5)
Casual sex partner	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	2 (1)	2 (4)	1 (1)	1 (1)	3 (5)
Acquaintance	2 (1)	0 (0)	1 (1)	0 (0)	3 (5)
Other	0 (0)	0 (0)	2 (2)	1 (1)	2 (3)
Equipment used after someone else last month (%)*					
Spoon	16 (11)	4 (9)	6 (6)	9 (9)	9 (14)
Water	17 (11)	5 (11)	7 (7)	12 (12)	5 (8)
Filter	10 (7)	0 (0)	6 (6)	6 (6)	2 (3)
Drug mix	5 (3)	1 (2)	3 (3)	4 (4)	3 (5)
Tourniquet	12 (8)	7 (16)	7 (7)	--	--
None**	112 (75)	36 (82)	86 (84)	67 (69)	51 (81)
Injected by someone after that person injected themselves or others last month (%)					
No	130 (81)	47 (85)	83 (75)	76 (78)	54 (86)
Yes	21 (13)	4 (7)	27 (24)	8 (8)	7 (11)
Not reported	10 (6)	4 (7)	1 (1)	13 (13)	2 (3)

* More than one option could be selected

Table 7.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=168	N=57	N=122	N=106	N=68
Sex with a regular partner last month (%)					
No	63 (38)	23 (40)	52 (43)	59 (56)	28 (41)
Yes	103 (61)	34 (60)	59 (48)	43 (41)	37 (54)
Not reported	2 (1)	---	11 (9)	4 (4)	3 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=103	N=34	N=59	N=59	N=37
Never	74 (72)	21 (62)	51 (86)	44 (75)	24 (65)
Sometimes	15 (15)	5 (15)	1 (2)	7 (12)	9 (24)
Every time	9 (9)	7 (21)	4 (7)	6 (10)	4 (11)
Not reported	5 (5)	1 (3)	3 (5)	2 (3)	0 (0)
Sex with other partner/s last month (%)					
No	145 (86)	48 (84)	86 (70)	94 (89)	57 (84)
Yes	16 (10)	7 (12)	19 (16)	7 (7)	8 (12)
Not reported	7 (4)	2 (4)	17 (14)	5 (5)	3 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=16	N=7	N=19	N=7	N=8
Never	7 (44)	2 (29)	4 (21)	4 (57)	3 (28)
Sometimes	5 (31)	2 (29)	5 (26)	1 (14)	2 (25)
Every time	3 (19)	3 (43)	9 (47)	2 (29)	3 (38)
Not reported	1 (6)	0 (0)	1 (5)	0 (0)	0 (0)
Sex work last month (%)					
No	157 (93)	54 (95)	107 (88)	101 (95)	64 (94)
Yes	3 (2)	2 (4)	2 (2)	2 (2)	1 (1)
Not reported	8 (5)	1 (2)	13 (11)	3 (3)	3 (4)
Condom used at last sex work last month (%)					
Yes	3 (100)	1 (100)	1 (50)	1 (50)	1 (100)

Table 7.1.4 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=168	N=57	N=122	N=106	N=68
Previous HIV test (%)					
Yes, last year	92 (55)	35 (61)	50 (41)	43 (41)	24 (35)
> 1 year ago	54 (32)	16 (28)	41 (34)	42 (40)	30 (44)
Never tested	22 (13)	5 (9)	18 (15)	15 (14)	12 (18)
Not reported	0 (0)	1 (2)	13 (11)	6 (6)	2 (3)
Previous HCV test (%)					
Yes, last year	99 (59)	37 (65)	71 (58)	56 (53)	30 (44)
> 1 year ago	53 (32)	17 (30)	37 (30)	36 (34)	27 (40)
Never tested	16 (10)	3 (5)	8 (7)	10 (9)	7 (10)
Not reported	0 (0)	0 (0)	6 (5)	4 (4)	4 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=0	N=31	N=68	N=48	N=32
Interferon/Interferon+Ribavirin	7 (10)	0 (0)	6 (9)	2 (4)	2 (6)
Other	0 (0)	29 (94)	1 (1)	1 (2)	0 (0)
No treatment	0 (0)	0 (0)	61 (90)	40 (83)	29 (91)
Not reported	0 (0)	1 (3)	0 (0)	1 (1)	1 (3)
Current treatment for HCV	N=0	N=0	N=0	N=0	N=0
Interferon/Interferon+Ribavirin	0	0	0	0	0

Table 7.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=168	N=57	N=122	N=106	N=68
Any treatment/therapy for drug use (%)					
No	46 (27)	13 (23)	31 (25)	28 (26)	13 (19)
Yes	120 (71)	43 (75)	88 (72)	77 (73)	53 (78)
Not reported	2 (1)	1 (2)	3 (2)	1 (1)	2 (3)
History of methadone maintenance treatment (%)					
Currently	66 (39)	24 (42)	47 (39)	44 (42)	20 (30)
Previously	41 (24)	12 (21)	24 (20)	19 (18)	18 (26)
Never	61 (36)	21 (37)	46 (38)	40 (38)	25 (37)
Not reported	0 (0)	0 (0)	5 (4)	3 (3)	5 (7)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	4 (7)	7 (6)	5 (5)	5 (7)
Previously	--	10 (18)	27 (22)	25 (24)	19 (28)
Never	--	39 (68)	85 (70)	75 (71)	42 (62)
Not reported	--	4 (7)	3 (2)	1 (1)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	2 (4)	5 (4)	4 (4)	1 (1)
Previously	--	2 (4)	14 (11)	13 (12)	13 (19)
Never	--	48 (84)	99 (81)	88 (83)	53 (78)
Not reported	--	5 (9)	4 (3)	1 (1)	1 (1)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=43
Yes, in the last month					5 (12)
Yes, 1-6 months ago					2 (5)
Yes, 6-12 months ago					3 (7)
Yes, more than one year ago					5 (12)
No, haven't tried to access OST					28 (65)

* New variable in 2008

Table 7.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=161	N=55	N=111	N=97	N=63
Needle Syringe Program	128 (80)	54 (98)	73 (66)	96 (99)	58 (92)
Chemist/Pharmacy	18 (11)	15 (27)	21 (19)	9 (9)	10 (16)
Personal sources	15 (9)	--	15 (14)	3 (3)	2 (3)
Dispensing/Vending Machine	3 (2)	--	3 (3)	0 (0)	1 (2)
Other sources	0 (0)	--	1 (1)	0 (0)	1 (2)

* More than one option could be selected

Table 7.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=68
Never	26 (38)
Monthly or less	21 (31)
2-4 times a month	11 (16)
2-3 times a week	7 (10)
4 or more times a week	2 (3)
Not reported	1 (1)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=41
1 or 2	8 (20)
3 or 4	11 (27)
5 or 6	7 (17)
7, 8 or 9	6 (15)
10 or more	6 (15)
Not reported	3 (7)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
2008	33	0 (0.0)	24	0 (0.0)	57	0 (0.0)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
2010	68	0 (0.0)	38	0 (0.0)	106	0 (0.0)
2011	43	0 (0.0)	25	0 (0.0)	68	0 (0.0)
χ^2 trend p value		---		---		---

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	91	52 (57)	43	30 (70)	134	82 (61)
2008	32	26 (81)	24	19 (79)	56	45 (80)
2009	73	38 (52)	45	24 (53)	119	63 (53)
2010	68	30 (44)	38	18 (47)	106	48 (45)
2011	42	17 (40)	25	14 (56)	67	31 (46)
χ^2 trend p value		0.008		0.026		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	83	46 (55)	28	18 (64)	111	64 (58)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.626		0.432		
2008						
Heterosexual	31	25 (81)	14	11 (79)	45	36 (80)
Bisexual	0	0 (0)	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	2	2 (100)	3	3 (100)
p value		1.000		1.000		1.000
2009						
Heterosexual	64	33 (52)	33	18 (55)	98	52 (53)
Bisexual	4	3 (75)	8	5 (63)	12	8 (67)
Homosexual	4	2 (50)	1	0 (0)	5	2 (40)
p value		0.853		0.691		0.602
2010						
Heterosexual	66	28 (42)	30	15 (50)	96	43 (45)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
2011						
Heterosexual	38	15 (39)	22	11 (50)	60	26 (43)
Bisexual	0	0 (0)	2	2 (100)	2	2 (100)
Homosexual	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.560		0.482		0.236

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	3	3 (100)	7	3 (43)	10	6 (60)
25 – 34	39	21 (54)	18	14 (78)	57	35 (61)
35+ years	49	28 (57)	18	13 (72)	67	41 (61)
p value		0.298		0.223		0.996
2008						
< 25 years	2	2 (100)	1	1 (100)	3	3 (100)
25 – 34	10	8 (80)	14	11 (79)	24	19 (79)
35+ years	20	16 (80)	9	19 (79)	29	23 (79)
p value		0.782		0.871		0.679
2009						
< 25 years	9	4 (44)	3	0 (0)	12	4 (33)
25 – 34	29	12 (41)	30	18 (60)	59	30 (51)
35+ years	35	22 (63)	12	6 (50)	48	29 (60)
p value		0.205		0.134		0.220
2010						
< 25 years	2	0 (0)	5	2 (40)	7	2 (29)
25 – 34	30	12 (40)	13	7 (54)	43	19 (44)
35+ years	36	18 (50)	20	9 (45)	56	27 (48)
p value		0.442		0.906		0.677
2011						
< 25 years	2	0 (0)	2	1 (50)	4	1 (25)
25 – 34	12	3 (25)	10	6 (60)	22	9 (41)
35+ years	28	14 (50)	13	7 (54)	41	21 (51)
p value		0.177		1.000		0.616

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	5	1 (20)	2	0 (0)	7	1 (14)
3 to 10 years	20	11 (55)	13	6 (46)	33	17 (52)
11 + years	65	39 (60)	26	22 (85)	91	61 (67)
p value		0.217		0.005		0.011
2008						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	5	5 (100)	8	6 (75)	13	11 (85)
11 + years	26	20 (77)	15	12 (80)	41	32 (78)
p value		0.427		0.782		0.771
2009						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	16	8 (50)	15	6 (40)	31	14 (45)
11 + years	51	29 (57)	22	15 (68)	74	45 (61)
p value		0.052		0.116		0.012
2010						
<3 years	4	0 (0)	0	0 (0)	4	0 (0)
3 to 10 years	13	5 (38)	12	4 (33)	25	9 (36)
11 + years	51	25 (49)	26	14 (54)	77	39 (51)
p value		0.181		0.307		0.108
2011						
<3 years	3	1 (33)	4	1 (25)	7	2 (29)
3 to 10 years	5	0 (0)	7	5 (71)	12	5 (42)
11 + years	32	15 (47)	13	8 (62)	45	23 (51)
p value		0.156		0.388		0.535

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Pharmaceutical opioids	2	1 (50)	33	23 (70)	35	24 (69)
Methamphetamine	4	0 (0)	33	15 (45)	38	16 (42)
Other	1	0 (0)	55	39 (71)	58	41 (71)
p value		0.233		0.053		0.017
2008						
Pharmaceutical opioids	0	0 (0)	12	9 (75)	12	9 (75)
Methamphetamine	0	0 (0)	12	11 (92)	12	11 (92)
Other	1	1 (100)	29	22 (76)	31	24 (77)
p value		--		0.498		0.524
2009						
Pharmaceutical opioids	1	0 (0)	30	19 (63)	32	19 (59)
Methamphetamine	7	0 (0)	23	9 (39)	30	9 (30)
Other	1	1 (100)	49	28 (57)	54	32 (59)
p value		0.011		0.166		0.014
2010						
Pharmaceutical opioids	1	0 (0)	34	16 (47)	35	16 (46)
Methamphetamine	2	0 (0)	27	9 (33)	29	9 (31)
Other	1	0 (0)	41	23 (56)	42	23 (55)
p value		--		0.187		0.153
2011						
Pharmaceutical opioids	2	0 (0)	19	7 (37)	22	8 (36)
Methamphetamine	3	1 (33)	13	6 (46)	18	7 (39)
Other	2	1 (50)	25	15 (60)	27	16 (59)
p value		1.000		0.326		0.236

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	3	1 (33)	80	53 (66)	84	55 (65)
Daily or more	3	0 (0)	41	25 (61)	45	26 (58)
Not last month	1	0 (0)	3	0 (0)	5	1 (20)
p value		0.459		0.063		0.108
2008						
Less than daily	0	0 (0)	30	23 (77)	31	24 (77)
Daily or more	1	1 (100)	22	19 (86)	23	20 (87)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.395		0.373
2009						
Less than daily	6	1 (17)	57	34 (60)	65	37 (57)
Daily or more	1	0 (0)	40	23 (58)	44	24 (55)
Not last month	2	0 (0)	5	1 (20)	7	1 (14)
p value		0.755		0.228		0.098
2010						
Less than daily	1	0 (0)	67	30 (45)	68	30 (44)
Daily or more	1	0 (0)	28	16 (57)	29	16 (55)
Not last month	2	0 (0)	7	2 (29)	9	2 (22)
p value		--		0.356		0.220
2011						
Less than daily	4	1 (25)	31	14 (45)	37	15 (41)
Daily or more	2	1 (50)	22	13 (59)	25	15 (60)
Not last month	1	0 (0)	4	1 (25)	5	1 (20)
p value		1.000		0.345		0.162

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	5	1 (20)	98	67 (68)	104	69 (66)
Receptive sharing	0	0 (0)	15	6 (40)	16	7 (44)
p value		---		0.043		0.098
2008						
No receptive sharing	1	1 (100)	42	34 (81)	43	35 (81)
Receptive sharing	0	0 (0)	8	8 (100)	9	9 (100)
p value		---		0.324		0.323
2009						
No receptive sharing	6	1 (17)	82	49 (60)	93	53 (57)
Receptive sharing	1	0 (0)	12	8 (67)	13	8 (62)
p value		1.000		0.759		1.000
2010						
No receptive sharing	1	0 (0)	81	38 (47)	82	38 (46)
Receptive sharing	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.229		0.224
2011						
No receptive sharing	1	0 (0)	47	26 (55)	50	27 (54)
Receptive sharing	5	2 (40)	4	1 (25)	10	3 (30)
p value		1.000		0.331		0.299

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 7.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	7	1 (14)	100	60 (60)	110	64 (58)
Imprisonment	0	0 (0)	20	15 (75)	20	15 (75)
p value		---		0.312		0.214
2008						
No imprisonment	1	1 (100)	43	33 (77)	44	34 (77)
Imprisonment	0	0 (0)	6	6 (100)	7	7 (100)
p value		---		0.324		0.320
2009						
No imprisonment	8	1 (13)	85	48 (56)	96	51 (53)
Imprisonment	0	0 (0)	15	10 (67)	16	10 (63)
p value		---		0.575		0.592
2010						
No imprisonment	3	0 (0)	78	29 (37)	81	29 (36)
Imprisonment	0	0 (0)	5	5 (100)	5	5 (100)
p value		--		0.010		0.008
2011						
No imprisonment	7	2 (29)	54	26 (48)	62	28 (45)
Imprisonment	0	0 (0)	2	2 (100)	4	3 (75)
p value		--		0.491		0.335

* Total includes people who did not report duration of drug injection

Table 7.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	7	1 (14)	115	73 (63)	125	77 (62)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.536		0.526
2008						
No sex work	1	1 (100)	51	40 (78)	53	42 (79)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
No sex work	9	1 (11)	92	54 (59)	104	57 (55)
Sex work	0	0 (0)	1	1 (100)	2	2 (100)
p value		---		1.000		0.502
2010						
No sex work	3	0 (0)	98	47 (48)	101	47 (47)
Sex work	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.497		0.499
2011						
No sex work	7	2 (29)	54	27 (50)	63	30 (48)
Sex work	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		1.000

* Total includes people who did not report duration of drug injection

Table 7.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	78	44 (56)	35	24 (69)	113	68 (60)
Indigenous	12	8 (67)	7	5 (71)	19	13 (68)
p value		0.550		1.000		0.614
2008						
Non Indigenous	29	23 (79)	20	16 (80)	49	39 (80)
Indigenous	3	3 (100)	2	1 (50)	5	4 (80)
p value		1.000		0.411		1.000
2009						
Non Indigenous	61	30 (49)	36	20 (56)	98	51 (52)
Indigenous	9	6 (67)	6	3 (50)	15	9 (60)
p value		0.479		1.000		0.593
2010						
Non Indigenous	61	27 (44)	33	15 (45)	94	42 (45)
Indigenous	7	3 (43)	5	3 (60)	12	6 (50)
p value		1.000		0.653		0.766
2011						
Non Indigenous	38	16 (42)	20	10 (50)	58	26 (45)
Indigenous	3	1 (33)	5	4 (80)	8	5 (63)
p value		1.000		0.341		0.459

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	88	50 (57)	43	30 (70)	131	80 (91)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		---		1.000
2008						
English speaking	32	26 (81)	22	17 (77)	54	43 (80)
Non-English speaking	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
English speaking	70	37 (53)	44	24 (55)	117	63 (54)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.467		0.466
2010						
English speaking	67	30 (45)	38	18 (47)	105	48 (46)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
2011						
English speaking	42	17 (40)	25	14 (56)	67	31 (46)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

* Total includes people whose gender was not reported or reported as transgender

Table 7.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	86	48 (56)	39	26 (67)	125	74 (59)
Other Oceania	2	2 (100)	1	1 (100)	3	3 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.754		1.000		0.557
2008						
Australia	30	24 (80)	17	13 (76)	47	37 (79)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	5	4 (80)	6	5 (83)
Other	0	0 (0)	1	1 (100)	1	1 (100)
p value		1.000		1.000		1.000
2009						
Australia	68	36 (53)	40	21 (53)	109	58 (53)
Other Oceania	1	0 (0)	1	1 (100)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.724		1.000		0.874
2010						
Australia	65	28 (43)	33	15 (45)	98	43 (44)
Other Oceania	0	0 (0)	2	2 (100)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	2 (100)	2	1 (50)	4	3 (75)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.187		0.365		0.134
2011						
Australia	39	14 (36)	24	13 (54)	63	27 (43)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.059		1.000		0.041

* Total includes people whose gender was not reported or reported as transgender

Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	7	6	6	5	6
N° surveyed	N=243	N=308	N=334	N=445	N=506
Response (%)	35%	37%	--	58%	55%
Gender (%)					
Male	166 (68)	206 (67)	216 (65)	310 (70)	341 (67)
Female	76 (31)	102 (33)	116 (35)	133 (30)	163 (32)
Transgender	1 (<1)	0 (0)	2 (<1)	1 (<1)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	1 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	192 (79)	258 (84)	273 (82)	373 (84)	415 (82)
Bisexual	37 (15)	22 (7)	34 (10)	36 (8)	45 (9)
Homosexual	8 (3)	7 (2)	8 (2)	8 (2)	14 (3)
Not reported	6 (2)	21 (7)	19 (6)	28 (6)	32 (6)
Age and duration of injection (years)					
<i>Median age</i>	33	34	34	35	37
Age range	14-62	16-65	17-61	18-62	18-63
<i>Age group (%)</i>					
<25 years	19 (8)	19 (6)	29 (9)	46 (10)	38 (8)
25+ years	224 (92)	289 (94)	305 (91)	399 (90)	464 (92)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	4 (1)
<i>Median age 1stIDU</i>	17	18	18	17	18
Age range	10-42	10-45	11-51	10-50	10-50
Not reported	6	9	9	9	11
<i>Median years IDU</i>	13	15	14	15	17
Range	<1-46	<1-40	<1-40	<1-42	<1-47
<i>Duration of drug injection (%)</i>					
<3 years	12 (5)	19 (6)	13 (91)	15 (3)	13 (3)
3+ years	225 (93)	280 (91)	312 (93)	421 (95)	481 (95)
Not reported	6 (2)	9 (3)	9 (3)	9 (2)	12 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	217 (89)	266 (86)	304 (91)	405 (91)	442 (87)
Yes	14 (6)	28 (9)	23 (7)	36 (8)	55 (11)
Not reported	12 (5)	14 (5)	7 (2)	4 (1)	9 (2)
Region/Country of birth (%)					
Australia	202 (83)	259 (84)	285 (85)	392 (88)	444 (88)
Other Oceania	5 (2)	5 (2)	8 (2)	9 (2)	11 (2)
Asia	7 (3)	10 (3)	7 (2)	7 (2)	6 (1)
UK & Ireland	12 (5)	20 (6)	12 (4)	13 (3)	20 (4)
Other	10 (4)	8 (3)	20 (6)	15 (3)	24 (5)
Not reported	7 (3)	6 (2)	2 (<1)	9 (2)	1 (<1)
Main language spoken at home by parents (%)					
English speaking	221 (91)	270 (88)	303 (91)	412 (93)	457 (90)
Non-English speaking	17 (7)	32 (10)	23 (7)	26 (6)	45 (9)
Not reported	5 (2)	6 (2)	8 (2)	7 (2)	4 (1)
Imprisonment last year (%)					
No	195 (80)	241 (78)	285 (85)	319 (72)	403 (80)
Yes	30 (12)	40 (13)	39 (12)	45 (10)	59 (12)
Not reported	18 (7)	27 (9)	10 (3)	81 (18)	44 (9)
Injected in prison (%)	N=30	N=40	N=39	N=45	N=59
Yes	9 (30)	12 (30)	12 (31)	15 (33)	19 (32)
Frequency of injection last month (%)					
Not last month	11 (5)	21 (7)	21 (6)	30 (7)	46 (9)
Less than weekly	30 (12)	53 (17)	44 (13)	72 (16)	68 (13)
Weekly not daily	53 (22)	61 (20)	69 (21)	101 (23)	109 (22)
Daily or more	143 (59)	167 (54)	196 (59)	235 (53)	278 (55)
Not reported	6 (2)	6 (2)	4 (1)	7 (2)	5 (1)

Table 8.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=243	N=308	N=334	N=445	N=506
Cocaine	0 (0)	2 (1)	0 (0)	4 (1)	2 (<1)
Heroin	131 (54)	180 (58)	205 (61)	265 (60)	307 (61)
Methadone	6 (2)	8 (3)	9 (3)	13 (3)	12 (2)
Methamphetamine	51 (21)	55 (18)	45 (13)	57 (13)	91 (18)
Performance/Image-enhancing drugs	1 (<1)	3 (1)	1 (<1)	1 (<1)	1 (<1)
Pharmaceutical opioids	8 (3)	22 (7)	21 (6)	34 (8)	26 (5)
Suboxone	--	--	3 (1)	13 (3)	16 (3)
Subutex/Buprenorphine	27 (11)	21 (7)	26 (8)	31 (7)	20 (4)
More than one	8 (3)	6 (2)	10 (3)	23 (5)	26 (5)
Other drug	6 (2)	2 (1)	8 (2)	4 (1)	2 (<1)
Not reported	5 (2)	9 (3)	6 (2)	0 (0)	3 (<1)
N° Injected last month	N=226	N=281	N=309	N=409	N=455
Places injected last month (%)*					
Own home	187 (85)	231 (84)	256 (83)	314 (77)	352 (77)
Friend's home	100 (46)	112 (41)	117 (38)	188 (46)	195 (43)
Dealer's home	35 (16)	65 (24)	56 (18)	84 (21)	75 (16)
Street, park, beach	82 (37)	91 (33)	109 (35)	133 (33)	161 (35)
Car	81 (37)	107 (39)	130 (42)	148 (36)	156 (34)
Public toilet	77 (35)	106 (39)	106 (34)	157 (38)	179 (39)
Commercial injecting room	2 (1)	3 (1)	6 (2)	3 (1)	2 (<1)
Squat	21 (10)	30 (11)	28 (9)	43 (11)	42 (9)
Use of new sterile needles & syringes last month (%)					
All injections	150 (66)	186 (66)	224 (72)	289 (71)	327 (72)
Most of the time	64 (28)	76 (27)	69 (22)	76 (19)	87 (19)
Half of the time	3 (1)	7 (2)	7 (2)	5 (1)	13 (3)
Some of the time	2 (1)	6 (2)	5 (2)	6 (1)	5 (1)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	7 (3)	6 (2)	4 (1)	33 (8)	23 (5)
Re-used another's used needle & syringe last month (%)					
None	172 (76)	226 (80)	252 (82)	307 (75)	330 (73)
Once	14 (6)	11 (4)	16 (5)	20 (5)	30 (7)
Twice	9 (4)	19 (7)	13 (4)	16 (4)	25 (5)
3-5 times	9 (4)	11 (4)	9 (3)	16 (4)	21 (5)
>5 times	10 (4)	7 (2)	11 (4)	11 (3)	16 (4)
Not reported	12 (5)	7 (2)	8 (3)	39 (10)	33 (7)
Number of people needle & syringe was re-used after last month (%)					
None	172 (76)	226 (80)	252 (82)	307 (75)	330 (73)
One	24 (11)	27 (10)	26 (8)	33 (8)	49 (11)
Two	2 (1)	2 (1)	1 (<1)	4 (1)	9 (2)
Three to five	3 (1)	1 (<1)	2 (<1)	4 (1)	5 (1)
More than five	2 (1)	0 (0)	1 (<1)	7 (2)	5 (1)
Don't know	8 (4)	13 (5)	7 (2)	8 (2)	20 (4)
Not reported	15 (7)	12 (4)	20 (6)	46 (11)	37 (8)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	21 (9)	19 (7)	24 (8)	41 (10)	47 (10)
Casual sex partner	2 (1)	0 (0)	0 (0)	4 (1)	3 (1)
Close friend	10 (4)	13 (5)	8 (3)	33 (8)	50 (11)
Acquaintance	6 (3)	2 (1)	2 (<1)	8 (2)	23 (5)
Other	3 (1)	3 (1)	4 (1)	6 (1)	13 (3)
Equipment used after someone else last month (%)*					
Spoon	70 (34)	96 (36)	105 (36)	128 (31)	163 (36)
Water	43 (21)	56 (21)	55 (19)	76 (19)	100 (22)
Filter	36 (17)	45 (17)	49 (17)	52 (13)	76 (17)
Drug mix	21 (10)	31 (12)	31 (11)	51 (12)	53 (12)
Tourniquet	16 (8)	20 (8)	23 (8)	--	--
None	118 (57)	151 (57)	167 (58)	220 (54)	246 (54)
Injected by someone after that person injected themselves or others last month (%)					
No	182 (81)	234 (83)	246 (80)	314 (77)	359 (79)
Yes	29 (13)	37 (13)	57 (18)	64 (16)	72 (16)
Not reported	15 (7)	10 (4)	6 (2)	31 (8)	24 (5)

* More than one option could be selected

Table 8.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=243	N=308	N=334	N=445	N=506
Sex with a regular partner last month (%)					
No	115 (47)	146 (47)	140 (42)	216 (49)	249 (49)
Yes	114 (47)	153 (50)	179 (54)	215 (48)	209 (41)
Not reported	14 (6)	9 (3)	15 (4)	14 (3)	48 (9)
Condom used with regular partner last month (%)					
N° surveyed	N=114	N=153	N=179	N=215	N=209
Never	82 (72)	101 (66)	126 (70)	138 (64)	146 (70)
Sometimes	20 (18)	22 (14)	23 (13)	31 (14)	29 (14)
Every time	7 (6)	19 (12)	24 (13)	36 (17)	25 (12)
Not reported	5 (4)	11 (7)	6 (3)	10 (5)	9 (4)
Sex with other partner/s last month (%)					
No	194 (80)	259 (84)	273 (82)	353 (79)	406 (80)
Yes	36 (15)	35 (11)	45 (13)	65 (15)	81 (16)
Not reported	13 (5)	14 (5)	16 (5)	27 (6)	19 (4)
Condom used with other partner/s last month (%)					
N° surveyed	N=36	N=35	N=45	N=65	N=81
Never	8 (22)	9 (26)	14 (31)	21 (32)	28 (35)
Sometimes	13 (36)	14 (40)	10 (22)	17 (26)	16 (20)
Every time	14 (39)	10 (29)	20 (44)	23 (35)	32 (40)
Not reported	1 (3)	2 (6)	1 (2)	4 (6)	5 (6)
Sex work last month (%)					
No	218 (90)	266 (86)	308 (92)	393 (88)	454 (90)
Yes	15 (6)	17 (6)	17 (5)	28 (6)	31 (6)
Not reported	10 (4)	25 (8)	9 (3)	24 (5)	21 (4)
Condom used at last sex work last month (%)					
Yes	12 (86)	11 (73)	15 (88)	21 (78)	25 (89)

Table 8.1.4 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=243	N=308	N=334	N=445	N=506
Previous HIV test (%)					
Yes, last year	151 (62)	151 (49)	174 (52)	233 (52)	264 (52)
> 1 year ago	65 (27)	109 (35)	121 (36)	144 (32)	166 (33)
Never tested	19 (8)	34 (11)	29 (9)	40 (9)	52 (10)
Not reported	8 (3)	14 (5)	10 (3)	28 (6)	24 (5)
Previous HCV test (%)					
Yes, last year	154 (63)	176 (57)	194 (58)	268 (60)	305 (60)
> 1 year ago	78 (32)	98 (32)	110 (33)	125 (28)	153 (30)
Never tested	6 (2)	20 (6)	14 (4)	24 (5)	18 (4)
Not reported	5 (2)	14 (5)	16 (5)	28 (6)	30 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=141	N=185	N=201	N=280	N=321
Interferon/Interferon+Ribavirin	8 (6)	15 (8)	14 (7)	16 (9)	23 (7)
Other	3 (2)	6 (3)	5 (2)	5 (2)	2 (<1)
No treatment	122 (87)	158 (85)	176 (88)	238 (85)	278 (87)
Not reported	8 (6)	6 (3)	6 (3)	11 (4)	18 (6)
Current treatment for HCV	N=3	N=5	N=2	N=4	N=6
Interferon/Interferon+Ribavirin	2	3	2	1	6
Other	1	2	0	3	0

Table 8.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=243	N=308	N=334	N=445	N=506
Any treatment/therapy for drug use (%)					
No	23 (9)	34 (11)	29 (9)	36 (8)	58 (11)
Yes	215 (88)	272 (88)	304 (91)	404 (91)	441 (87)
Not reported	5 (2)	2 (1)	1 (<1)	5 (1)	7 (1)
History of methadone maintenance treatment (%)					
Currently	78 (32)	100 (32)	88 (26)	140 (31)	169 (33)
Previously	81 (33)	104 (34)	125 (37)	155 (35)	157 (31)
Never	79 (33)	99 (32)	114 (34)	133 (30)	162 (32)
Not reported	5 (2)	5 (2)	7 (2)	17 (4)	18 (4)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	40 (13)	52 (16)	69 (16)	57 (11)
Previously	--	121 (39)	136 (41)	169 (38)	197 (39)
Never	--	141 (46)	141 (42)	200 (45)	234 (46)
42)Not reported	--	6 (2)	5 (2)	7 (2)	18 (4)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	38 (12)	54 (16)	66 (15)	69 (14)
Previously	--	69 (22)	94 (28)	123 (28)	137 (27)
Never	--	196 (64)	181 (54)	248 (56)	281 (56)
Not reported	--	5 (2)	5 (2)	8 (2)	19 (4)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=264
Yes, in the last month					8 (3)
Yes, 1-6 months ago					15 (6)
Yes, 6-12 months ago					15 (6)
Yes, more than one year ago					29 (11)
No, haven't tried to access OST					197 (75)

* New variable in 2008

Table 8.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=226	N=281	N=309	N=409	N=455
Needle Syringe Program	185 (82)	263 (94)	229 (74)	385 (94)	425 (93)
Chemist/Pharmacy	49 (22)	112 (40)	62 (20)	75 (18)	92 (20)
Personal sources	51 (23)	--	64 (21)	58 (14)	46 (10)
Dispensing/Vending Machine	0 (0)	--	0 (0)	0 (0)	0 (0)
Other sources	8 (4)	--	13 (4)	13 (3)	4 (1)

* More than one option could be selected

Table 8.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=506
Never	138 (27)
Monthly or less	112 (22)
2-4 times a month	70 (14)
2-3 times a week	72 (14)
4 or more times a week	100 (20)
Not reported	14 (3)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=354
1 or 2	77 (22)
3 or 4	97 (27)
5 or 6	57 (16)
7, 8 or 9	40 (11)
10 or more	53 (15)
Not reported	30 (8)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	163	0 (0.0)	76	0 (0.0)	240	0 (0.0)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
2010	305	2 (0.7)	131	0 (0.0)	438	2 (0.5)
2011	335	4 (1.2)	162	0 (0.0)	499	4 (0.8)
χ^2 trend p value		0.389		---		0.387

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	139	100 (72)	65	48 (74)	205	149 (73)
2008	188	141 (75)	90	58 (64)	278	199 (72)
2009	212	120 (57)	115	60 (52)	329	182 (55)
2010	303	204 (67)	130	72 (55)	435	278 (64)
2011	332	229 (69)	158	93 (59)	492	324 (66)
χ^2 trend p value		0.412		0.055		0.082

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	124	91 (73)	37	30 (81)	161	121 (75)
Bisexual	9	5 (56)	24	16 (67)	33	21 (64)
Homosexual	3	2 (67)	2	1 (50)	6	4 (67)
p value		0.470		0.229		0.289
2008						
Heterosexual	165	122 (74)	67	44 (66)	232	166 (72)
Bisexual	5	4 (80)	16	9 (56)	21	13 (62)
Homosexual	4	3 (75)	3	3 (100)	7	6 (86)
p value		1.000		0.435		0.481
2009						
Heterosexual	186	108 (58)	82	40 (49)	270	150 (56)
Bisexual	11	5 (45)	22	14 (64)	33	19 (58)
Homosexual	4	1 (25)	4	2 (50)	8	3 (38)
p value		0.344		0.412		0.637
2010						
Heterosexual	269	183 (68)	97	52 (54)	367	236 (64)
Bisexual	13	10 (77)	21	13 (62)	34	23 (68)
Homosexual	3	2 (67)	4	1 (25)	7	3 (43)
p value		0.893		0.409		0.442
2011						
Heterosexual	300	212 (71)	102	60 (59)	403	273 (68)
Bisexual	10	5 (50)	35	18 (51)	45	23 (51)
Homosexual	9	5 (56)	5	2 (40)	14	7 (50)
p value		0.230		0.581		0.035

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	9	2 (22)	8	4 (50)	17	6 (35)
25 – 34	72	48 (67)	33	25 (76)	106	74 (70)
35+ years	58	50 (86)	24	19 (79)	82	69 (84)
p value		<0.001		0.250		<0.001
2008						
< 25 years	9	3 (33)	9	1 (11)	18	4 (22)
25 – 34	79	54 (68)	48	32 (67)	127	86 (68)
35+ years	100	84 (84)	33	25 (76)	133	109 (82)
p value		0.001		0.001		<0.001
2009						
< 25 years	15	2 (13)	14	1 (7)	29	3 (10)
25 – 34	95	49 (52)	49	27 (55)	145	77 (53)
35+ years	102	69 (68)	52	32 (62)	155	102 (66)
p value		<0.001		0.001		<0.001
2010						
< 25 years	14	3 (21)	29	7 (24)	43	10 (23)
25 – 34	112	69 (62)	44	26 (59)	157	96 (61)
35+ years	177	132 (75)	57	39 (68)	235	172 (73)
p value		<0.001		<0.001		<0.001
2011						
< 25 years	18	8 (44)	20	5 (25)	38	13 (34)
25 – 34	102	68 (67)	60	40 (67)	163	109 (67)
35+ years	210	152 (72)	77	48 (62)	287	200 (70)
p value		0.046		0.004		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	7	1 (14)	5	1 (20)	12	2 (17)
3 to 10 years	30	14 (47)	24	19 (79)	55	34 (62)
11 + years	97	81 (84)	35	27 (77)	132	108 (82)
p value		<0.001		0.019		<0.001
2008						
<3 years	8	2 (25)	9	4 (44)	17	6 (35)
3 to 10 years	35	19 (54)	21	10 (48)	56	29 (52)
11 + years	139	115 (83)	57	43 (75)	196	158 (81)
p value		<0.001		0.027		<0.001
2009						
<3 years	6	2 (33)	6	0 (0)	12	2 (17)
3 to 10 years	44	16 (36)	36	13 (36)	81	30 (37)
11 + years	159	101 (64)	68	43 (63)	227	144 (63)
p value		0.003		0.001		<0.001
2010						
<3 years	10	4 (40)	4	2 (50)	14	6 (43)
3 to 10 years	40	18 (45)	44	15 (34)	84	33 (39)
11 + years	247	177 (71)	81	54 (67)	329	323 (71)
p value		0.001		0.001		<0.001
2011						
<3 years	5	0 (0)	8	3 (38)	13	3 (23)
3 to 10 years	49	29 (59)	37	15 (41)	86	44 (51)
11 + years	274	198 (72)	107	71 (66)	382	270 (71)
p value		0.001		0.008		<0.001

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	4	2 (50)	101	78 (77)	106	81 (76)
Methamphetamine	4	0 (0)	36	25 (69)	42	27 (64)
Other	4	0 (0)	46	36 (78)	53	38 (72)
p value		0.091		0.595		0.324
2008						
Heroin	6	3 (50)	151	114 (76)	161	120 (75)
Methamphetamine	7	3 (43)	42	29 (69)	50	32 (64)
Other	4	0 (0)	52	38 (73)	59	40 (68)
p value		0.232		0.698		0.338
2009						
Heroin	4	0 (0)	194	117 (60)	201	119 (59)
Methamphetamine	1	0 (0)	41	18 (44)	45	21 (47)
Other	6	2 (33)	68	36 (53)	77	39 (51)
p value		0.424		0.130		0.188
2010						
Heroin	8	4 (50)	246	169 (69)	257	176 (68)
Methamphetamine	1	0 (0)	52	22 (42)	56	25 (45)
Other	5	2 (54)	115	74 (64)	122	77 (63)
p value		1.000		0.002		0.004
2011						
Heroin	8	1 (13)	283	202 (71)	297	208 (70)
Methamphetamine	1	1 (100)	87	49 (56)	89	50 (56)
Other	4	1 (25)	95	61 (64)	103	64 (62)
p value		0.245		0.026		0.037

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	4	0 (0)	59	45 (76)	66	48 (73)
Daily or more	7	1 (14)	115	88 (77)	124	91 (73)
Not last month	1	1 (100)	8	4 (50)	10	5 (50)
p value		0.054		0.238		0.281
2008						
Less than daily	8	3 (38)	96	74 (77)	108	79 (73)
Daily or more	5	2 (40)	137	101 (73)	147	107 (73)
Not last month	2	1 (50)	15	10 (67)	17	11 (65)
p value		0.949		0.648		0.761
2009						
Less than daily	5	0 (0)	104	62 (60)	111	64 (58)
Daily or more	7	2 (29)	182	100 (55)	193	104 (54)
Not last month	0	0 (0)	19	9 (47)	21	10 (48)
p value		0.190		0.547		0.648
2010						
Less than daily	2	1 (50)	189	127 (67)	195	132 (68)
Daily or more	11	5 (45)	193	123 (64)	206	129 (63)
Not last month	1	0 (0)	26	13 (50)	29	15 (52)
p value		1.000		0.225		0.204
2011						
Less than daily	3	0 (0)	168	106 (63)	173	106 (61)
Daily or more	10	3 (30)	251	176 (70)	269	186 (69)
Not last month	0	0 (0)	44	28 (64)	45	28 (62)
p value		0.528		0.276		0.206

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	8	0 (0)	129	97 (75)	140	100 (71)
Receptive sharing	2	1 (50)	36	28 (78)	39	30 (77)
p value		0.200		0.829		0.549
2008						
No receptive sharing	13	5 (38)	188	140 (74)	209	150 (72)
Receptive sharing	0	0 (0)	40	32 (80)	41	33 (80)
p value		---		0.547		0.335
2009						
No receptive sharing	11	2 (18)	234	135 (58)	249	140 (56)
Receptive sharing	1	0 (0)	44	23 (52)	47	24 (51)
p value		1.000		0.512		0.526
2010						
No receptive sharing	11	5 (45)	287	184 (64)	303	193 (64)
Receptive sharing	2	1 (50)	57	37 (65)	59	38 (64)
p value		1.000		1.000		1.000
2011						
No receptive sharing	10	2 (20)	306	197 (64)	323	203 (63)
Receptive sharing	1	0 (0)	84	64 (76)	87	66 (76)
p value		1.000		0.049		0.030

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 8.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	10	1 (10)	149	111 (75)	163	115 (71)
Imprisonment	1	1 (100)	26	20 (77)	28	22 (79)
p value		0.182		1.000		0.498
2008						
No imprisonment	15	6 (40)	198	141 (71)	220	152 (69)
Imprisonment	1	0 (0)	33	27 (82)	35	27 (77)
p value		1.000		0.291		0.427
2009						
No imprisonment	12	2 (17)	261	140 (54)	282	148 (52)
Imprisonment	0	0 (0)	38	28 (74)	38	28 (74)
p value		---		0.023		0.015
2010						
No imprisonment	10	3 (30)	299	183 (61)	315	192 (61)
Imprisonment	1	1 (100)	40	27 (68)	42	28 (67)
p value		0.364		0.492		0.505
2011						
No imprisonment	12	3 (25)	372	238 (64)	392	248 (63)
Imprisonment	1	0 (0)	53	42 (79)	56	42 (75)
p value		1.000		0.030		0.100

* Total includes people who did not report duration of drug injection

Table 8.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	9	0 (0)	170	129 (76)	183	133 (73)
Sex work	2	1 (100)	11	8 (73)	13	10 (77)
p value		0.018		0.730		1.000
2008						
No sex work	15	6 (40)	219	164 (75)	241	175 (73)
Sex work	0	0 (0)	14	11 (79)	15	11 (73)
p value		---		1.000		1.000
2009						
No sex work	11	2 (18)	284	160 (56)	303	168 (55)
Sex work	1	0 (0)	15	8 (53)	17	8 (47)
p value		1.000		1.000		0.618
2010						
No sex work	11	5 (45)	366	239 (65)	384	250 (65)
Sex work	3	1 (33)	24	12 (50)	28	14 (50)
p value		1.000		0.185		0.152
2011						
No sex work	12	3 (23)	421	274 (65)	442	283 (64)
Sex work	0	0 (0)	28	23 (82)	29	23 (79)
p value		--		0.097		0.110

* Total includes people who did not report duration of drug injection

Table 8.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	123	87 (71)	60	46 (77)	184	134 (73)
Indigenous	9	9 (100)	3	0 (0)	12	12 (75)
p value		0.113		0.017		1.000
2008						
Non Indigenous	165	121 (73)	77	50 (65)	242	171 (71)
Indigenous	16	14 (88)	10	6 (60)	26	20 (77)
p value		0.366		0.739		0.650
2009						
Non Indigenous	195	52 (51)	102	52 (51)	299	164 (55)
Indigenous	12	8 (73)	11	8 (73)	23	15 (65)
p value		1.000		0.213		0.389
2010						
Non Indigenous	281	192 (68)	113	66 (58)	396	260 (66)
Indigenous	18	10 (56)	17	6 (35)	35	16 (46)
p value		0.301		0.115		0.026
2011						
Non Indigenous	292	201 (69)	136	82 (60)	429	284 (66)
Indigenous	33	25 (76)	20	9 (45)	54	35 (65)
p value		0.550		0.229		0.879

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	126	92 (73)	60	43 (72)	187	136 (73)
Non-English speaking	10	7 (70)	4	4 (100)	14	11 (79)
p value		1.000		0.566		0.763
2008						
English speaking	162	120 (74)	85	57 (67)	247	177 (72)
Non-English speaking	21	17 (81)	5	1 (20)	26	18 (69)
p value		0.601		0.052		0.821
2009						
English speaking	193	107 (55)	103	54 (52)	298	163 (55)
Non-English speaking	16	11 (69)	7	3 (43)	23	14 (61)
p value		0.432		0.702		0.666
2010						
English speaking	277	188 (68)	126	69 (55)	404	258 (64)
Non-English speaking	23	13 (57)	2	2 (100)	25	15 (60)
p value		0.356		0.502		0.675
2011						
English speaking	293	200 (68)	150	88 (59)	444	289 (65)
Non-English speaking	36	27 (75)	7	4 (57)	44	32 (73)
p value		0.452		1.000		0.405

* Total includes people whose gender was not reported or reported as transgender

Table 8.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	114	85 (75)	56	40 (71)	171	126 (74)
Other Oceania	2	2 (100)	1	0 (0)	3	2 (67)
Asia	4	3 (75)	1	1 (100)	5	4 (80)
UK & Ireland	9	6 (67)	2	2 (100)	11	8 (73)
Other	5	1 (20)	4	4 (100)	9	5 (56)
p value		0.092		0.371		0.753
2008						
Australia	159	120 (75)	76	47 (62)	235	167 (71)
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)
Asia	5	4 (80)	1	1 (100)	6	5 (83)
UK & Ireland	11	7 (64)	8	8 (100)	19	15 (79)
Other	9	8 (89)	3	1 (33)	12	9 (75)
p value		0.142		0.068		0.311
2009						
Australia	180	105 (58)	99	51 (52)	281	158 (56)
Other Oceania	5	3 (60)	2	1 (50)	7	4 (57)
Asia	5	2 (40)	2	1 (50)	7	3 (43)
UK & Ireland	7	3 (43)	5	4 (80)	12	7 (58)
Other	14	6 (43)	6	3 (50)	20	9 (45)
p value		0.650		0.873		0.832
2010						
Australia	260	178 (68)	122	65 (53)	383	244 (64)
Other Oceania	8	7 (88)	1	0 (0)	9	7 (78)
Asia	5	3 (60)	1	1 (100)	6	4 (67)
UK & Ireland	11	6 (55)	2	2 (100)	13	8 (62)
Other	15	7 (47)	1	1 (100)	18	10 (56)
p value		0.242		0.179		0.855
2011						
Australia	283	198 (70)	148	87 (59)	431	287 (66)
Other Oceania	10	6 (60)	1	1 (100)	11	7 (64)
Asia	6	4 (67)	0	0 (0)	6	4 (67)
UK & Ireland	15	9 (60)	4	2 (50)	19	11 (58)
Other	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.808		1.000		0.939

* Total includes people whose gender was not reported or reported as transgender

Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2007	2008	2009	2010	2011
Number of sites	2	2	2	3	3
N° surveyed	N=110	N=196	N=222	N=219	N=192
Response (%)	51%	73%	80%	56%	77%
Gender (%)					
Male	71 (65)	123 (63)	134 (60)	127 (58)	114 (59)
Female	39 (35)	73 (37)	87 (39)	92 (42)	77 (40)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	93 (85)	158 (81)	185 (83)	183 (84)	159 (83)
Bisexual	8 (7)	22 (11)	15 (7)	14 (6)	17 (9)
Homosexual	7 (6)	7 (4)	10 (5)	8 (4)	9 (5)
Not reported	2 (2)	9 (5)	12 (5)	14 (6)	7 (4)
Age and duration of injection (years)					
<i>Median age</i>	36.5	35	36	40	40
<i>Age range</i>	16-55	17-65	15-62	18-63	16-64
<i>Age group (%)</i>					
<25 years	10 (9)	12 (6)	16 (7)	8 (4)	8 (4)
25+ years	100 (91)	183 (93)	206 (93)	211 (96)	183 (95)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	1 (<1)
<i>Median age 1stIDU</i>	18	18	18	18	19
<i>Age range</i>	12-49	11-47	11-52	11-50	11-47
Not reported	2	5	7	3	5
<i>Median years IDU</i>	15	15	16	18	18
<i>Range</i>	<1-37	<1-42	<1-44	<1-47	<1-45
<i>Duration of drug injection (%)</i>					
<3 years	8 (7)	3 (2)	9 (4)	11 (5)	6 (3)
3+ years	100 (91)	188 (96)	206 (93)	205 (94)	180 (94)
Not reported	2 (2)	5 (3)	7 (3)	3 (1)	6 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	102 (93)	179 (91)	208 (94)	200 (91)	177 (92)
Yes	5 (5)	9 (5)	12 (5)	11 (5)	13 (7)
Not reported	3 (3)	8 (4)	2 (1)	8 (4)	2 (1)
Region/Country of birth (%)					
Australia	90 (82)	149 (76)	179 (81)	176 (80)	150 (78)
Other Oceania	1 (1)	16 (8)	8 (4)	13 (6)	11 (6)
Asia	1 (1)	2 (1)	5 (2)	3 (1)	3 (2)
UK & Ireland	9 (8)	18 (9)	18 (8)	16 (7)	19 (10)
Other	5 (5)	7 (4)	7 (3)	7 (3)	9 (5)
Not reported	4 (4)	4 (2)	5 (2)	4 (2)	0 (0)
Main language spoken at home by parents (%)					
English speaking	105 (95)	186 (95)	216 (97)	208 (95)	186 (97)
Non-English speaking	2 (2)	10 (5)	5 (2)	7 (3)	6 (3)
Not reported	3 (3)	0 (0)	1 (<1)	4 (2)	0 (0)
Imprisonment last year (%)					
No	85 (77)	168 (86)	193 (87)	160 (73)	162 (84)
Yes	18 (16)	21 (11)	21 (9)	16 (7)	16 (8)
Not reported	7 (6)	7 (4)	8 (4)	43 (20)	14 (7)
Injected in prison (%)	N=18	N=21	N=21	N=16	N=16
Yes	6 (33)	8 (38)	7 (33)	3 (19)	4 (25)
Frequency of injection last month (%)					
Not last month	6 (5)	7 (4)	6 (3)	11 (5)	11 (6)
Less than weekly	9 (8)	15 (8)	22 (10)	29 (13)	27 (14)
Weekly not daily	21 (19)	49 (25)	43 (19)	48 (22)	46 (24)
Daily or more	73 (66)	124 (63)	150 (68)	131 (60)	106 (55)
Not reported	1 (1)	1 (1)	1 (<1)	0 (0)	2 (1)

Table 9.1.2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2007	2008	2009	2010	2011
Last drug injected (%)	N=110	N=196	N=222	N=219	N=192
Cocaine	0 (0)	0 (0)	2 (1)	0 (0)	1 (<1)
Heroin	28 (25)	62 (32)	74 (33)	66 (30)	48 (25)
Methadone	4 (4)	5 (3)	12 (5)	13 (6)	12 (6)
Methamphetamine	34 (31)	54 (28)	43 (19)	58 (26)	65 (34)
Performance/Image-enhancing drugs	0 (0)	0 (0)	1 (<1)	1 (<1)	0 (0)
Pharmaceutical opioids	23 (21)	42 (21)	37 (17)	31 (14)	34 (18)
Suboxone	--	--			11 (6)
Subutex/Buprenorphine	7 (6)	18 (9)	16 (7)	8 (4)	8 (4)
More than one	5 (5)	10 (5)	11 (5)	22 (10)	12 (6)
Other drug	6 (6)	0 (0)	18 (8)	14 (6)	0 (0)
Not reported	3 (3)	5 (3)	8 (4)	6 (3)	1 (<1)
N° Injected last month	N=103	N=188	N=215	N=208	N=179
Places injected last month (%)*					
Own home	91 (93)	171 (92)	196 (91)	174 (84)	147 (82)
Friend's home	48 (49)	100 (54)	107 (50)	79 (38)	69 (39)
Dealer's home	31 (32)	56 (30)	49 (23)	42 (20)	42 (23)
Street, park, beach	23 (23)	55 (30)	51 (24)	45 (22)	23 (13)
Car	41 (42)	80 (43)	75 (35)	61 (29)	50 (28)
Public toilet	19 (19)	45 (24)	60 (28)	42 (20)	48 (27)
Commercial injecting room	0 (0)	2 (1)	1 (<1)	0 (0)	1 (<1)
Squat	8 (8)	18 (10)	19 (9)	7 (3)	9 (5)
Use of new sterile needles & syringes last month (%)					
All injections	58 (56)	119 (63)	148 (69)	131 (63)	126 (70)
Most of the time	29 (28)	56 (30)	56 (26)	47 (23)	33 (18)
Half of the time	6 (6)	5 (3)	4 (2)	5 (2)	2 (1)
Some of the time	7 (7)	3 (2)	3 (1)	2 (1)	6 (3)
Not last month	0 (0)	3 (2)	1 (<1)	0 (0)	0 (0)
Not reported	3 (3)	2 (1)	3 (1)	23 (11)	12 (7)
Re-used another's used needle & syringe last month (%)					
None	75 (73)	150 (80)	168 (78)	151 (73)	131 (73)
Once	10 (10)	11 (6)	13 (6)	8 (4)	7 (4)
Twice	1 (1)	10 (5)	12 (6)	13 (6)	9 (5)
3-5 times	11 (11)	8 (4)	12 (6)	4 (2)	9 (5)
>5 times	3 (3)	8 (4)	6 (3)	4 (2)	9 (5)
Not reported	3 (3)	1 (1)	4 (2)	28 (13)	14 (8)
Number of people needle & syringe was re-used after last month (%)					
None	75 (73)	150 (80)	168 (78)	151 (73)	131 (73)
One	13 (13)	16 (9)	23 (11)	16 (8)	20 (11)
Two	1 (1)	2 (1)	5 (2)	4 (2)	1 (<1)
Three to five	1 (1)	1 (1)	1 (<1)	1 (<1)	2 (1)
More than five	1 (1)	0 (0)	1 (<1)	1 (<1)	3 (2)
Don't know	4 (4)	8 (4)	6 (3)	5 (2)	4 (2)
Not reported	9 (9)	11 (6)	11 (5)	30 (14)	18 (10)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	12 (12)	16 (9)	18 (8)	21 (10)	19 (11)
Casual sex partner	1 (1)	3 (2)	0 (0)	2 (1)	2 (1)
Close friend	7 (7)	8 (4)	13 (6)	11 (5)	8 (4)
Acquaintance	0 (0)	3 (2)	5 (2)	6 (3)	5 (3)
Other	1 (1)	2 (1)	5 (2)	3 (1)	5 (3)
Equipment used after someone else last month (%)*					
Spoon	22 (22)	37 (23)	48 (24)	36 (17)	42 (23)
Water	14 (14)	29 (18)	37 (19)	28 (13)	15 (8)
Filter	13 (13)	20 (12)	35 (18)	23 (11)	17 (10)
Drug mix	12 (12)	20 (12)	20 (10)	19 (9)	11 (6)
Tourniquet	17 (17)	23 (14)	20 (10)	--	--
None**	63 (64)	100 (61)	131 (66)	126 (61)	107 (60)
Injected by someone after that person injected themselves or others last month (%)					
No	83 (81)	150 (80)	172 (80)	160 (77)	27 (15)
Yes	16 (16)	30 (16)	39 (18)	23 (11)	140 (78)
Not reported	4 (4)	8 (4)	4 (2)	25 (12)	12 (7)

* More than one option could be selected

Table 9.1.3 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2007	2008	2009	2010	2011
N° surveyed	N=110	N=196	N=222	N=219	N=192
Sex with a regular partner last month (%)					
No	42 (38)	81 (41)	103 (46)	99 (45)	86 (45)
Yes	66 (60)	113 (58)	113 (51)	109 (50)	93 (48)
Not reported	2 (2)	2 (1)	6 (3)	11 (5)	13 (7)
Condom used with regular partner last month (%)					
N° surveyed	N=66	N=113	N=113	N=109	N=93
Never	46 (70)	80 (71)	89 (79)	77 (71)	70 (75)
Sometimes	8 (12)	12 (11)	12 (11)	12 (11)	10 (11)
Every time	8 (12)	14 (12)	5 (4)	12 (11)	10 (11)
Not reported	4 (6)	7 (6)	7 (6)	8 (7)	3 (3)
Sex with other partner/s last month (%)					
No	97 (88)	164 (84)	180 (81)	187 (85)	163 (85)
Yes	11 (10)	29 (15)	32 (14)	22 (10)	24 (13)
Not reported	2 (2)	3 (2)	10(5)	10 (5)	5 (3)
Condom used with other partner/s last month (%)					
N° surveyed	N=11	N=29	N=32	N=22	N=24
Never	2 (18)	6 (21)	12 (38)	8 (36)	11 (46)
Sometimes	4 (36)	14 (48)	9 (28)	6 (27)	5 (21)
Every time	5 (45)	7 (24)	11 (34)	8 (36)	7 (29)
Not reported	0 (0)	2 (7)	0 (0)	0 (0)	1 (4)
Sex work last month (%)					
No	99 (90)	177 (90)	203 (91)	200 (91)	173 (90)
Yes	4 (4)	11 (6)	11 (5)	6 (3)	10 (5)
Not reported	7 (6)	8 (4)	8 (4)	13 (6)	9 (5)
Condom used at last sex work last month (%)					
Yes	4 (100)	9 (82)	8 (73)	5 (83)	8 (80)

Table 9.1.4 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2007	2008	2009	2010	2011
N° surveyed	N=110	N=196	N=222	N=219	N=192
Previous HIV test (%)					
Yes, last year	58 (53)	99 (51)	111 (50)	113 (52)	104 (54)
> 1 year ago	38 (35)	75 (38)	78 (35)	60 (27)	63 (33)
Never tested	12 (11)	14 (7)	26 (12)	33 (15)	19 (10)
Not reported	2 (2)	8 (4)	7 (3)	13 (6)	6 (3)
Previous HCV test (%)					
Yes, last year	62 (56)	108 (55)	128 (58)	124 (57)	115 (60)
> 1 year ago	34 (31)	65 (33)	71 (32)	63 (29)	58 (30)
Never tested	11 (10)	15 (8)	15 (7)	13 (6)	8 (4)
Not reported	3 (3)	8 (4)	8 (4)	19 (9)	11 (6)
Any treatment for HCV (%)					
N° self-reported previous positive HCV test	N=31	N=90	N=92	N=120	N=106
Interferon/Interferon+Ribavirin	2 (6)	9 (10)	13 (14)	19 (16)	21 (20)
Other	1 (3)	4 (4)	1 (1)	2 (2)	3 (3)
No treatment	27 (87)	75 (83)	72 (78)	92 (77)	77 (73)
Not reported	1 (3)	2 (2)	6 (7)	7 (6)	5 (5)
Current treatment for HCV	N=1	N=5	N=5	N=5	N=8
Interferon/Interferon+Ribavirin	1	3	5	4	6
Other	0	2	0	1	2

Table 9.1.5 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2007	2008	2009	2010	2011
N° surveyed	N=110	N=196	N=222	N=219	N=192
Any treatment/therapy for drug use (%)					
No	31 (28)	54 (28)	57 (26)	50 (23)	43 (22)
Yes	76 (69)	139 (71)	158 (71)	165 (75)	147 (77)
Not reported	3 (3)	3 (2)	7 (3)	4 (2)	2 (1)
History of methadone maintenance treatment (%)					
Currently	21 (19)	39 (20)	53 (24)	53 (25)	41 (21)
Previously	27 (25)	55 (28)	52 (23)	56 (26)	59 (31)
Never	60 (55)	99 (51)	112 (50)	97 (44)	84 (44)
Not reported	2 (2)	3 (2)	5 (2)	11 (5)	8 (4)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	21 (11)	27 (12)	21 (10)	19 (10)
Previously	--	59 (30)	43 (19)	44 (20)	39 (20)
Never	--	111 (57)	149 (67)	152 (69)	124 (65)
Not reported	--	5 (3)	3 (1)	2 (1)	10 (5)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	18 (9)	25 (11)	25 (11)	32 (17)
Previously	--	24 (12)	28 (13)	30 (14)	25 (13)
Never	--	149 (76)	164 (74)	160 (73)	129 (67)
Not reported	--	5 (3)	5 (2)	4 (2)	6 (3)
Tried to access OST but unsuccessful because the program was full (%)					
N° not currently on OST					N=117
Yes, in the last month					5 (4)
Yes, 1-6 months ago					5 (4)
Yes, 6-12 months ago					1 (1)
Yes, more than one year ago					18 (15)
No, haven't tried to access OST					88 (75)

* New variable in 2008

Table 9.1.6 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

Source of needles/syringes (%)*	2007	2008	2009	2010	2011
N° Injected last month	N=103	N=188	N=215	N=208	N=179
Needle Syringe Program	52 (50)	159 (85)	102 (47)	175 (84)	154 (86)
Chemist/Pharmacy	35 (34)	96 (51)	72 (33)	55 (26)	44 (25)
Personal sources	35 (34)	--	46 (21)	32 (15)	24 (13)
Dispensing/Vending Machine	1 (1)	--	0 (0)	1 (1)	4 (2)
Other sources	2 (2)	--	5 (2)	4 (2)	3 (2)

* More than one option could be selected

Table 9.1.7 Number (percentage) of respondents by frequency and quantity of alcohol consumption

Frequency of alcohol consumption (%)	2011
N° surveyed	N=192
Never	72 (38)
Monthly or less	39 (20)
2-4 times a month	29 (15)
2-3 times a week	21 (11)
4 or more times a week	22 (11)
Not reported	9 (4)
Number of standard drinks on a typical day when drinking alcohol (%)	
N° reporting alcohol consumption	N=111
1 or 2	34 (31)
3 or 4	39 (35)
5 or 6	13 (12)
7, 8 or 9	9 (8)
10 or more	6 (5)
Not reported	10 (9)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2007	54	1 (1.9)	31	0 (0.0)	85	1 (1.2)
2008	106	2 (1.9)	62	0 (0.0)	168	2 (1.2)
2009	126	1 (0.8)	85	1 (1.2)	212	2 (0.9)
2010	121	0 (0.0)	92	1 (1.1)	213	1 (0.5)
2011	112	1 (0.9)	77	3 (3.9)	190	4 (2.1)
χ^2 trend p value		0.254		0.059		0.606

* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007	54	23 (43)	31	14 (45)	85	37 (44)
2008	101	59 (58)	59	32 (54)	160	91 (57)
2009	125	60 (48)	85	42 (49)	211	102 (48)
2010	119	65 (55)	92	54 (59)	211	119 (56)
2011	110	69 (63)	73	34 (47)	184	104 (57)
χ^2 trend p value		0.057		0.900		0.111

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.2 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heterosexual	50	23 (46)	23	11 (48)	73	34 (47)
Bisexual	1	0 (0)	4	1 (25)	5	1 (20)
Homosexual	3	0 (0)	3	1 (33)	6	1 (17)
p value		0.253		0.828		0.257
2008						
Heterosexual	91	53 (58)	39	19 (49)	130	72 (55)
Bisexual	4	2 (50)	14	10 (71)	18	12 (67)
Homosexual	3	1 (33)	4	2 (50)	7	3 (43)
p value		0.707		0.332		0.509
2009						
Heterosexual	109	52 (48)	68	32 (47)	177	84 (47)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	4	2 (50)	6	2 (17)	10	4 (40)
p value		0.851		0.143		0.162
2010						
Heterosexual	110	62 (56)	65	40 (62)	175	102 (58)
Bisexual	3	1 (33)	11	5 (45)	14	6 (43)
Homosexual	0	0 (0)	8	3 (38)	8	3 (38)
p value		0.583		0.316		0.316
2011						
Heterosexual	98	64 (65)	55	27 (49)	153	91 (59)
Bisexual	4	0 (0)	11	5 (45)	16	6 (38)
Homosexual	3	1 (33)	6	2 (33)	9	3 (33)
p value		0.006		0.845		0.090

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.3 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
< 25 years	6	2 (33)	3	0 (0)	9	2 (22)
25 – 34	18	4 (22)	13	6 (46)	31	10 (32)
35+ years	30	17 (57)	15	8 (53)	45	25 (56)
p value		0.058		0.237		0.052
2008						
< 25 years	5	1 (20)	5	0 (0)	10	1 (10)
25 – 34	39	21 (54)	25	15 (60)	64	36 (56)
35+ years	56	36 (64)	29	17 (59)	85	53 (62)
p value		0.126		0.039		0.007
2009						
< 25 years	8	2 (25)	6	0 (0)	14	2 (14)
25 – 34	36	17 (47)	33	18 (55)	70	35 (50)
35+ years	81	41 (51)	46	24 (52)	127	65 (51)
p value		0.382		0.042		0.030
2010						
< 25 years	2	0 (0)	6	3 (50)	8	3 (38)
25 – 34	31	16 (52)	30	14 (47)	61	30 (49)
35+ years	86	49 (57)	56	37 (66)	142	86 (61)
p value		0.296		0.197		0.174
2011						
< 25 years	6	1 (17)	2	1 (50)	8	2 (25)
25 – 34	25	13 (52)	24	8 (33)	49	21 (43)
35+ years	78	54 (69)	47	25 (53)	126	80 (63)
p value		0.017		0.254		0.007

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.4 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3 to 10 years	16	4 (25)	11	2 (18)	27	6 (22)
11 + years	33	18 (55)	17	12 (71)	50	30 (60)
p value		0.031		0.006		<0.001
2008						
<3 years	0	0 (0)	2	1 (50)	2	1 (50)
3 to 10 years	23	8 (35)	17	5 (29)	40	13 (33)
11 + years	74	48 (65)	40	26 (65)	114	74 (65)
p value		0.011		0.047		0.002
2009						
<3 years	4	0 (0)	5	1 (20)	9	1 (11)
3 to 10 years	20	6 (30)	22	7 (32)	42	13 (31)
11 + years	95	52 (55)	58	34 (59)	154	86 (56)
p value		0.018		0.040		0.001
2010						
<3 years	6	0 (0)	4	2 (50)	10	2 (20)
3 to 10 years	13	4 (31)	21	11 (52)	34	15 (44)
11 + years	98	60 (61)	66	40 (61)	164	100 (61)
p value		0.001		0.733		0.014
2011						
<3 years	2	0 (0)	4	3 (75)	6	3 (50)
3 to 10 years	19	6 (32)	15	7 (47)	34	13 (38)
11 + years	83	57 (69)	54	24 (44)	138	82 (59)
p value		0.002		0.588		0.073

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.5 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Heroin	0	0 (0)	22	17 (77)	23	18 (78)
Methamphetamine	4	0 (0)	22	5 (23)	26	5 (19)
Other	3	0 (0)	31	13 (42)	34	13 (38)
p value		--		0.001		<0.001
2008						
Heroin	1	1 (100)	49	34 (69)	52	37 (71)
Methamphetamine	1	0 (0)	40	13 (33)	42	13 (31)
Other	0	0 (0)	62	38 (61)	63	39 (62)
p value		0.157		0.001		<0.001
2009						
Heroin	1	1 (100)	70	38 (54)	71	39 (55)
Methamphetamine	3	0 (0)	36	7 (19)	41	7 (17)
Other	5	0 (0)	87	52 (60)	93	52 (56)
p value		0.011		<0.001		<0.001
2010						
Heroin	3	1 (33)	61	42 (69)	66	45 (68)
Methamphetamine	2	0 (0)	53	17 (32)	55	17 (31)
Other	5	1 (20)	79	53 (67)	84	54 (64)
p value		1.000		<0.001		<0.001
2011						
Heroin	2	2 (100)	42	26 (62)	46	30 (65)
Methamphetamine	2	0 (0)	57	23 (40)	61	25 (41)
Other	2	1 (50)	72	46 (64)	76	49 (64)
p value		0.600		0.018		0.010

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.6 HCV antibody prevalence by frequency of drug injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Less than daily	5	0 (0)	20	7 (35)	25	7 (28)
Daily or more	2	0 (0)	51	26 (51)	54	27 (50)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value						
2008						
Less than daily	1	0 (0)	50	27 (54)	52	27 (52)
Daily or more	1	1 (100)	100	59 (59)	104	63 (61)
Not last month	0	0 (0)	4	1 (25)	4	1 (25)
p value						
2009						
Less than daily	5	0 (0)	56	23 (41)	62	23 (37)
Daily or more	3	1 (33)	138	76 (55)	144	79 (55)
Not last month	1	0 (0)	2	0 (0)	4	0 (0)
p value						
2010						
Less than daily	4	1 (25)	80	46 (58)	84	47 (56)
Daily or more	5	1 (20)	110	67 (61)	117	70 (60)
Not last month	1	0 (0)	8	2 (25)	10	2 (20)
p value		1.000		0.147		0.051
2011						
Less than daily	2	1 (50)	68	36 (53)	70	37 (53)
Daily or more	4	2 (50)	94	55 (59)	102	61 (60)
Not last month	0	0 (0)	8	3 (38)	10	5 (50)
p value		1.000		0.453		0.639

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.7 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used someone else's used needle & syringe last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No receptive sharing	5	0 (0)	55	26 (47)	61	27 (44)
Receptive sharing	2	0 (0)	13	6 (46)	15	6 (40)
p value		---		1.000		1.000
2008						
No receptive sharing	2	1 (50)	121	70 (58)	127	74 (58)
Receptive sharing	0	0 (0)	28	16 (57)	28	16 (57)
p value		---		1.000		1.000
2009						
No receptive sharing	7	1 (14)	150	73 (49)	160	75 (47)
Receptive sharing	1	0 (0)	40	24 (60)	42	25 (60)
p value		1.000		0.218		0.167
2010						
No receptive sharing	9	2 (22)	136	78 (57)	147	82 (56)
Receptive sharing	0	0 (0)	28	18 (64)	28	18 (64)
p value		--		0.535		0.533
2011						
No receptive sharing	5	2 (40)	118	68 (58)	125	72 (58)
Receptive sharing	1	1 (100)	30	13 (43)	33	16 (48)
p value		1.000		0.218		0.431

* Total includes people who did not report duration of drug injection ** Excludes people who did not inject last month

Table 9.3.8 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No imprisonment	7	0 (0)	59	27 (46)	66	27 (41)
Imprisonment	0	0 (0)	14	7 (50)	15	8 (53)
p value		---		1.000		0.402
2008						
No imprisonment	2	1 (50)	133	74 (56)	139	78 (56)
Imprisonment	0	0 (0)	18	12 (67)	18	12 (67)
p value		---		0.453		0.456
2009						
No imprisonment	9	1 (11)	172	82 (48)	185	85 (46)
Imprisonment	0	0 (0)	19	15 (79)	20	15 (75)
p value		---		0.014		0.018
2010						
No imprisonment	10	2 (20)	143	77 (54)	156	81 (52)
Imprisonment	0	0 (0)	15	11 (73)	15	11 (73)
p value		--		0.179		0.174
2011						
No imprisonment	3	2 (67)	146	79 (54)	154	86 (56)
Imprisonment	2	0 (0)	13	10 (77)	16	11 (69)
p value		0.400		0.148		0.429

* Total includes people who did not report duration of drug injection

Table 9.3.9 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years		3+ years		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
No sex work	5	0 (0)	69	32 (46)	75	33 (44)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		---		1.000		0.630
2008						
No sex work	2	1 (50)	140	79 (56)	146	83 (57)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
p value		---		0.510		0.507
2009						
No sex work	9	1 (11)	178	90 (51)	193	93 (48)
Sex work	0	0 (0)	10	5 (50)	10	5 (50)
p value		---		1.000		1.000
2010						
No sex work	9	2 (22)	182	106 (58)	194	110 (57)
Sex work	1	0 (0)	5	3 (60)	6	3 (50)
p value		1.000		1.000		1.000
2011						
No sex work	6	3 (50)	156	84 (54)	166	91 (55)
Sex work	0	0 (0)	8	4 (50)	9	5 (56)
p value		--		1.000		1.000

* Total includes people who did not report duration of drug injection

Table 9.3.10 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Non Indigenous	51	21 (41)	28	12 (43)	79	33 (42)
Indigenous	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.576		0.647
2008						
Non Indigenous	93	54 (58)	53	31 (58)	146	85 (58)
Indigenous	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.313		0.309		0.079
2009						
Non Indigenous	122	57 (47)	78	39 (50)	201	96 (48)
Indigenous	1	1 (100)	7	3 (43)	8	4 (50)
p value		0.472		1.000		1.000
2010						
Non Indigenous	113	61 (54)	80	46 (58)	193	107 (55)
Indigenous	3	1 (33)	7	6 (86)	10	7 (70)
p value		0.597		0.234		0.518
2011						
Non Indigenous	101	64 (63)	68	33 (49)	170	98 (58)
Indigenous	7	4 (57)	5	1 (20)	12	5 (42)
p value		0.708		0.363		0.369

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.11 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
English speaking	52	22 (42)	30	14 (47)	82	36 (44)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.504
2008						
English speaking	95	55 (58)	58	32 (55)	153	87 (57)
Non-English speaking	6	4 (67)	1	0 (0)	7	4 (57)
p value		1.000		0.458		1.000
2009						
English speaking	120	55 (46)	85	42 (49)	205	97 (47)
Non-English speaking	4	4 (100)	0	0 (0)	5	4 (80)
p value		0.049		---		0.198
2010						
English speaking	111	58 (52)	89	51 (57)	200	109 (55)
Non-English speaking	6	5 (83)	1	1 (100)	7	6 (86)
p value		0.215		1.000		0.135
2011						
English speaking	105	65 (62)	72	34 (47)	178	100 (56)
Non-English speaking	5	4 (80)	1	0 (0)	6	4 (67)
p value		0.649		1.000		0.699

* Total includes people whose gender was not reported or reported as transgender

Table 9.3.12 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2007						
Australia	43	18 (42)	26	13 (50)	69	31 (45)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	6	1 (17)	3	1 (33)	9	2 (22)
Other	3	2 (67)	2	0 (0)	5	2 (40)
p value		0.230		0.607		0.397
2008						
Australia	77	44 (57)	43	24 (56)	120	68 (57)
Other Oceania	6	1 (17)	7	2 (29)	13	3 (23)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	8	6 (75)	5	4 (80)	13	10 (77)
Other	7	5 (71)	4	2 (50)	11	7 (64)
p value		0.139		0.374		0.042
2009						
Australia	102	46 (45)	67	34 (51)	169	80 (47)
Other Oceania	3	1 (33)	5	3 (60)	8	4 (50)
Asia	4	3 (75)	0	0 (0)	5	3 (60)
UK & Ireland	9	7 (78)	9	2 (22)	18	9 (50)
Other	4	2 (50)	3	2 (67)	7	4 (57)
p value				0.364		0.972
2010						
Australia	95	52 (55)	74	43 (58)	169	95 (56)
Other Oceania	7	1 (14)	6	2 (33)	13	2 (23)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	9	6 (67)	7	5 (71)	16	11 (69)
Other	4	2 (50)	2	1 (50)	6	3 (50)
p value		0.148		0.594		0.057
2011						
Australia	90	55 (61)	51	23 (45)	142	79 (56)
Other Oceania	4	3 (75)	7	5 (71)	11	8 (73)
Asia	2	2 (100)	1	1 (100)	3	3 (100)
UK & Ireland	11	7 (64)	8	4 (50)	19	11 (58)
Other	3	2 (67)	6	1 (17)	9	3 (33)
p value		0.945				0.287

* Total includes people whose gender was not reported or reported as transgender

Participating NSP services

Year		07	08	09	10	11
Number of NSP sites		52	52	51	53	53
Australian Capital Territory		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
New South Wales		20	22	20	22	21
Albury	Albury Community Health Centre		✓	✓	✓	✓
Ballina/Byron	Harm Reduction Services	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services		✓	✓	✓	✓
Canterbury	Resource and Education Program for IDUs	✓	✓	✓	✓	
Gosford	Gosford Needle Syringe Program	✓	✓	✓	✓	✓
Liverpool	Health ConneXions	✓	✓	✓	✓	✓
Long Jetty	Long Jetty Needle Syringe Program	✓	✓	✓	✓	✓
Kings Cross	K2 Health Service	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre	✓	✓	✓	✓	✓
Kogarah/Sutherland	Central Access Service	✓	✓	✓	✓	✓
Mt Druitt	Kelly Close Needle Syringe Program	✓	✓	✓	✓	✓
Murwillumbah/Tweed	Harm Reduction Services	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services	✓	✓	✓	✓	✓
North Sydney	Responsive User Services in Health	✓	✓			
Parramatta	HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS (Port Kembla and Nowra)	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDU	✓	✓	✓	✓	✓
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
Wagga Wagga	Albury Community Health Centre				✓	✓
Northern Territory		3	3	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Queensland		7	8	8	8	8
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP		✓	✓	✓	✓

Year		07	08	09	10	11
Number of NSP sites		52	52	51	53	53
South Australia		7	7	7	7	7
Adelaide	South Australia Voice for Intravenous Education (SAVIVE) Norwood	✓	✓	✓	✓	✓
Adelaide	SAVIVE, Parks Community Health Service	✓	✓	✓	✓	✓
Adelaide	Noarlunga Community Health Service	✓	✓	✓	✓	✓
Adelaide	Nunkuwarnin Yunti Community Health Centre	✓	✓	✓	✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Port Adelaide Community Health Service	✓	✓	✓	✓	✓
Salisbury	SAVIVE, Northern Metropolitan Community Health Service NSP and Shopfront	✓	✓	✓	✓	✓
Tasmania		5	4	4	4	4
Clarence	Clarence Community Health Centre	✓	✓	✓	✓	✓
Glenorchy	Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart	Hobart NSP Service	✓	✓	✓	✓	✓
Hobart	The Link - Youth Health Service	✓				
Launceston	Salvation Army Launceston	✓	✓	✓	✓	✓
Victoria		7	6	6	5	6
Barwon	Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	✓
Bendigo	Bendigo NSP Services	✓				
Collingwood	InnerSpace NSP	✓	✓	✓	✓	✓
Footscray	Health Works					✓
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services	✓	✓	✓	✓	✓
Northcote	Northcote NSP Services	✓	✓	✓		
St Kilda	St Kilda NSP	✓	✓	✓	✓	✓
Western Australia		2	2	2	3	3
South West Coast	Western Australia Substance Users Association (WASUA)				✓	✓
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data presented in this report were analysed using Stata, Version 12 (Stata Corporation, College Station TX). Changes in HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trend. Associations between demographic and behavioural variables and HIV and HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. While the majority of survey questions were consistent over all survey years, this was not always the case. Notably, supplementary response options were added to items assessing drug treatment history as new opioid replacement therapies became available.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

List of Tables

1. Demographic characteristics and drug use

Table 1.1.1	Number (%) of respondents by demographic characteristics and year of survey
Table 1.1.2	Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey
Table 1.1.3	Number (%) of respondents by sexual behaviour in the month prior to survey and year of survey
Table 1.1.4	Number (%) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey
Table 1.1.5	Number (%) of respondents by treatment for drug use and year of survey
Table 1.1.6	Number (%) of respondents by source of needle and syringe acquisition in the last month
Table 1.1.7	Number (%) of respondents by frequency and quantity of alcohol consumption

2. HIV prevalence

Table 1.2.1	HIV antibody prevalence by gender and year of survey
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and year of survey
Table 1.2.3	HIV antibody prevalence by age group, gender and year of survey
Table 1.2.4	HIV antibody prevalence by duration of drug injection, gender and year of survey
Table 1.2.5	HIV antibody prevalence by last drug injected, gender and year of survey
Table 1.2.6	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey
Table 1.2.7	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and year of survey
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and year of survey
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and year of survey

3. Hepatitis C prevalence

Table 1.3.1	HCV antibody prevalence by gender and year of survey
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and year of survey
Table 1.3.3	HCV antibody prevalence by age group, gender and year of survey
Table 1.3.4	HCV antibody prevalence by duration of drug injection, gender and year of survey
Table 1.3.5	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey
Table 1.3.6	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey
Table 1.3.7	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey
Table 1.3.8	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey
Table 1.3.9	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey
Table 1.3.10	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey
Table 1.3.11	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey
Table 1.3.12	HCV antibody prevalence by region/country of birth, gender and year of survey